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ABSTRACT 
 
Popeye domain containing (Popdc) proteins are a novel class of cAMP-binding proteins, which are 
highly expressed in heart and skeletal muscle. Genetic inactivation of Popdc1 and -2 genes in mice 
revealed a role in regulating heart rhythm in response to β-adrenergic signalling. Furthermore, it was 
shown that Popdc1 is involved in muscle regeneration.  
This thesis aims at shedding light on the function of Popdc1 and -2 in the heart and in skeletal muscle 
tissue on the protein level in order to get a deeper insight into the molecular mechanisms underlying 
the observed phenotypes in striated muscle tissue of model organisms.  
The two-pore domain potassium channel TREK-1 and the caveolae-associated protein Caveolin-3 are 
the first identified cardiac interaction partners of Popdc proteins. In this thesis, domains have been 
mapped that are involved in protein-protein interaction with TREK-1 and Caveolin-3.  
Towards the goal to identify additional interaction partners for Popdc proteins in striated muscle tissue 
a co-immunoprecipitation (CoIP) assay followed by protein mass spectrometry was devised. Among 
the list of interacting proteins were the adaptor proteins Ankyrin-B, and -G, and the Na
+
/Ca
2+
 
exchanger 1 (NCX-1). Their interaction with Popdc1 and/or -2 was confirmed by co-transfection 
analysis in Cos-7 cells and CoIP experiments using heart tissue. Furthermore, physical interaction 
with the Na
+
 channel α-subunit SCN5A, as well as with Dysferlin and Dystrophin could be established.  
It has been known for about a decade that Popdc proteins are able to form homodimers. Here, 
interaction of different members of the Popdc protein family with each other and the formation of 
heteromeric complexes are reported.  
A familial case of AV-block and muscular dystrophy has recently been associated with a point 
mutation in POPDC1. This point mutation was introduced into the human POPDC1 cDNA. Since the 
mutation was localised to the cyclic nucleotide binding-site, cAMP binding was tested by affinity 
pull-down. A significant reduction in cAMP-binding capacity was observed.  
Furthermore, the role of Popdc proteins in skeletal muscle regeneration was studied using a 
Cardiotoxin-induced injury mouse model. Differences in cross-sectional area of regenerating fibres of 
wildtype and Popdc2 null mutant muscles point to a different time course of regeneration after loss of 
Popdc2. In addition, subcellular localisation of Popdc1 and Popdc2 proteins in myoblasts was 
examined. Although being established as integral membrane proteins with three hydrophobic helices, 
the Popdc1 and -2 proteins were found to be present in the nucleus of primary myoblasts and also in 
established cell lines. These data suggest that Popdc proteins, in addition to their membrane function, 
also have a role as nuclear proteins in different cell types. A region in the Popdc1 protein, which is 
involved in nuclear localisation, was determined by deletion analysis.  
Taken together, experiments performed for this thesis have expanded the understanding of the protein 
interaction network Popdc proteins are acting in. The identification of several novel protein interaction 
partners and the definition of domains involved in some of these interactions may help to explain the 
observed striated muscle pathologies caused by mutations of Popdc genes in model organisms and in 
patients.  
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1 INTRODUCTION 
 
1.1 Striated muscle tissue 
 
Muscles make up about 45-50% of a human’s body weight. Therefore, they represent the largest 
group of tissues. Three types of muscle exist: skeletal, cardiac, and smooth muscle. Muscle tissue is 
classified into two major groups. According to the ultrastructural appearance striated (skeletal and 
cardiac muscles) and non-striated muscles (smooth muscles) are being discerned. Other categories 
are made depending on whether they can be controlled voluntarily or not. This in turn depends on 
whether muscles are innervated by the somatic (voluntary: skeletal muscle) or autonomous nervous 
system (involuntary: cardiac and smooth muscles) (Sherwood 2003; Nielsen and Christensen 2011). 
 
Smooth muscles are found in blood vessels and in the muscle layer of hollow organs with exception of 
the heart. Smooth muscle cells are spindle-like cells. In contrast to skeletal muscle fibres (see below) 
only a single nucleus is present. Smooth muscle cells contract slowly, but energy demands are low, so 
that they have a low fatigability.  
Cardiac muscle shows some similarities to skeletal muscle like the above mentioned striation. 
However, there are important differences between both muscle types. In contrast to the polynucleated 
muscle fibres, adult cardiac myocytes have only one or two nuclei (Lüllmann-Rauch 2003).  
 
Moreover, in the heart, differences exist also among myocytes with regard to structural, electrical and 
mechanical properties (reviewed in (Ng et al. 2010)).  
Also in skeletal muscle differences between muscle fibres are present, e.g. with regard to energy 
metabolism and contractility properties (reviewed in (Schiaffino and Reggiani 2011)).  
 
In mammalian muscles four main fibre types are present, namely type I, type IIa, type IIb, and type IIx, 
which are classified with regard to different contractile features like speed of contraction, and 
metabolic characteristics, i.e. how energy in form of ATP is produced. These, however, are not the 
only differences between fibre types (Schiaffino and Reggiani 2011). The proportion of each fibre type 
in a particular muscle differs with regard to different skeletal muscle groups (Jennekens et al. 1971; 
Johnson et al. 1973). The composition also varies with regard to the same muscle in different 
individuals, and is modulated by physical activity, age, sex, and many other variables (Simoneau and 
Bouchard 1995). 
Type I fibres are slow-oxidative fibres, as they show oxidative energy production via the respiratory 
chain. This is reflected in greater capillarisation, elevated oxidative enzyme activity, a greater amount 
of mitochondria, and high levels of the oxygen-binding protein myoglobin, which results in a 
pronounced red colour of muscles, which are comprised predominantly by type I fibres (Essen et al. 
1975; Ingjer 1979; Nemeth and Lowry 1984). Type I fibres can contract only slowly due to the low 
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ATPase activity of myosin, which results in a slow cross-bridge cycle. Their fatigability is low. 
Therefore, muscles functioning in maintaining posture of the body, for example, have a high proportion 
of type I fibres (Sherwood 2003). 
Muscles, which are important for fast movements, are made up predominantly by type II fibres. 
Similarly to type I fibres, type IIa fibres are oxidative, as the required ATP is mainly produced via the 
respiratory chain. Type IIb fibres in contrast show a more glycolytic metabolism. 
Compared to type I and type IIa fibres, type IIb fibres are those contracting fastest, however, they are 
also the quickest to fatigue. Therefore they are predestined for fast movements where a maximum of 
force is required (Schiaffino and Reggiani 2011). 
 
 
1.1.1 The contractile apparatus 
 
Cardiac and skeletal muscle show not only microscopically visible, but also functional similarities. 
However, also significant differences exist. 
One feature shared by both muscle types is the presence of myofibrils, which are responsible for 
contraction. Myofibrils are composed of sarcomeres, which are the smallest functional, i.e. contractile 
unit in the muscle, arranged in a regularly repeating manner. They are comprised of thick and thin 
filaments, which are arranged in a particular order so that myofibrils appear to be striated when 
observed microscopically. Several sarcomeric components can be discerned. The Z-disc forms the 
boundaries of a sarcomere and therefore, one Z-disc belongs to two neighbouring sarcomeres. The 
centre of a sarcomere is formed by the M-line (middle). Furthermore the I-band (isotropic), which 
surrounds the Z-discs, and the A-band (anisotropic) band can be distinguished. The A-band consists 
of both thin and think filaments, whereas the I-band is only formed of thin filaments. In the middle of a 
sarcomere is the M-line, which consists of myosin filaments and associated proteins. The main 
components of the thin filaments are actin, troponin, and tropomyosin, but also other proteins like the 
actin-binding protein nebulin are part of thin filaments. In contrast, thick filaments are mainly made up 
of myosin molecules (Lüllmann-Rauch 2003; Holland and Ohlendieck 2013; van Eldik and Passier 
2013). Several other proteins have been identified to play a role in sarcomeres, e.g. the M-line protein 
myomesin, which is supposed to link the thick filaments (Agarkova and Perriard 2005).  
A similar function has alpha-actinin, which crosslinks actin filaments of neighbouring sarcomeres at 
the Z-disc (Luther 2009). Other components of the Z-disc include telethonin (T-cap), which also binds 
to proteins in the t-tubules and is important for t-tubule development, structure, and function (Zhang et 
al. 2009; Ibrahim et al. 2013). Anchored at Z-discs is also titin, which connects thick filaments to the  
Z-discs. It stabilises the sarcomeres and plays roles for muscle elasticity and passive muscle force 
(Fukuda et al. 2008; Gautel 2011; van Eldik and Passier 2013). The actual contraction involves the 
sliding of thin filaments past thick filaments, which causes shortening of the sarcomere and therefore 
contraction of the myofibril and the muscle. Mechanistic explanations how this is accomplished are 
delivered by the cross-bridge and swinging lever-arm hypotheses of muscle contraction  
(Holmes 1997). According to the cross-bridge hypothesis, myosin cross-bridges (“heads”) are bound 
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to actin in a 45° conformation. These actin-myosin complexes are dissociated by ATP binding to 
myosin. ATP is then hydrolysed to ADP and Pi by the ATPase activity of myosin, resulting of the  
cross-bridge to switch to the 90° conformation. This in turn allows actin to bind again to myosin. 
Subsequently, ADP and Pi are released, which leads to a conformational change of the myosin  
cross-bridge, so that it moves back to the 45° conformation. This is the underlying mechanism of the 
power stroke, which is a rowing-like movement of the myosin cross-bridge. This results in pulling the 
thin filaments towards the M-line. The swinging lever-arm hypothesis explains the power stroke on the 
basis of a movement of only the distal carboxyl terminal portion of myosin, whereas the main part of 
the cross-bridge remains bound to actin with a relatively fixed geometry (Holmes 1997). 
 
 
1.2 Electrical activity in the heart 
 
Muscle contractions are governed by electrical activities.  
In the heart, rhythmic alteration between contraction and relaxation is the mechanical basis for the 
pump function. For a normal cardiac cycle it is important that the atria contract first to pump the blood 
into the ventricles, which need to be relaxed at this time point. As soon as the ventricles are filled, the 
ventricular myocardium contracts to release the blood into the pulmonary artery (right ventricle) or 
aorta (left ventricle). Relaxation of the atria and ventricles allows them to be filled with blood again so 
that the heart can undergo a new cardiac cycle. 
These contractions and relaxations are coordinated by the cardiac conduction system. Pacemaker 
cells in the sinoatrial node (SAN) autonomously initiate electrical excitation, which is transmitted to the 
atria and allows these to contract. It is further propagated to the atrioventricular node (AVN), where 
conduction to the ventricles is delayed shortly to allow the ventricles to be filled with blood efficiently. 
Via His bundle and Purkinje fibres excitation reaches the apex of the heart and the working ventricular 
myocardium.  
Physiological correlates of excitations are action potentials, which are localised changes in membrane 
potentials. They can be divided into four phases: phase 0 comprises the rapid upstroke mainly caused 
by the activation of voltage-gated sodium channels (Nav). Following the upstroke is a transient 
repolarisation phase (phase 1), which is the result of inactivation of Nav channels and activation of fast 
transient voltage gated outward K
+
 channels (Ito,f). This transits into a plateau phase (phase 2), which 
is mainly the result of the activation of voltage-gated Ca
2+
 channels (Cav), particularly L-type Ca
2+
 
channels. The next phase (phase 3) is the repolarisation phase. This is mainly triggered by outward 
potassium currents, which become dominant due to inactivation of Cav channels. Finally, inward 
rectifying potassium currents are activated leading to a complete repolarisation (Nerbonne and Kass 
2005; George 2013) (Figure 1.1). 
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Figure 1.1: Ion currents underlying cardiac action potentials 
Action potential waveforms are different in ventricular (left) and atrial cardiomyocytes (right) due to 
different properties of underlying currents (Figure from (Nerbonne and Kass 2005)). 
 
 
The different phases of an action potential are not the same in different regions of the myocardium, 
resulting in different action potential waveforms. For example, the plateau phase is more prominent in 
ventricular myocyte compared to atrial and pacemaker cells of SAN and AVN. In addition, in the 
pacemaker cells the upstroke phase (phase 0) is slower than in working cardiomyocytes. Phase 1, the 
transient repolarisation, is missing, as well as the plateau phase, which is most prominent in 
ventricular myocytes. There is also no resting membrane potential, but a pacemaker potential, which 
results in a new action potential as soon as a certain threshold is achieved (Nerbonne and Kass 
2005). The underlying mechanisms are not fully understood but two models have been developed to 
describe the generation of pacemaker potentials in the sinus node, the “membrane (M) clock” and the 
“Ca
2+
 clock” models. The basis for the membrane clock are ion channels and transporters located at 
the surface membrane of pacemaker cells including L- and T-type Ca
2+
 channels, hyperpolarisation-
activated, funny channels, the Na
+
/Ca
2+
 exchanger (NCX), and the Na
+
/K
+
 ATPase. The Ca
2+
 clock 
model explains pacemaking on the basis of intracellular Ca
2+
 cycling, which causes rhythmic 
oscillation also in the absence of sarcolemmal function (Lakatta et al. 2010). Molecular correlates are 
Ca
2+
 channels and pumps in the sarcoplasmic reticulum including sarco-/endoplasmic reticulum Ca
2+
 
ATPase (SERCA) 2 and ryanodine receptors (RyRs). The separation of these clocks is only possible 
in experimental setups or in bioinformatical modelling, however, in normal pacemaker cells both 
mechanisms are functionally connected and important to initiate the heart beat. This is taken into 
account in the “coupled clock” model (Figure 1.2). 
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Figure 1.2: The “coupled clock” model 
The interplay of the “membrane (M) clock” (blue lettering), and “Ca
2+
 clock”(black lettering) is regulated 
by cAMP/PKA and Ca
2+
/CaMKII pathways (red) (Figure from (Maltsev and Lakatta 2012)). 
 
 
Cardiomyocytes are electrically (and metabolically) coupled by gap junctions, allowing excitation 
spread throughout the heart. Gap junctions consist of two hemichannels, one from either of the 
neighbouring cells. Each of this hemichannels is composed of 6 connexin subunits. Connexins are 
transmembrane domains with different biophysical properties. Depending of the required conduction 
velocity, different connexins are expressed in different regions of the heart (reviewed in (Verheule and 
Kaese 2013). 
 
An action potential leads to depolarisation of the cell membrane and to the opening of voltage-gated 
calcium channels, the so-called L-type Ca
2+
 channels or dihydropyridine receptors (DHPRs). This 
results in Ca
2+
 entering the cell. This is an opening stimulus for ryanodine receptors (RyRs). In skeletal 
muscle, both dihydropyridine and ryanodine receptors are directly coupled, so that Ca
2+
 influx is not 
essential for the activation of RyRs. In the heart, RyRs are activated by the inward flux of Ca
2+ 
ions 
through DHPRs (calcium-induced calcium release) (Protasi 2002). The released Ca
2+
 binds to the 
myofilament protein troponin C leading to contraction. Subsequently, Ca
2+
 concentration is decreased 
mainly by pumping it back to the SR via SERCA2 and by transport out of the cell via NCX, but also, to 
a minor extent, via the sarcolemmal Ca
2+
-ATPase and the mitochondrial Ca
2+
-uniporter (Bers 2002).  
Efficient calcium cycling, i.e. the increase and decrease of intracellular Ca
2+
, is guaranteed by the 
close neighbourhood between t-tubules and the SR, arranged in so-called dyads in cardiac myocytes 
and in triads in skeletal myocytes (Brette and Orchard 2007; Al-Qusairi and Laporte 2011). In 
pacemaker cells a close apposition of the SR and the plasma membrane has been found, which 
suggest a tight spatial coupling of the Ca
2+
 clock events in the SR and the membrane clock in the 
plasma membrane. The region in which the SR associates with the t-tubules is the so-called terminal 
cisternae or junctional SR. In skeletal muscle, two elements of junctional SR are surrounding a central 
t-tubule, whereas in the heart, only one SR element is associated with one t-tubule (Arai et al. 1994). 
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The t-tubules, sometimes also referred to as the TATS or transverse-axial tubular system, are an 
extensive network of transversal and longitudinal membrane invaginations, spreading through the 
whole depth of the cells, allowing also sarcomeres, which are lying deep in the cell to be close to the 
site of calcium release. This guarantees synchronous Ca
2+
 release throughout the cell, and the 
efficient and simultaneous activation of the entire contractile apparatus within the cell (Ibrahim et al. 
2011). The most complex t-tubule network within the heart is present in ventricular myocytes 
(Ferrantini et al. 2013). In atrial myocytes, and in the cardiac conduction system, the t-tubule system is 
much less developed with regard to density, or even absent (Di Maio et al. 2007). Also in neonatal 
cardiomyocytes no t-tubules are present, but develop shortly after birth (Ibrahim et al. 2011). 
It has been shown that t-tubules undergo strong remodelling when cardiac myocytes are placed in 
culture (Mitcheson et al. 1996) or during heart disease (Ibrahim et al. 2011; Ferrantini et al. 2013) .  
T-tubules in the heart and skeletal muscle show some structural differences, e.g. cardiac t-tubules 
have a wide lumen in contrast to their counterparts in skeletal muscle, which show a narrow lumen 
(Ferrantini et al. 2013). 
 
 
1.2.1 Caveolae as important microdomains in striated muscle 
 
Lipid rafts are cholesterol and sphingolipid-rich sub-compartments of the cell membrane. Specialised 
forms of lipid rafts are caveolae (Latin for “little caves”), which are flask-like invaginations of the cell 
membrane (Simons and Ikonen 1997). Important protein components of caveolae are cavins and 
caveolins. Caveolins are about 20kDa in size, are able to form oligomeric complexes, and insert into 
the plasma membrane asymmetrically, thereby contributing to the flask-like shape of caveolae (Harvey 
and Calaghan 2012). Three caveolin isoforms exist (Cav1, -2, and -3). Caveolin-3 is the 
muscle-specific isoform, which localises to the sarcolemma in skeletal muscle fibres and to 
sarcolemma and t-tubules in cardiomyocytes (Hagiwara et al. 2002). However, no caveolae are 
present in areas with close connection to junctional SR (Levin and Page 1980). 
Caveolae play various physiological roles, e.g. in vesicular trafficking, mechanosensation and 
transduction, and in signalling processes like ß-adrenergic signalling, and therefore in the control of 
cAMP production (Razani et al. 2002).  
In man, mutations in the CAV3 gene are associated with neuromuscular diseases like limb-girdle 
muscular dystrophy and rippling muscle disease (Williams and Lisanti 2004), and with congenital LQT 
and sudden infant death syndromes (Vatta et al. 2006; Cronk et al. 2007; Gazzerro et al. 2011). 
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1.2.2 The second messenger cAMP 
 
Cyclic adenosine monophosphate (cAMP, adenosine 3′,5′-cyclic monophosphate) is produced by 
membrane-bound adenylyl cyclases, which are activated by Gs protein-mediated signalling and 
inhibited after Gi stimulation (Ahmed and Angers 2013). Cyclic AMP is an important second 
messenger molecule, involved in the control of a plethora of cellular processes. It acts through the 
interaction with four classes of effector proteins: protein kinase A (PKA), exchange protein directly 
activated by cAMP (Epac), hyperpolarisation-activated cyclic nucleotide-gated cation (HCN) channels, 
(Rehmann et al. 2007), and Popeye domain containing (Popdc) proteins (Froese et al. 2012) (see 
below). 
 
Particularly diverse are the functions of PKA. Among many other functions, PKA is involved in several 
points of Ca
2+
 handling, e.g. it has been shown that PKA phosphorylates voltage-gated L-type Ca
2+
 
channels, thereby increasing conductivity and Ca
2+
 influx (Kamp and Hell 2000). Another important 
target is phospholamban, which has an inhibitory effect on SERCA2 in its unphosphorylated state. 
Phosphorylation of phospholamban results in an increase of SERCA2 activity, which leads to an 
increase in SR Ca
2+
 loading (Brittsan and Kranias 2000). PKA also phosphorylates calstabin2 
(FKBP12.6), which is a subunit of the RyR2 complex. This leads to a dissociation of FKBP12.6 from 
RyR2 and a higher RyR2 open probability, resulting in an increased SR Ca
2+
 release (Marx et al. 
2000). 
 
RyRs2 and phospholamban are also modulated by Ca
2+
/calmodulin-dependent protein kinase (CaMK) 
II, which in turn is modulated by Epac (Pereira et al. 2007). Other ways by which Epac proteins 
modulate Ca
2+
 induced Ca
2+
 release have been described, e.g. via phospholipase C (PLC) epsilon 
(Oestreich et al. 2007).  
Important cAMP targets are HCN channels, which are regulated by direct binding of cAMP 
(DiFrancesco and Tortora 1991; Wainger et al. 2001). Particularly important is the HCN4 channel, 
which is the main molecular correlate of the If current in cardiac pacemaker cells (Bucchi et al. 2012). 
It is believed that cAMP-binding to HCN channels is involved in the chronotropic response of the heart 
after ß-adrenergic stimulation (DiFrancesco 1993). It has been shown that reduction of If current in 
human results in sinus bradycardia (Baruscotti et al. 2010). Global inducible depletion of Hcn4 in adult 
mice, results in cardiac arrhythmia characterised by periods of sinus pauses. However, a normal 
response to adrenergic stimulation is seen, suggesting that Hcn4 is not essential for heart rate 
adaptation under stress, but for stabilising cardiac rhythm (Herrmann et al. 2007; Lakatta and Maltsev 
2012).  
 
The two main Gs-coupled receptors in the heart are ß1- and ß2-adrenoceptors (ARs), which both are 
activated by catecholamine hormones. In contrast to ß1-adrenergic signalling, which spreads 
throughout the cell, stimulation of the ß2-AR leads to locally confined responses (Nikolaev et al. 2006). 
This is partially due to the different localisation of the two receptors. Whereas ß1-ARs are present 
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across the cell surface, ß2-ARs are locally restricted to t-tubules with regard to their distribution 
(Nikolaev et al. 2010). Interestingly, ß2-AR localisation is dependent on lipid rafts/caveloae as 
cholesterol depletion by methyl-ß-cyclodextrin (MßCD) leads to redistribution of these receptors 
(Nikolaev et al. 2010). In addition, cAMP signalling is modulated through degradation by 
phosphodiesterases (PDEs) (Rochais et al. 2006). Furthermore, cAMP levels are also controlled by 
buffering through PKA (Saucerman et al. 2006; Nikolaev et al. 2010). In addition, cAMP signalling is 
regulated by AKAPs (A kinase anchoring proteins), which localises PKA and other proteins like PDEs 
to specific subcellular compartments (reviewed in (Kritzer et al. 2012)). Further regulation of cAMP 
signalling is accomplished by desensitisation of ß2-ARs through SUMOylation of Caveolin-3 (Fuhs 
and Insel 2011). 
 
 
1.3 Skeletal muscle structure and regeneration 
 
Skeletal muscles are built from muscle fibres. Muscle fibres are polynucleated cells (syncytia). The 
nuclei are located in the periphery of the fibre, directly beneath the plasma membrane, which is also 
called sarcolemma. The cytoplasm or sarcoplasm contains the myofibrils. Muscle fibres vary in size. 
They can extend several centimetres (Sherwood 2003).  
By connective tissue, muscle fibres are arranged into different bundles. Each fibre is surrounded by a 
basal lamina, and connective tissue of the so-called endomysium, which is important for the tear 
strength of the muscle. Several fibres are grouped together and form bundles, the fascicles. Fascicles 
are encompassed by connective tissue called the perimysium. In turn, several fascicles are grouped 
together to form a whole muscle. The muscle is covered by the epimysium. Endo-, peri-, and 
epimysium form a continuum with each other and with aponeuroses and tendons to attach one muscle 
to another and to bones, respectively. On top of the epimysium there is a further connective tissue 
layer, which is called the fascia (Lüllmann-Rauch 2003; Sherwood 2003).  
The smallest functional units of a muscle are the motor units. These are elements consisting of a 
motor neuron and of the muscle fibres that are innervated by it (Schiaffino and Reggiani 2011). 
Skeletal muscle has a remarkable ability to repair and regenerate. Small injuries to the muscle can be 
repaired without cell death. More severe muscle injuries causing necrosis are inducing regeneration 
with the formation of new myofibres or myofibre segments. This is accomplished in three stages 
including an inflammatory reaction, a phase characterised by activation, proliferation, differentiation, 
and fusion of satellite cells, and a stage of maturation and remodelling of regenerated fibres (reviewed 
in (Ciciliot and Schiaffino 2010)). A special role have satellite cells, as they are essential for muscle 
regeneration (Sambasivan et al. 2011). Moreover, satellite cells contribute to muscle growth after birth 
and muscle hypertrophy. Satellite cells are a heterogeneous population of transcriptionally and 
mitotically inactive skeletal muscle-specific stem cells, which are normally located between 
sarcolemma and the basal lamina of muscle fibres. They are activated through different stimuli, 
proliferate, and migrate to the site of damage. Most of these myoblasts undergo differentiation and 
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fusion with each other or with fibres. Others go back to the quiescent state and become new satellite 
cells. These processes are orchestrated by a number of different transcription factors (reviewed in (Yin 
et al. 2013)).  
 
 
1.4 The Popeye domain containing gene family 
 
Aiming to identify novel cardiac-specific genes, the first member of the Popeye domain containing 
(Popdc) gene family has been discovered and cloned independently by two groups (Reese et al. 1999; 
Andree et al. 2000). It was named Bves (Blood vessel epicardial substance), according to the 
expression patterns observed by immunolabelling, and Popeye1 (Pop1), in reference to the  
comic-strip hero “Popeye the sailor”, due to its predominant expression in striated muscle tissue. 
Today the most common names are Bves or Popeye domain containing 1 (Popdc1). In this thesis, the 
gene is referred to as Popdc1 to indicate its membership to the Popdc family, which includes two other 
genes named Popdc2 and Popdc3 (Andree et al. 2000). 
 
 
1.4.1 Evolution of Popdc genes 
 
Popdc genes are highly conserved during evolution. In higher vertebrates, three Popdc genes are 
present, whereas often two Popdc genes, which appear to be orthologues to Popdc1 and Popdc3, are 
found in lower chordates and invertebrates (Brand 2005). However, there is an increasing number of 
species, which divert from this pattern. Thus, sea urchins (a primitive deuterostome), leaf cutter ants 
and the monarch butterfly have three Popdc genes like vertebrates. Orthology has not been fully 
clarified until now. It is thus likely that the condition of three genes that are found in higher vertebrates 
have also been created independently in invertebrates. Also species with higher numbers of Popdc 
genes exist like the water flea Daphnia pulex, which harbours five Popdc genes (Schindler et al. 
2012), or the tick Ixodes scapularis with eight Popdc genes (Thomas Brand, personal communication). 
An exemption are species of the order Diptera, including the fruit fly Drosophila melanogaster with 
only a single Popdc orthologue, DmBves (Lin et al. 2007). The biological significance to loose or retain 
duplicated Popdc genes is an unresolved issue. Latest sequence data revealed that a Popdc gene is 
already present in Hydra and other Cnidaria and thus, Popdc genes are present from the start of 
metazoan evolution (Thomas Brand, personal communication). A significant homology at the structural 
level and for a few bacteria species also on the sequence level are found between Popdc proteins and 
the transcription factors CAP (Catabolite Activator Protein) and CRP (cAMP Receptor Protein), which 
suggests that possibly the transmembrane Popdc proteins found in invertebrates and vertebrates have 
their ancestral roots in a transcription factor involved in metabolic regulation (Schindler et al. 2012; 
Simrick et al. 2013). 
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In higher vertebrates, Popdc1 and Popdc3 are on the same genetic locus, namely on chromosome 
6q21 in humans, chromosome 10 in the mouse and chromosome 3 in the chick. The two genes are 
separated by approximately 17kb in man and mouse, and about 9kb in the chick (Andree et al. 2000; 
Osler et al. 2006). Interestingly, also in lower chordates and in invertebrates the Popdc orthologues 
are found to be clustered on the same chromosomal locus, suggesting their origin by tandem 
duplication (Davidson and Levine 2003; Davidson et al. 2003; Brand 2005).  
There is some evidence of co-regulation of both genes. Significant overlap of expression of Popdc1 
and Popdc3 has been reported in the mouse and chick. Moreover, in the chick fusion transcripts 
containing sequences of both POPDC1 and POPDC3 have been identified (Andree et al. 2000). 
Similarly, also in bovines, horses, panda bears, turkey, and pufferfish Popdc1/Popdc3 fusion 
transcripts have been predicted. These data suggest that Popdc1 and Popdc3 genes have no clear 
border and that both genes are utilised in a combinatorial fashion. Interestingly, a bidirectional 
promoter is predicted to drive transcription of Popdc1 and of an antisense RNA, which is coded in the 
intergenic region between Popdc1 and -3, and comprises also parts of the Popdc3 gene (Schindler et 
al. 2012). Popdc3 is expressed at much lower levels than Popdc1. It is therefore tempting to speculate 
that this antisense RNA is suppressing Popdc3 expression, however, direct experimental evidence 
has not been obtained yet.  
The Popdc2 gene, which shows high similarity to Popdc3, is only present in higher vertebrates. It is 
found on a different chromosome, namely chromosome 3 in men, chromosome 16 in the mouse, and 
chromosome 1 in the chick. It is supposed that Popdc2, and -3 have originated from a common 
ancestor because they show higher similarity to each other (~50% sequence identity on the protein 
level) than to Popdc1 (~25-30% sequence identity) (Brand 2005). Although Popdc genes show high 
similarity in their coding sequences, their gene structure is not conserved, e.g. they differ in the 
number of exons. For example, the human POPDC1 gene consists of 5 exons, whereas in the mouse 
11, in the chick 8, and in the fruit fly 7 exons are present (Osler et al. 2006). 
 
 
1.4.2 Expression patterns of Popdc proteins 
 
All three members of the Popdc gene family are predominantly expressed in heart and skeletal 
muscle, however, also other expression domains exist.  
In addition to being expressed in striated muscle, Popdc1 expression has also been detected in 
smooth muscle cells of bladder, uterus, and the gastrointestinal tract. Other expression domains are in 
the brain, various epithelia, spinal ganglia, thymus, and testes, as well as in the stomach, the lungs, 
the kidneys, and spleen (Reese et al. 1999; Andree et al. 2000; Osler and Bader 2004; Ripley et al. 
2004; Vasavada et al. 2004; Osler et al. 2006; Smith and Bader 2006; Torlopp et al. 2006; Hager and 
Bader 2009).  
Although Popdc1 has a relatively broad expression pattern, there is no doubt that the highest levels 
are present in cardiac and skeletal muscle cells. There is, however, controversy on some expression 
domains. Popdc1 expression was initially detected in blood vessels and the epicardium and therefore 
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named Blood vessel epicardial substance (Bves) (Reese et al. 1999). However, neither  
ß-galactosidase (LacZ) staining of tissue from a genetically modified mouse having a LacZ gene 
inserted into the first coding exon of the Popdc1 gene, which leads to an inactivation of this gene, nor 
immunostaining using commercially available antibodies performed on chick or mouse tissue, nor in 
situ hybridisation studies could confirm these findings. Only a strong myocardial expression was seen 
in the heart. Significantly, although in the first Popdc paper published by Reese et al. in 1999 
prominent POPDC1 expression in the chick proepicardium has been reported, the structure which 
gives raise to the epicardium, RT-PCR analysis for POPDC1, -2, and -3 revealed that none of the 
members of the Popdc gene family is expressed at significant levels in the chick proepicardium 
(Andree et al. 2002; Andree et al. 2002; Torlopp et al. 2006). 
In the heart, Popdc1 expression levels are chamber-specific. Postnatally the expression in the 
ventricles is down-regulated, whereas atrial expression remains at high levels. The strongest 
expression can be observed in the cardiac conduction system (Breher 2009; Froese et al. 2012). 
Popdc2 expression has been studied in detail employing different techniques like in situ hybridisation, 
and RT-PCR, but also by LacZ staining on tissues of a genetically modified mouse model, which has 
been engineered by deleting the first coding exon of the Popdc2 locus with a LacZ gene (Froese and 
Brand 2008).  
Popdc2 shows several overlapping expression domains to Popdc1, particularly in muscle tissues. In 
the heart, also Popdc2 expression is confined to the myocardium. In contrast to Popdc1, which shows 
higher expression in the atria than in the ventricles, Popdc2 is equally highly expressed in the four 
chambers. Popdc2 has also been detected in skeletal muscle. However, in skeletal muscle expression 
levels are lower compared to Popdc1 (and Popdc3) (Froese and Brand 2008). Similar to Popdc1 the 
strongest expression has been detected in the sinus node and other parts of the cardiac conduction 
system (Froese et al. 2012). Expression in epicardium and coronary vessels could not be detected. 
Like Popdc1, Popdc2 is also expressed in smooth muscle tissue and epithelia of various organs. 
Expression patterns and levels may slightly differ in different species. An example is the expression of 
Popdc genes in the brain. In mice, other than for Popdc1 no expression of Popdc2 is seen in the brain, 
however, Popdc2 transcripts have been detected in the rat brain, although at very low levels (Breher 
et al. 2004; Parnes et al. 2007; Froese and Brand 2008; Froese et al. 2012).  
Although expressed at much lower levels than Popdc1 and -2, Popdc3 is also predominantly 
expressed in striated muscle tissue. In the heart, only myocytes do express Popdc3, whereas other 
cell types like epi- and endocardium are devoid of expression. Other expression domains of Popdc3 
are found in the lung and the intestine (Andree et al. 2000; Andree et al. 2002; Kim et al. 2010; Luo et 
al. 2012). 
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1.4.3 Structure and biochemical properties of Popdc proteins 
 
Popdc proteins (Figure 1.3) have been shown to be transmembrane proteins containing three 
hydrophobic helices. The proteins have a short extracellular N-terminus, which contains two sites of  
N-glycosylation. Glycosylation is quite extensive in these proteins. Therefore, Popdc1 with a predicted 
molecular weight of about 43kDa migrates on SDS polyacrylamide gels at about 58kDa. It has been 
speculated that glycosylation plays an important role for membrane localisation of Popdc proteins or 
protects the proteins from proteolytic decay (Knight et al. 2003; Vasavada et al. 2004; Hager and 
Bader 2009). 
 
 
Figure 1.3: Working model of Popdc proteins 
Popdc proteins have a short extracellular N-terminus, three transmembrane domains, and an 
intracellularly localised C-terminus containing the evolutionary conserved Popeye domain. The 
proteins form homodimers, which are stabilised by a disulfide bond. 
 
 
In the intracellular part of the proteins (C-terminus) the evolutionary conserved Popeye domain 
(PFAM: PF04831) is present, which consists of about 150 amino acids (Andree et al. 2000). This 
domain contains a functional cyclic nucleotide binding domain. Interestingly, at the primary sequence 
level the cyclic nucleotide binding cassette is quite distinct to other known cAMP-binding domains, i.e. 
protein kinase A (PKA), Epac, and HCN channels, but 3D modelling showed high similarity of the 
structures of different cAMP-binding domains. By cAMP affinity pull-down, radioligand binding assay 
and FRET analysis Froese and colleagues have demonstrated that Popdc proteins are able to bind 
cAMP, but not cGMP (Figure 1.4). The binding affinity is approximately 10 times higher compared to 
Epac1 and nearly in the same range as that of PKA. Two sequence motifs, DSPE and FQVT have 
been reported to be crucial for cAMP binding. Particularly charge-to-alanine mutations at position 
D200 in Popdc1 and D184 in Popdc2 leads to a strong decrease in cAMP binding. Although the 
physiological relevance of the cAMP binding ability of Popdc proteins has not yet been established, it 
1 Introduction  29 
has been shown that binding of cAMP to Popdc proteins has an effect on the interaction with the 
two-pore domain potassium channel TREK-1 (Froese et al. 2012) (see below). 
 
Popdc proteins form homodimers, which are stabilised by disulfide bonds. Thus, Popdc1 is migrating 
in a denaturating SDS gel at about 120kDa in the absence of a reducing agent like 
ß-mercaptoethanol, and at about 60kDa if a reducing agent is present (Knight et al. 2003; Vasavada et 
al. 2004). Homodimerisation is believed to be necessary for maintenance of epithelial integrity and 
junctional stability. It has been reported previously that conserved lysines at the carboxy-terminal end 
of the Popeye domain mediate homodimerisation (Kawaguchi et al. 2008; Hager and Bader 2009). 
Recent data, however, show that a Popdc1 protein lacking this sequence motif is still able to form 
homodimers, indicating the presence of another not yet identified homodimerisation domain. In 
contrast, this truncated Popdc1 protein leads to a dramatic decrease of endogenous Popdc1 
localisation to the plasma membrane. As a consequence, also the localisation of tight junction or tight 
junction associated proteins are altered, resulting in impaired epithelial function (Russ et al. 2011). 
 
 
Figure 1.4: cAMP binding of Popdc proteins 
POPDC1 extracted from chicken heart lysates is precipitated and eluted from cAMP agarose with 
increasing concentrations of unbound cAMP (T: total protein lysate; C: control incubation with 
EtOH-NH agarose; P: pellet; S: supernatant) (A). All three members of the Popeye domain containing 
protein family bind cAMP as shown by Western blot analysis after cAMP precipitation using 
transfected Cos-7 cells (B). FRET analysis using a bi-molecular FRET sensor based on Popdc1-CFP 
and YFP-TREK-1 reveals modulation of Popdc1-TREK-1 interaction upon stimulation with 
isoproterenol (C), but not with sodium nitroprusside (SNP) (D). Radioligand binding assay using the 
recombinantly expressed C-terminus of Popdc1 shows binding to cAMP with high affinity, whereas 
affinity to cGMP is negligibly low (E) (panels taken from (Froese et al. 2012)). 
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1.4.4 Functional impact of the Popeye domain containing protein family 
 
1.4.4.1 Popdc1 is a component of cell-cell contacts and regulates epithelial function 
 
Tight junctions are fulfilling two main tasks, the barrier and the fence function. The barrier function is to 
regulate the passage of molecules and cells through the cell layer, whereas the fence function blocks 
diffusion of proteins from the apical membrane into the baso-lateral membrane and vice versa, and 
thus maintains apical-basal cell polarity (Sawada et al. 2003).  
Popdc1 co-localises with important protein compounds of tight junctions such as occludin and ZO-1 in 
mature epithelia, including murine small intestine epithelium. Furthermore, direct interaction of Popdc1 
and ZO-1 has been established by GST pull-down assay. It has been concluded that this interaction 
plays an important role in the formation and the regulation of the integrity of epithelial monolayers 
(Osler et al. 2005). It has also been shown that in human corneal epithelial cells Popdc1, presumably 
through interaction with ZO-1, sequesters GEF-H1, an activator of RhoA, and ZONAB/DbpA at tight 
junctions and thereby not only regulates the position of these proteins to tight junctions but also 
modulates the downstream signalling of these proteins. Also in trabecular meshwork cells Popdc1 
inhibits RhoA signalling leading to a decreased phosphorylation of myosin light chain, a downstream 
target of the RhoA-ROCK signalling pathway. Thus, Popdc1 is supposed to regulate trabecular 
meshwork cell contraction and thereby aqueous outflow and intraocular pressure in the eye. 
Furthermore, overexpression of Popdc1 leads to an increase in tight junction formation and 
augmented function resulting in a decreased permeability and increased transepithelial resistance 
(Russ et al. 2010; Russ et al. 2011). It has been shown in zebrafish that Popdc1 also interacts with 
aPKC (atypical protein kinase C), which plays a role for tight junction integrity by recruiting and 
tethering of components of the tight junction signalling complex (Wu et al. 2012). Popdc1 is therefore 
an essential component of tight junctions and important for epithelial function. 
In addition to tight junctions, Popdc1 also regulates adherens junctions. In human corneal epithelial 
cells as well as colorectal cancer cells E-cadherin expression and ß-catenin localisation correlate with 
Popdc1 expression. Furthermore, WNT signalling is inhibited by Popdc1 overexpression in a HEK293 
WNT reporter cell line and in colorectal cancer cells. By modulating both, tight junctions and adherens 
junctions, Popdc1 is regulating epithelial-mesenchymal transition (EMT), when epithelial cells adopt a 
mesenchymal or fibroblast-like phenotype, and mesenchymal-epithelial transition, when cells with 
mesenchymal features turn into epithelia (Williams et al. 2011). 
Interestingly, Popdc1 localises early at cell-cell contact sites, and transfection of Popdc1 to 
non-adherent L-cells results in aggregation of these cells, leading to the conclusion that Popdc1 itself 
is a cell adhesion molecule mediating cell aggregation in a Ca
2+
-independent manner (Wada et al. 
2001). When these experiments were carried out it was erroneously believed that the long C-terminus 
of Popdc1 would localise extracellularly. Therefore, the interpretation of these experiments, particularly 
with regard to the underlying mechanisms, has to be reconsidered. However, all these experiments 
together are underlining the important role of Popdc1 in cell adhesion, cell-cell contact, and epithelial 
function. The physiological impact of Popdc1 on epithelia has also been shown in the context of the 
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Xenopus eye, where morpholino oligonucleotide-mediated knockdown of Popdc1 has revealed the 
importance of the protein for growth and regeneration of the cornea epithelium (Ripley et al. 2004). 
Also in early embryogenesis, the epithelial function of Popdc1 seems to play important roles. 
Knockdown-based studies in Drosophila have shown impaired pole cell migration (Lin et al. 2007), and 
in Xenopus, injection of morpholino oligonucleotides causes an arrest in gastrulation characterised by 
abnormal epithelial movements and impaired organogenesis (Ripley et al. 2006). It has also been 
reported in the zebrafish that knockdown of popdc1 (zbves) leads to developmental defects and arrest 
at the end stage of gastrulation. Additionally, epidermal and pericardial oedemas have been observed, 
which could be due to impaired epithelial function and permeability (Wu et al. 2012). The gastrulation 
phenotype, however, is discussed controversially, since in the Brand lab no gastrulation defect has 
been observed after splice site morpholino-mediated knockdown of either popdc gene (Kirchmaier et 
al. 2012; Poon et al., unpublished data). Likewise, shRNA-mediated depletion of Popdc1 (DmBves) in 
Drosophila does not provide evidence for an early phenotype during gastrulation, but leads to cardiac 
arrhythmias (Bodmer et al., unpublished data). In contrast to these recently published knockdown-
based studies by Ripley et al. and Wu et al. is also the lack of any embryonic phenotype after genetic 
inactivation of either Popdc1 or of Popdc2 or of both genes together in the mouse (Andree et al. 2002; 
Froese et al. 2012). 
Although important functions of Popdc1 for contact structures in epithelia has been described, it has 
not been studied whether the protein does function in similar ways in cardiac and skeletal muscle, 
however, the accumulation of Popdc1 at intercalated discs in the heart might indicate a potential role 
for cell-cell contacts in cardiomyocytes (Breher 2009). 
 
 
1.4.4.2 Popdc1 regulates cell shape and motility 
 
Beside its role in cell-cell adhesion, a further molecular mechanism has been provided, which could 
explain Popdc1 function in epithelia and the results of previous studies showing effects like impaired 
epithelial morphogenesis and cell movements upon Popdc1 knockdown. By a yeast two-hybrid 
screen, GEFT has been identified as a novel interaction partner of Popdc1, and interaction has been 
confirmed by GST pull-down. A domain, which seems to be necessary but not sufficient to mediate 
interaction, has been mapped to an intracellular portion within the Popeye domain of Popdc1 between 
aa 250 and 300 (Smith et al. 2008). GEFT is a guanine nucleotide exchange factor (GEF) for 
Rho-family GTPases Rac1 and Cdc42 activating these small G proteins by catalysing the exchange of 
GDP to GTP. GEFT is highly expressed in brain, heart and skeletal muscle. Overexpression of GEFT 
leads to a re-organisation of the actin cytoskeleton and alteration in cell morphology and cell 
migration. Moreover, overexpression promotes cell proliferation. GEFT may therefore have an 
influence on tumourigenesis (Guo et al. 2003). Smith and colleagues transfected a truncated Popdc1 
construct lacking the transmembrane domains into NIH3T3 cells and observed a reduced activation of 
Rac1 and Cdc42, but not of RhoA with the consequence that cells transfected with Popdc1 show a 
reduced speed of cell locomotion compared to controls. Directionality of cell movement, however, is 
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not changed. Additionally, transfected cells show a more prominent roundness. Moreover, transfection 
of this C-terminal Bves construct into C2C12 myoblasts markedly reduces differentiation of those cells. 
Although several potential mechanisms how Popdc1 could regulate GEFT and Rac/Cdc42 have been 
proposed by the authors of the study, it is still unclear how Popdc1 modulates the nucleotide binding 
ability of GEFT and controls Rac/Cdc42 activity. Among the possibilities are direct control mechanisms 
of GEFT and its nucleotide binding ability or indirect ways including regulation of GEFT by 
sequestering it and therefore preventing it from activating its downstream effectors. It is also 
speculated that Popdc1 may affect proper subcellular localisation of GEFT (Smith et al. 2008; Hager 
and Bader 2009).  
Until now the effect of Popdc1-GEFT interaction in muscle cells remains unclear. 
 
 
1.4.4.3 Popdc1 controls vesicular transport and fusion 
 
In 2010, a study has been published by the Bader group demonstrating an interaction of Popdc1 with 
the vesicle-associated membrane protein Vamp3 (Hager et al. 2010). Vamp3 or cellubrevin is a 
ubiquitously expressed vesicular SNARE protein. It is involved in vesicle fusion and in trafficking of 
several membrane proteins such as transferrin or ß-integrin, and thereby regulates cell motility 
(McMahon et al. 1993; Galli et al. 1994; Proux-Gillardeaux et al. 2005; Tayeb et al. 2005; Luftman et 
al. 2009). Hager et al. have found by CoIP and GST pull-down that Popdc1 directly interacts with 
Vamp3 and that both colocalise in epithelial cells, in the heart and skeletal muscle, although there was 
no full overlap. When they overexpressed a dominant-negative form of Popdc1 in MDCK cells, which 
only contains the first 118 amino acids of the protein (Bves118), transferrin uptake decreases and 
exocytosis is slower compared to untransfected control cells. Reduction of transferrin internalisation is 
also observed in vivo when either Popdc1 or Vamp3 are depleted by antisense morpholinos injected 
into Xenopus embryos, in comparison to control morpholino-injected embryos. Rescue by co-injection 
with Popdc1 RNA and Vamp3 RNA, respectively, transferrin internalisation is restored, demonstrating 
the specifity of the knockdown. Also ß1-integrin internalisation is decreased in MDCK cells expressing 
the dominant-negative Bves118 isoform. The reduction is comparable to cells overexpressing tetanus 
neurotoxin, which inactivates Vamp3 by cleavage. Likewise, cell spreading, which depends on integrin 
recycling, is significantly reduced in Bves118 and tetanus neurotoxin expressing cells compared to 
controls, resulting in a smaller increase of cell area. Also in morpholino-injected Xenopus cells, a 
reduction in cell spreading can be observed. Furthermore, Popdc1 knockdown results in 
morphological defects, which are comparable to integrin depletion (Hager et al. 2010). Taken together, 
through interaction with Vamp3 Popdc1 controls important cellular and physiological processes where 
vesicular transport is required. Therefore, Popdc1-Vamp3 interaction is yet another mechanism, which 
could explain the roles of Popdc1 in cell adhesion and motility, as well as phenotypes observed after 
knockdown of Popdc1 in epithelia such as developmental defects in frog, fly, and zebrafish.  
Further evidence for a role of Popdc1 in vesicular trafficking and fusion comes from a recent study 
demonstrating the interaction of Popdc1 with the N-myc Downstream Regulated Gene 4 (NDRG4) 
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(Benesh et al. 2013). It has been shown that fusion of Vamp3-positive recycling endosomes with the 
cell surface membrane is regulated by the interaction of Popdc1 and NDRG4. Furthermore, abolishing 
of this interaction randomises and accelerates directional movement of epicardial cells by interfering 
with the autocrine ECM deposition pathway, by which internalised fibronectin is recycled and finally 
re-secreted (Benesh et al. 2013). 
 
 
1.4.4.4 Popdc genes and cancer 
 
Consistent with the impact of Popdc1 on cell motility and cell adhesion, and its role in junction 
structures and EMT, a hallmark of cancer and key process for invasiveness of tumours (Micalizzi et al. 
2010), are studies demonstrating that in human patients several different cancer types are associated 
with a down-regulation of POPDC1 and -3. The first study indicating a possible role of Popdc genes in 
cancer has been published in 2008, showing that in tumour tissue from non-small cell lung cancer 
patients the POPDC1 promoter is significantly more frequently and at higher levels methylated in 
comparison to matched normal tissue leading to a reduced expression of POPDC1 in the cancerous 
tissue (Feng et al. 2008). However, hypermethylation of the POPDC1 promoter has not been 
observed in the cancer-free lung, including pre-cancerous lungs of tobacco smokers, suggesting that 
the role of POPDC1 might emerge at later stages of lung cancer (Feng et al. 2008; Salskov et al. 
2011). Similarly, down-regulation of POPDC1 and -3, but not of POPDC2, has been revealed in 
gastric cancer. In an initial study published in 2010 by Kim et al., down-regulation of POPDC1 and -3 
expression has been observed in 8 out of 11 gastric cancer cell lines. Moreover, an at least 2-fold 
down-regulation of POPDC1 and -3 has been present in the majority of gastric tumour samples, 
whereas only in a few samples POPDC2 has been found to be down-regulated 2-fold. These data give 
further support of a co-regulation of Popdc1 and Popdc3 and a divergent regulation of Popdc2. As 
major causes of down-regulation gene silencing by promoter hypermethylation as well as histone 
deacetylation have been determined, and treatment of gastric cancer cell lines with the DNA 
methylation inhibitor 5-aza-dC and the histone deacetylase inhibitor TSA strongly increases POPDC1 
and -3 expression. As suggested by Kim et al., there is a mechanism of down-regulation other than 
promoter hypermethylation. They have shown that EGF treatment, which is known to promote cell 
migration and invasion by positive regulation of Rac1 and Cdc42, leads to an immediate decrease of 
POPDC1 and -3 expression probably through repression by SnaiI, which is up-regulated after EGF 
stimulation (Lee et al. 2008; Kim et al. 2010).  
These data are reminiscent of the findings in Drosophila where gurken (EGF homologue in 
Drosophila) suppresses DmBves expression in the dorsal follicular epithelium of the egg chamber (Lin 
et al. 2007). A similar regulation has also been observed for Popdc genes in rat neonatal cardiac 
myocytes where serum treatment blocks Popdc1, and -3, but also Popdc2 expression (Parnes et al. 
2007).  
By transwell migration and Matrigel plug assays using cells which have been transfected with 
POPDC3 shRNAs or treated with EGF it has been shown that loss of POPDC3 in gastric cancer leads 
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to enhanced cell migration and invasion. This is accompanied by a reduction of ZO-1 and occludin 
expression. It has therefore been proposed that down-regulation of POPDC1 and -3 contributes to a 
loss of cell-cell contacts as well as to enhanced cell motility by up-regulation of Rac1 and Cdc42, 
resulting in increased cell migration and invasion (Kim et al. 2010). Another study suggests that also 
the function of Popdc1 on Vamp3-mediated vesicle trafficking and the role in integrin-dependent cell 
movements may have an impact on cancer progression (Hager et al. 2010). Interestingly, Kim and 
colleagues have not found a correlation between BVES or POPDC3 methylation with age, gender, or 
histology. Moreover, promoter methylation and expression levels of these two genes have not been 
correlated with tumour stage, as down-regulation was revealed in early stage as well as in 
advanced-stage tumours (Kim et al, 2010). 
In their study published in 2012 Luo and colleagues could not see a relationship between POPDC1 
expression and age, gender, and histologic type either. Furthermore, POPDC1 expression did not 
correlate with tumour size or location. However, in contrast to Kim et al., Luo and colleagues found an 
association between POPDC1 expression with histologic differentiation, depth of invasion, regional 
lymph node metastasis, distant metastasis, and TNM stages. Moreover, also 3-year survival rate did 
correlate with POPDC1 expression. Patients with high expression had a median survival of 55 months, 
whereas patients with low expression had a median survival rate of just 21 months. Moreover, the  
1- and 3-year survival rates were reduced as well. The 1-year survival rate was 81.65% in the group 
showing high POPDC1 expression compared to 78.68% of patients with low expression. The 
difference in the 3-year survival rate was even more dramatic. It was 73.4% for patients with high 
expression levels, and 12.18% for patients with low POPDC1 expression. Moreover, low POPDC1 
expression had a much higher impact on 3-year survival with regard to extent and statistical 
significance for patients with early stage tumours (TNM stage I and II) than late stage tumours (TNM 
stage III and IV). Compared to patients with high POPDC1 levels, patients with early stage tumours 
revealed a reduction in the 3-year survival rate of >51.3% whereas a 34.8% reduction was observed 
for patient with late stage tumours (Luo et al. 2012). Likewise, POPDC3 expression was analysed in 
gastric cancer tissue, and similar results were obtained, however, in contrast to POPDC1 there was no 
statistical significant correlation (Luo et al. 2012) between POPDC3 expression and histologic 
differentiation. 
It is noteworthy that both proteins, POPDC1 and -3, have been detected at plasma membrane and 
cytoplasm in non-neoplastic and cancerous tissue, but in contrast to non-cancerous tissue tumours 
showed a predominant cytoplasmic distribution. In addition to differences in expression levels, 
differences in subcellular localisation are also supposed to play a role in gastric cancer (Luo et al. 
2012; Luo et al. 2012).  
In addition to gastric and lung cancer, abnormal POPDC1 and -3 expression and its impact on 
tumourigenesis has been described for colorectal cancer (Williams et al. 2011) and uveal melanoma 
(Jayagopal et al. 2011).  
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1.4.4.5 Popdc proteins interact with ion channels 
 
In 2012, Froese et al. have demonstrated that all three members of the Popdc protein family are able 
to interact with the potassium channel TREK-1 (TWIK-related K
+
 channel 1).  
TREK-1 is a mechano-sensitive member of the two-pore domain potassium channel (K2P) family, 
which consists of 6 subfamilies: TWIK, TREK, TASK, TALK, THIK, and TRESK channels (Enyedi and 
Czirjak 2010). All of these channels function as a dimer of two subunits each showing the 
arrangement of two pore-forming units, flanked by two transmembrane helices. TREK-1 is mainly 
regulated via its intracellular localised carboxyl terminus by stimuli including membrane stretch, 
intracellular pH, temperature, phosphorylation or protein-protein interactions (reviewed in (Honore 
2007)). Many of these regulatory mechanisms are mediated by the so-called post-M4 regulatory 
region, which is part of the C-terminus of TREK-1. The post-M4 regulatory region also contains the 
interaction site for AKAP150 (A kinase anchoring protein 150). Binding of AKAP150 changes the 
conductivity of TREK-1. Furthermore, it modulates inhibition of the channel via Gs and Gq-coupled 
receptor signalling, with an acceleration of the Gs transduced inhibition and an increase of inhibition 
via Gq-coupled receptors (Sandoz et al. 2006). Another TREK-1 interacting protein is Mtap2 
(Microtubule-associated protein 2), which is involved in the microtubule-dependent transport of the 
channel to the plasma membrane. Mtap2 and AKAP150 can bind to TREK-1 simultaneously and 
modulate the channel synergistically (Sandoz et al. 2008). Another interaction partner, which promotes 
surface localisation and whole-cell currents of TREK-1, is ß-COP. This protein is part of the COPI 
complex and involved in vesicular transport. Interestingly, ß-COP1 protein interaction is not mediated 
by the C-terminus of TREK-1 but by its N-terminus (Kim et al. 2010). 
TREK-1 is predominantly expressed in neurons, but also in other cell types like smooth muscle cells, 
osteoblasts, tenocytes, odontoblasts, and many more others (Koh et al. 2001; Gardener et al. 2004; 
Bryan et al. 2006; Hughes et al. 2006; Honore 2007; Magra et al. 2007; Magloire et al. 2008). 
In the heart, TREK-1 is expressed in endocardium and myocardium (Liu and Saint 2004; Kelly et al. 
2006). Expression levels of TREK-1 in the atria are higher than in the ventricles (McGrath and de Bold 
2009). By immunostaining of ventricular cardiomyocytes TREK-1 has been observed in longitudinal 
stripes at the cell surface (Terrenoire et al. 2001; Tan et al. 2002; Niu and Sachs 2003; Xian Tao et al. 
2006). In rats, expression is up-regulated in hypertrophic hearts and upon acute mechanically 
stretching based on a Langendorff perfusion approach (Cheng et al. 2006; Zhao et al. 2007). It is 
believed that a main function of TREK-1 in the heart is being a stretch sensor. Furthermore, a role in 
atrial natriuretic peptide (ANP) secretion has been suggested (McGrath and de Bold 2009).  
Trek-1 null mutants in mice have a normal life span, they are fertile, and no obvious morphological 
changes of heart, lung, or the brain were reported. However, a couple of neurological alterations could 
be observed in these animals, e.g. a reduced sensitivity towards volatile anaesthetics, changes in pain 
perception, and a reduced susceptibility to depression and epilepsy. Furthermore, Trek-1
-/- 
mice show 
a higher sensitivity to central nervous ischemia (Heurteaux et al. 2004; Alloui et al. 2006; Heurteaux et 
al. 2006).  
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Using Xenopus oocytes as heterologous expression system, TREK-1 has been identified as 
interaction partner of Popdc1. Co-expression of both Popdc1 and TREK-1 results in a current, which is 
about 2-fold higher than the current when TREK-1 is expressed alone. This interaction is specific for 
TREK-1 as conductivity of the closely related TASK-1 channel is not enhanced by Popdc1. Physical 
interaction has been shown by a GST pull-down approach demonstrating specific binding of TREK-1 
to the C-terminus of Popdc1. Similarly, to Popdc1, also in the presence of Popdc2 or -3 TREK-1 
current is increased about 2-fold in frog oocytes indicating that all three members of the Popdc family 
are interacting with TREK-1 Thus, TREK-1 is the only protein so far, which has been identified as 
protein interaction partner for Popdc2 and -3. The increase in TREK-1 conductivity is accompanied by 
an about 2-fold higher membrane localisation of TREK-1. It is therefore believed that Popdc proteins 
modulate TREK-1 trafficking. Importantly, in the presence of theophylline, which increases cAMP 
levels by blocking the cAMP-degrading phosphodiesterases (PDEs), the effect of Popdc 
co-expression is abolished and no increase in TREK-1 conductivity is observed anymore compared to 
the current when TREK-1 is expressed alone. Moreover, in a bi-molecular FRET sensor using 
Popdc1-CFP and YFP-TREK-1, increasing of cAMP levels results in an immediate change in FRET 
ratio independent of PKA activity. However, the effect of this instantaneous conformational change of 
the Popdc-TREK-1 complex on channel properties is currently not known. Taken together, Popdc 
proteins interact with TREK-1 and modulate this K2P channel in a cAMP-dependent manner with a 
two-stage response, an immediate reaction of the conformational change and a longer-term regulation 
of TREK-1 trafficking. Thus, it is believed that Popdc proteins modulate the resting membrane 
potential and thereby the excitability of cardiac myocytes. The physiological impact thereof, however, 
has not been determined yet (Boukens and Christoffels 2012; Froese et al. 2012). 
 
 
1.4.4.6 Popdc proteins in the heart  
 
Depletion of Popdc1 or -2 in mouse and zebrafish model systems results in severe cardiac 
arrhythmias (Froese et al. 2012; Kirchmaier et al. 2012).    
In Popdc1
-/-
 as well as Popdc2
-/-
 mice, the presence of stress-induced sinus bradycardia has been 
reported by Froese et al. Null mutants do not differ in their heart rates from their wildtype littermates at 
rest, but when they are subjected to either physical (swimming) or mental (hot air jet) stress, heart 
rates of the null mutants are significantly lower compared to wildtype animals. This bradycardia is 
characterised by an increased presence of sinus pauses (temporary loss of sinus node activity) 
occurring during and after stress, which results in a high variability in the beating rate (Figure 1.5).  
A similar effect has been observed after pharmacological stimulation of ß-adrenergic signalling by 
isoproterenol injection. However, no difference between mutants and wildtype animals has been 
described after administration of carbachol, which activates acetylcholine receptors and thereby 
mimics the effect of parasympathetic stimulation. Carbachol treatment leads to a similar drop in heart 
rate in both wildtype and mutants suggesting that parasympathetic stimulation is not altered. In both 
mouse models the bradycardia develops in an age-dependent manner. Young animals (3 months old) 
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do not have sinus bradycardia, but the older the animals grow, the more severe the phenotype 
becomes. Also in isolated hearts, more sinus pauses occur in Popdc1
-/-
 and Popdc2
-/-
 mice, showing 
that the bradycardia is not due to impaired function of the autonomic nervous system. No functional 
alterations can be detected with regard to the atrioventricuar (AV) node. The working myocardium 
seems not to be affected in younger Popdc null mutant mice, however, in very old Popdc2
-/- 
mice 
ventricular fibrillation occurs after ß-adrenergic stimulation. Recent studies on Popdc1/Popdc2 double 
null mutants also show a functional impairment of the working myocardium as atrial fibrillation, 
polymorphic ventricular tachycardia, and extrasystoles have been observed in addition to sinus 
pauses. In isolated ventricular myocytes, ß-adrenergic stimulation leads to 
delayed-after-depolarisations (DADs), spontaneously generated action potentials, and shortening of 
action potential durations. In addition, AV block has been observed in the double null mutants, 
showing that the AVN is affected as well (Simrick et al. 2012; Simrick et al. 2013).  
 
 
Figure 1.5: Age-dependent stress-induced sinus bradycardia in Popdc1
-/-
 and Popdc2
-/-
 mice 
Heart rate analyses of 8 month old wildtype and Popdc1
-/-
 (A) or Popdc2
-/-
 mice (C) before (green), 
during (blue), and after swim stress (red) show maladaptation of the mutants to stress. Number of 
sinus pauses in wildtype and Popdc1
-/-
 (B) or Popdc2
-/-
 mice (D) during a 30 minute period after swim 
stress show an age-dependent increase in the null mutants (panels modified from (Froese et al. 
2012)). 
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In addition to the electrophysiological phenotype, degeneration of the primary pacemaker structure in 
the heart, the sinoatrial node (SAN) has been described in older Popdc1
-/-
 and Popdc2
-/-
 mice  
(8 months) (Froese et al. 2012). Interestingly, this loss of tissue is more prominent in the inferior part 
of the SAN, which is particularly important for pacemaking after adrenergic stimulation (Opthof 1988). 
Furthermore, single SAN cells of null mutants have less cellular extensions and therefore the 
remaining SAN tissue has a more compact appearance.  
These findings are reminiscent to the sick sinus syndrome (SSS) in humans, which affects mainly the 
elderly. Similar to the observed phenotypes in Popdc null mutants, hearts of SSS patients have 
difficulties to adapt beating frequency to physiological demands (Rodriguez and Schocken 1990). It 
has therefore been hypothesised that in some SSS patients the disease is caused by abnormal Popdc 
gene expression or function. However, little is known about Popdc proteins in human diseases. It has 
recently been reported, that mRNAs of POPDC1 and -3, and to a lesser extent also of POPDC2 are 
lower in failing compared to normal control hearts, but the degree of down-regulation varies from 
patient to patient. The reduction of POPDC1 in failing hearts and the patient-to-patient variations in 
expression have also been seen on the protein level using Western blot analysis. It is noteworthy that 
no link between POPDC expression levels and aetiology or severity of heart failure could be 
established (Gingold-Belfer et al. 2011).  
In zebrafish, morpholino oligonucleotide-mediated knockdown of popdc2 results in misshaped heart 
chambers with reduced myofibrillar content and a lack of trabeculation, and embryonic heart failure 
characterised by large pericardial oedema. Also heart looping is affected. When lower morpholino 
concentrations are used, the morphological abnormalities are reduced, however, a bradyarrhythmic 
phenotype with cardiac conduction defects and a 3:1 or 2:1 atrio/ventricular rhythm is observed 
between 4 and 7 days post fertilisation (dpf). With the help of SPIM (Single Plane Illumination 
Microscopy) microscopy, analysis of Ca
2+
 transients in different compartments of the heart of a 
transgenic reporter line (Tg(cmlc2:gCaMP)s878) expressing a fluorescent Ca
2+
 sensor in the 
myocardium has been carried out to study cardiac conduction in more detail. The morphants show 
high variability in heart rhythms in both atrium and ventricle, and irregular action potential durations. 
Particularly affected is cardiac repolarisation. Similar to null mutants in mice, some embryos display a 
sinoatrial block and a dramatic slowing of the heart rate. Furthermore, also partial or complete AV 
blocks have been reported in the morphants. By confocal imaging of the heart, structural alterations 
like aberrant myocyte morphology in the atrium and AV canal or defective valves have been ruled out 
as causing the electrophysiological phenotypes. At present it is not clear whether the observed defects 
are due to a role of popdc2 in the development of cardiac conduction tissue or to a direct function of 
the gene in action potential generation (Kirchmaier et al. 2012). 
 
 
1.4.4.7 Popdc proteins in skeletal muscle 
 
All three members of the Popdc family are abundantly expressed in skeletal muscle, and therefore, 
muscular phenotypes caused by knockout or knockdown have been analysed in more detail.  
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In zebrafish, morpholino oligonucleotide-mediated knockdown of popdc2 results in aberrant tail 
morphology with abnormal myotomal segment boundaries. Furthermore, alignment of myofibrils is 
disturbed. In addition, the presence of ruptured myofibrils has been reported. Moreover, areas without 
myofibrils can be seen. The level of disorganisation increases with the age of the embryos. 
Interestingly, specification of fibre types with regard to slow and fast-twitching fibres is not altered in 
popdc2 morphants, and both fibre types are affected by the knockdown. In addition, from 24dpf on, 
myotendinous junctions are severely affected. Myotomal borders are abnormally thin and 
disorganised, and proteins important for cell-matrix adhesion like the Focal Adhesion Kinase and 
vinculin are expressed discontinuously in the junction region. In addition to these phenotypes 
observed in tail musculature, craniofacial muscles are smaller and abnormally shaped or even missing 
(Kirchmaier et al. 2012).  
Also upon knockdown of popdc1 a muscular phenotype is observed (Kar Lai Poon, personal 
communication). In contrast to the developmental defects seen in zebrafish morphants, null mutants of 
Popdc1 in the mouse develop normally. However, a reduced regenerative capacity of muscles devoid 
of Popdc1 has been observed. When hindlimb muscles (Mm gastrocnemius and soleus) of Popdc1
+/-
 
and Popdc1
-/-
 mice are injected with the snake venom Cardiotoxin, which causes muscle damage and 
subsequent regeneration, muscles of heterozygous mice regenerate much faster than that of 
homozygous animals. The damage is fully repaired 10 days after Cardiotoxin injection in the 
heterozygous, whereas in the null mutants, the injury is clearly visible at this time point. Moreover, the 
newly formed myotubes are still small in size, and their nuclei are centrally localised, which is 
indicative of not yet fully maturated fibres. Only at day 20 after injection, muscles from Popdc1
-/-
 mice 
are fully regenerated and do not show any difference to the heterozygous muscles. As revealed by 
RT-PCR analysis this delay of regeneration is accompanied by prolonged expression of MyoD, Myf5 
and Myogenin, which are important factors for muscle regeneration (Andree et al. 2002).   
Therefore, in both mouse and zebrafish depletion of Popdc proteins results in myopathies. However, 
the molecular basis of the observed phenotypes has not been established yet. It has been proposed 
that the effect of Popdc1 on cell motility and the interaction with GEFT and Vamp2 and -3 may be 
important (Smith et al. 2008; Hager and Bader 2009; Hager et al. 2010; Kirchmaier et al. 2012). Both 
interacting proteins have been implicated in muscle development and/or regeneration before. GEFT 
promotes regeneration when overexpressed in Cardiotoxin-injured muscle. Likewise, overexpression 
of GEFT in the C2C12 myoblast cell line leads to increased myotube formation (Bryan et al. 2005). 
Moreover, overexpression of the C-terminus of Popdc1 in this cell line inhibits differentiation (Smith et 
al. 2008). Vamp2, which interaction with Popdc1 has recently been demonstrated in a GST pull-down 
assay (Hager et al. 2010), is expressed in quiescent satellite cells and its expression is up-regulated in 
immature myotubes (Tajika et al. 2007), which is at least partially reminiscent to Popdc1. However, in 
contrast to Popdc1, whose expression is strongly up-regulated in isolated and therefore activated 
myoblasts, as demonstrated by increased LacZ activity in the transgenic Popdc1
-/- 
mice, Vamp2 has 
been shown to be down-regulated in proliferating myoblasts. Vamp2 co-localises with markers of 
recycling endosomes, however, not much is known about the role of Vamp2 in skeletal muscle (Tajika 
et al. 2010). Consequently, the role of Popdc1-Vamp2 interaction in this context is not clear at present.  
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1.5 Aims of this thesis 
 
Since the first publications reporting the identification and isolation of Popdc genes in 1999 and 2000, 
respectively, the understanding of the role of these proteins has increased immensely. However, most 
knowledge has been obtained for the epithelial function of Popdc1, the best studied Popdc family 
member. Also in the heart and skeletal muscle, which are the main expression domains of Popdc 
proteins, important functions of Popdc proteins have been revealed, particularly with the help of in vivo 
studies using mice and zebrafish as model organisms. However, not much is known about the 
underlying mechanisms of the cardiac and skeletal muscle phenotypes (see above).  
 
Recently, Popdc proteins have been established as novel cAMP binding proteins and interaction of the 
K2P channel TREK-1 with all three Popdc protein family members has been demonstrated. However, 
the observed phenotypes such as stress-induced bradycardia or the delay in skeletal muscle 
regeneration cannot be explained on the basis of interaction with TREK-1 alone or any other of the 
other previously identified partners, i.e. ZO-1, GEFT, Vamp2/3, NDRG4, and aPKC (see above). It has 
therefore been hypothesised that additional interaction partners may exist (Boukens and Christoffels 
2012; Froese et al. 2012; Schindler et al. 2012). Therefore, it was  intended to analyse additional 
Popdc interacting proteins in striated muscle tissue in order to reveal the functional networks Popdc 
proteins are involved in these tissues. It was also intended to analyse some of the novel interactions 
with regard to binding sites.  
 
Only recently, mutations in POPDC1 and POPDC2 have been identified in several patients suffering 
from cardiomyopathy, cardiac conduction defects, and/or muscular dystrophy. Aiming at unravelling 
the underlying pathomechanism, some of these mutations should be tested in vitro with regard to 
important properties of these proteins like cAMP binding and homodimerisation. 
 
Another project of this thesis is to get deeper insight into the role of Popdc proteins in skeletal muscle. 
It was shown previously that Popdc1-LacZ expression in activated murine satellite cells is 
up-regulated (Andree et al. 2002). However, nothing was known about the properties of Popdc 
proteins in this context, e.g. with regard to subcellular localisation. Moreover, since skeletal muscle 
regeneration has been shown to be impaired in Popdc1 null mutants, the regenerative capacity of 
Popdc2
-/-
 muscle was investigated.  
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2 METHODS 
 
2.1 Molecular biological methods 
 
2.1.1 Principles of molecular cloning 
 
Molecular cloning is the process to produce recombinant DNA. In this thesis it was used to generate 
the different plasmid constructs used to express recombinant proteins in eukaryotic and bacterial cells. 
These constructs were made up of coding DNA sequences of the proteins of interest, i.e. the protein, 
which was going to be expressed, for example Popdc1, inserted into an expression vector. Expression 
vectors usually contain information, which is necessary for propagation in bacteria cells. There are 
also sequences e.g. Kozak sequences, which are important for translation of the protein of interest. 
Some expression vectors have also sequences coding for peptides or proteins, which were aimed to 
be fused N- or C-terminally to the protein of interest, i.e. tags like GFP (Green Fluorescent Protein). It 
is therefore important to make sure that the insert is cloned in frame with those tags. This was 
accomplished by choosing suitable restriction endonucleases, with which both vector and insert DNAs 
were digested to generate compatible ends, which allowed vector and insert to be combined.  
Most vector plasmids contain elements called multiple cloning sites (MCS). These are DNA 
sequences where recognition sequences for several restriction endonucleases are accumulated. If the 
insert could not be cloned in frame by cutting out the sequence from one vector and putting it into 
another by using one of the enzymes represented in the MCS, recognition sites for appropriate 
enzymes had to be added by polymerase chain reaction (PCR). PCR was also useful to make 
constructs for mutated proteins (2.1.2). The respective PCR product was precipitated as delineated in 
chapter 2.1.3 and, just as the vector, restriction enzyme-digested (2.1.4) to obtain compatible ends. 
Both digested PCR product and vector DNA were subjected to agarose gel electrophoresis (2.1.5) and 
purification by gel extraction (2.1.6) to remove the restriction enzymes. This was particularly important 
when the enzyme could not be heat-inactivated. With the help of T4 DNA Ligase, the PCR fragment 
was cloned into the vector by fusing both insert and vector DNAs. The setup of this reaction is detailed 
in chapter 2.1.7. The ligated constructs were transformed into chemically competent E.coli bacteria 
cells (2.1.8). Single colonies were selected and propagated. From these clones, plasmid DNA was 
isolated (2.1.9). By restriction enzyme digest and sequencing (2.1.11) of the respective plasmid DNA, 
clones were identified harbouring the correct constructs and safely stored as glycerol stocks at -80°C 
(2.1.12).  
 
 
 
2 Methods 42 
2.1.2 Polymerase chain reaction (PCR) 
 
2.1.2.1 Standard PCR 
 
Phusion™ polymerase (Thermo Scientific, #F-530) was utilised to amplify DNA fragments used for 
cloning. Phusion polymerase is a proof reading polymerase with high fidelity, so there is a low risk of 
incorporating undesired mutations via the PCR (polymerase chain reaction) reaction. The PCR 
reaction setup is detailed in Table 2.1.  
 
 
Table 2.1: PCR reaction setup 
Reagent Volume [µl] 
5x Phusion
 
HF buffer  10 
dNTP mix; c= 2.5nM each 4 
Primer (forward); c = 10 pm/µl 2.5 
Primer (reverse); c = 10 pm/µl 2.5 
Template DNA
 
1 (1-10ng) 
Phusion Polymerase (2U/µl) 0.5 
 ad 50µl H2O 
 
 
PCR reaction was performed using the T3000 Thermocycler from Biometra. Cycle conditions are 
listed in Table 2.2. 
 
 
Table 2.2: PCR cycling conditions 
Step Temperature Time N(cycles) 
Initial Denaturing 98°C 30sec 1 
Denaturing 98°C 5sec 
35 
Annealing primer-specific 15sec 
Elongation 72°C 
amplificate-specific (elongation 
rate: 30sec/1kb) 
Final Elongation 72°C 5min 1 
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2.1.2.2 Overlap-extension PCR 
 
In this work, overlap-extension (OE-) PCR was used to generate the Popdc3c constructs and the 
POPDC1-POPDC2 chimeras. 
 
 
 
Figure 2.1: Principle of OE-PCR 
Details are outlined in the text. 
 
 
The principle of OE-PCR is shown in Figure 2.1:. Basically, OE-PCR consists of a series of reactions 
as described in chapter 2.1.2.1. The first two reactions were set up using primer pairs P1/P2 and 
P3/P4 in order to amplify the two DNA fragments which should be fused. These reactions did not differ 
from the procedure described for the standard PCR (2.1.2.1). The samples were then purified by 
agarose gel electrophoresis (2.1.5) followed by gel elution of the amplified DNA (2.1.6). These steps 
were particularly important to remove the primers used for the first two PCR reactions. The so purified 
DNA fragments were used for the extension step. In this reaction both fragments were fused together, 
and the single strands were filled up. This resulted in a double-stranded product, which was used as 
the template for the fourth reaction using primer pair P1/P4. The extension reaction was set up as 
shown in Table 2.3.  
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Table 2.3: Setup for OE-PCR reaction 
Reagent Volume [µl] 
5x Phusion
 
HF buffer  10 
dNTP mix; c= 2.5nM each 4 
fragment A (gel-purified) 3 
fragment B (gel-purified) 3 
Phusion Polymerase (2U/µl) 0.5 
 ad 50µl H2O 
 
 
The cycle conditions were the same as detailed in Table 2.2, but only 10 cycles were performed. 
Then, primer P1 and P4 were added (2.5µl of 10pmol/µl each) and in 25 more cycles the final DNA 
fragment was generated, which was used for cloning (see Figure 2.1). 
 
 
2.1.2.3 Site-directed mutagenesis 
 
Point mutations were introduced into human POPDC1 cDNA by site-directed mutagenesis. This is a 
PCR-based method, by which the entire plasmid containing the cDNA was amplified. Both of the two 
primers were harbouring the desired point mutations, and they were designed to anneal to the same 
sequence on opposite strands of the parental plasmid DNA. The mutagenic primers (Table 2.4) were 
designed using the QuikChange
®
 Primer Design Program (Agilent Technologies). They were obtained 
from Invitrogen in HPLC-purified quality to enhance mutagenesis efficiency.  
 
 
Table 2.4: Mutagenesis primers 
construct primer 
POPDC1[R172H] (g515a) 
sense: 5'-taaaacctcagttgatgaccatctgagtattctcttgaagg-3' 
antisense: 5'-ccttcaagagaatactcagatggtcatcaactgaggtttta-3’ 
POPDC1[S201F] (c602t) 
sense: 5'-aacatttacccctgtgcctttatagattttcctgaatttagatcaac-3' 
antisense: 5'-gttgatctaaattcaggaaaatctataaaggcacaggggtaaatgtt-3' 
POPDC1[L281P] (t842c) 
sense: 5'-gctggaacatcagcccagcctctgcacac-3' 
antisense: 5'-gtgtgcagaggctgggctgatgttccagc-3' 
Mutagenised nucleotides are underlined. 
 
 
The reaction was set up in quadruplicate according to Table 2.5.  
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Table 2.5: Reaction setup for site-directed mutagenesis PCR 
Reagent Volume [µl] 
H2O 28 
5x Phusion
 
HF buffer  10 
dNTP mix; c= 2.5nM each 4 
Primer (sense); c = 10 pm/µl 2.5 
Primer (antisense); c = 10 pm/µl 2.5 
Template plasmid 
 
1 (10-25pg) 
DMSO (Sigma-Aldrich, #D9170) 1.5 
Phusion Polymerase (2U/µl) 0.5 
 
 
Mutagenised DNA was synthesised in a Biometra T3000 Thermocycler as outlined in Table 2.6. When 
cycling was finished, the samples were precipitated (2.1.3) and the pelletised DNA was resuspended 
in 25µl H2O. By the addition of 3µl NEBuffer 4 and 2µl DpnI (NEB, #R0176), digestion of the parental 
DNA was accomplished after 2h incubation at 37°C. Thereafter the enzyme was inactivated at 80°C 
for 20min. 5µl of the sample were used to transform chemically competent XL1 blue cells (2.1.8). DpnI 
only recognises adenomethylated DNA. DNA synthesised by PCR is not methylated, however, 
plasmid DNA propagated in and isolated from XL1 blue (dam
+
) cells like the parental template is. 
Therefore, only the parental DNA is targeted. DpnI recognition sites are relatively frequently present, 
so that effective degradation could be obtained. This prevented the re-transformation of parental 
non-mutagenised DNA into XL1 blue cells and thus increased mutagenesis efficiency dramatically, i.e. 
the likelihood to pick a bacteria clone having the mutagenised plasmid. Plasmid DNA was isolated 
from single colonies (2.1.9). The insert was fully sequenced to make sure that it contained the desired 
mutation and that only this mutation was present and no other one was introduced (2.1.11). Clones 
which took up plasmids meeting these criteria were kept as glycerol stocks (2.1.12). The mutated DNA 
was used for subcloning into the different vectors (2.1.1).  
 
 
Table 2.6: Cycling conditions for site-directed mutagenesis 
Step Temperature Time N(cycles) 
Initial Denaturing 98°C 30sec 1 
Denaturing 98°C 10sec 
20 
Annealing 60°C 30sec 
Elongation 72°C 
template-specific (elongation 
rate: 30sec/1kb) 
Final Elongation 72°C 8min 1 
 
 
2 Methods 46 
2.1.3 Precipitation of DNA 
 
200µl PCR product were vigorously mixed with 20µl of a 3M sodium acetate solution, pH 5.2. 
Subsequently, 500µl ice-cold ethanol (EtOH) were added and the tube vortexed again. The sample 
was then incubated at -80°C for 20 minutes and centrifuged at >16,000 x g at 4°C for 20-30 minutes. 
The supernatant was discarded and the pellet was washed twice with 70% EtOH. To remove all traces 
of EtOH, the pellet was air-dried and resuspended in 36µl H2O, and subjected to restriction 
endonuclease digestion (2.1.4).  
 
 
2.1.4 Restriction endonuclease digestion 
 
Complementary ends for ligation reactions were performed by restriction endonuclease digestion 
using enzymes and buffers from New England BioLabs. Digestion reactions were set up as detailed in 
Table 2.7. 
 
Table 2.7: Setup for restriction endonuclease digestion 
Reagent Volume [µl] 
 control digest for cloning 
10x buffer as recommended by manufacturer 2 5 
10x BSA 2 5 
DNA 5 30 
enzyme 0.5 (each) 2 (each) 
 ad 20µl H2O ad 50µl H2O 
 
If only one restriction enzyme was used in the digestion setup, the vector DNA was subsequently 
dephosphorylated to prevent it from re-ligation with itself in the ligation reaction. For this purpose 1/10 
volume of 10x buffer for Antarctic phosphatase were added to the digestion mix along with 1µl 
Antarctic phosphatase (NEB, #M0289, c = 5,000U/ml) and incubated for another hour at 37°C. The 
phosphatase was then heat inactivated at 65°C for 20 minutes.   
The digestion samples were subsequently subjected to agarose gel electrophoresis and gel extraction 
(2.1.6). 
For control digest 5µl of DNA obtained by DNA mini-preparation using the alkaline lysis (2.1.9.1) 
method were digested for at least 2 hours using the setup displayed in Table 2.7. 
After digestion samples were subjected to agarose gel electrophoresis and DNA fragments were 
visualised under UV light exposure (2.1.5). 
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2.1.5 Agarose gel electrophoresis 
 
     
50x TAE: 242g Tris 
57.1ml glacial acetic acid 
100ml 0.5M EDTA, pH8.0 
ad 1l H2O 
1x TAE:  20ml 10x TAE  
ad 1l H2O 
 
     
1% agarose gel:  
 
0.5g agarose 
ad 50ml 1x TAE 
 
 6x sample 
buffer: 
2.5g Ficoll type 400 
Orange G 
ad 10ml H2O 
     
In order to analyse restriction endonuclease digestion, agarose gel electrophoresis was performed. 
Therefore, 0.5g agarose (Roth, #2267.3) were heated in a microwave in 50ml 1x TAE buffer until 
agarose was dissolved completely resulting in a 1% agarose solution. The solution was cooled down 
on ice before 5µl ethidium bromide were added. Ethidium bromide intercalates into DNA strands and 
can then be visualised by UV light. After addition of ethidium bromide, the solution was poured into a 
gel tray containing an appropriate comb. As soon as the agarose solution had formed a gel, the gel 
tray was put into an electrophoresis chamber filled with TAE buffer and the comb was removed. 
Subsequently, samples were loaded onto the gel along with a 10kb DNA ladder (GeneRuler™, 
Thermo Scientific, #SM0332). To separate the negatively charged DNA fragments in an electric field, 
a constant potential of 120V was applied. DNA fragments were visualised using a UV transilluminator 
(Syngene).    
 
 
2.1.6 Extraction of DNA fragments from agarose gels  
 
To extract and purify DNA from agarose gels the QIAGEN QIAquick
®
 Gel Extraction Kit (#28706) was 
used according to the manufacturer’s protocol. Briefly, DNA bands separated by agarose gel 
electrophoresis (2.1.5) and visualised on an UV table were excised using a razor blade, taking care to 
keep exposure to UV light as low as possible to minimise damage of the DNA, which would lead to a 
reduced cloning efficiency. After excision, agarose bits were transferred to a microcentrifuge tube and 
weighed. 3 volumes per 1 gel volume of buffer QG were added and the agarose was melted at 50°C 
on a thermomixer facilitated by slight shaking. When the agarose was dissolved completely (after 
~10 minutes), 1 gel volume of isopropanol was added. After vortexing, the sample was applied to a 
QIAquick column and centrifuged for 1 minute at 16,000 x g allowing the DNA to bind to the silica 
matrix of the column. Subsequently, the flow-through was discarded and 500µl of fresh buffer QG 
were added to the column to remove all traces of agarose. After centrifugation as before, the 
flow-through was discarded again and the column was washed with 750µl buffer PE to remove 
contaminating salts. To improve the efficiency of this step, the column was incubated for 3 minutes in 
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buffer PE before the buffer was removed by centrifugation (16,000 x g, 1min). To remove any residual 
ethanol, which is a component of buffer PE, the column was centrifuged again at 16,000 x g for 
1 minute. Then, the column was placed into a fresh 1.5ml tube and 50µl of H2O was added on the top 
of the QIAquick column membrane. After 1 minute of incubation DNA was eluted by centrifugation for 
1 minute at 16,000 x g. Eluted DNA fragments were either used immediately for ligation reaction or 
stored at -20° until required. 
 
 
2.1.7 Ligation reaction 
 
T4 DNA ligase purchased from Promega (#M180A) was used to carry out ligation of digested vector 
and inserts. T4 DNA ligase is an enzyme that catalyses the connection of DNA between the 
5’-phosphate and the 3’-hydroxyl groups of adjacent nucleotides.  
 
The ligation reaction (Table 2.8) was set up and incubated at RT for at least 4 hours, before 
chemically competent XL1 blue Escherichia (E.) coli cells were transformed as described in chapter 
2.1.8.  
 
 
Table 2.8: Ligation reaction setup 
Reagent Volume 
 Mix1 Mix2 
10x T4 ligase buffer  1µl 1µl 
vector DNA (digested)  1µl 1µl 
insert DNA  1µl 3µl 
T4 DNA ligase (3U/µl) 1µl 1µl 
H2O
 
6µl  4µl 
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2.1.8 Generation and transformation of competent Escherichia coli bacterial 
cells 
 
2.1.8.1 Generation of competent Escherichia coli cells 
 
LB medium: 10g NaCl 
10g peptone 
  5g yeast extract 
ad 1l H2O 
  pH 7.5 
   
     
Transformation 
buffer TfbI: 
100mM RbCl 
50mM MnCl2 
30mM potassium acetate 
10mM CaCl2 
15% (v/v) glycerol 
 pH 5.8 (0.1M acetic acid) 
  
     
Transformation 
buffer TfbII: 
10mM RbCl 
10mM MOPS 
30mM potassium acetate 
75mM CaCl2 
15% (v/v) glycerol 
 pH 6.5 (0.1M NaOH) 
  
     
1µl of an Escherichia (E.) coli strain glycerol stock was seeded in 3ml LB medium and grown overnight 
at 37°C under vigorous shaking. In the next morning, 1ml of this culture was inoculated in 100ml fresh 
LB medium and grown under shaking at 37°C. The growth was controlled by taking out 0.5ml of the 
bacteria suspension, diluting it with 0.5ml LB medium and measuring the optical density at a 
wavelength of 600nm (= an OD600) using the BioPhotometer plus from Eppendorf. When OD600 of 0.5 
was reached indicating the bacteria to be in the logarithmic growth phase, which results in the highest 
transformation competency, the culture flask was put on ice for 15 minutes to cool down the 
suspension and thereby slowing down bacterial growth before cells were pelleted at 1,500 x g for 
5 minutes at 4°C. The supernatant was discarded and cells were resuspended in 40ml ice-cold TfbI 
buffer. After 15 minutes incubation on ice cells were centrifuged again as before. Again, the 
supernatant was discarded, and the cell pellet was resuspended in 4ml ice-cold buffer TfbII. After 
incubation on ice for another 15 minutes, 100µl aliquots of the suspension were transferred into sterile 
1.5ml tubes, snap-frozen in liquid nitrogen, and stored at -80°C until required for transformation. 
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2.1.8.2 Transformation of competent bacterial cells 
 
An aliquot of 100µl chemical competent E.coli cells was thawed on ice before 5µl of ligation products 
or 1µl of purified plasmid DNA was added. To give the cells time to uptake plasmid DNA they were 
incubated on ice for 20-30 minutes. Following incubation, the cells were heated at 42°C for 1 minute in 
a thermomixer (Eppendorf). After this step, the cells were cooled down on ice for 2-3 minutes. Then 
500µl LB medium without antibiotics were added and the vial was incubated on a thermomixer at 37°C 
for 1 hour under vigorous shaking. During this time, the bacteria express the antibiotic resistance gene 
encoded by the plasmid, e.g. ß-lactamase, which mediates resistance to ampicillin, and allows positive 
selection for transformed cells. After 1 hour, the vial containing the bacteria was centrifuged at 
1,000 x g for 1 minute, about 500µl of the supernatant were removed, and the bacteria pellet was 
resuspended in the remaining medium (~100µl) and transferred to LB-agar plates, which have been 
made up from 15g agar-agar dissolved in 1l LB medium, supplemented with the appropriate 
antibiotic(s) (Table 2.9). The plate was incubated overnight at 37°C. The plate was put upside down to 
prevent forming condensation water to flush away the colonies. Only cells expressing resistance 
gene(s) against the antibiotic(s) were able to grow, thereby selecting for transformed vs. 
non-transformed cells. 
  
 
Table 2.9: List of antibiotics added to nutrition media 
antibiotic final concentration 
ampicillin (Amp) 100µg/ml 
kanamycin (Kan) 50µg/ml 
tetracyclin (Tet) 15µg/ml 
chloramphenicol (Cam) 34µg/ml 
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2.1.9 Purification of plasmid DNA 
 
2.1.9.1 Small-scale purification (mini-prep) employing the alkaline lysis method 
 
     
Lysis buffer: 0.2M NaOH 
1% (w/v) SDS  
   
     
     
GET buffer: 50mM glucose 
10mM EDTA 
25mM Tris-HCl, pH 8.0 
10µg/ml RNase 
 Precipitation 
buffer: 
60ml 5M potassium acetate 
11.5ml acetic acid 
28.5ml H2O 
     
A single colony or 1µl of a glycerol stock was inoculated in 3mL LB medium (+ antibiotics, Table 2.9). 
The culture was grown at 37°C overnight under vigorous shaking to ensure proper oxygenation of the 
culture. The bacteria were harvested by centrifugation for 1 minute at 6,000 x g. The supernatant was 
discarded and the bacteria pellet was resuspended in 100µl ice-cold GET buffer. Bacteria cells were 
lysed by adding 200µl lysis buffer, which is a mixture of the detergent SDS, which solubilises proteins 
and phospholipids of the cell membrane, and NaOH, which helps to denature proteins and DNA. By 
adding 150µl precipitation buffer, cellular proteins and genomic DNA are precipitated by the high 
concentration of salts in the presence of SDS. Potassium acetate neutralises the alkaline pH and 
therefore facilitates small circular plasmid DNA to re-nature, which therefore remains solubilised and is 
not precipitated in the next step. To get rid of the precipitate, the samples were centrifuged at 
maximum speed (>16,000 x g) for 15 minutes. To ensure that all traces of genomic DNA had been 
removed, the supernatant was transferred to a fresh tube and centrifuged again at maximum speed 
(>16,000 x g) for 10 minutes. In a fresh tube, 900µl isopropanol were added to the supernatant 
causing a precipitation of the plasmid DNA, which subsequently was recovered by centrifugation at 
maximum speed (> 16,000 x g) for 15 minutes. The supernatant was removed, leaving the plasmid 
DNA pellet back in the tube, which was then washed with 1ml 70% (v/v) ethanol (EtOH). This wash 
step was necessary to remove co-precipitated salts and the isopropanol, which is less volatile than 
ethanol and would therefore increase the time of drying the plasmid DNA pellet. After an additional 
centrifugation step, all traces of ethanol were removed and the pellet was air-dried, before it was 
resuspended in 50µl of H2O. The drying step is indispensable as traces of ethanol would impair 
enzymes, e.g. those used for restriction digestion. 
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2.1.9.2 Small-scale purification (mini-prep) using the QIAGEN QIAprep Spin Mini Kit 
 
If very clean plasmid DNA was required, e.g. for sequencing, the QIAGEN QIAprep
 
 Spin Mini Kit 
(#27106) was used for purification according to the manufacturer’s instructions. The principal is very 
similar to the alkaline lysis method (2.1.9.1). However, instead of precipitating the plasmid DNA with 
isopropanol, the DNA is purified with a column. Briefly, 3ml bacteria culture were harvested by 
centrifugation for 1 minute at 6,000 x g. The bacteria were resuspended in 250µl buffer P1 and lysed 
by adding of 250µl P2. After addition of 350µl N3 buffer, the solution was centrifuged twice at 
maximum speed (> 16,000 x g) for 10-15 minutes to remove precipitated genomic DNA and debris. 
The supernatant was applied to a QIAprep spin column and centrifuged for 1 minute at >16,000 x g to 
allow the plasmid DNA to bind to the silica matrix of the column. The flow-through was discarded and 
the column was washed using 0.5ml buffer PB followed by centrifugation for 1 minute at >16,000 x g. 
The flow-through after PB washing was discarded and 750µl buffer PE was added to the column to 
remove contaminating salts from the plasmid DNA. The column was centrifuged twice in order to 
remove all traces of buffer PE (ethanol), and the flow-through was discarded. Subsequently, the spin 
column was transferred to a fresh 1.5ml tube, and DNA was eluted by adding of 50µl H2O, incubating 
for 1 minute and centrifugation for another minute. The DNA was stored at -20°C until further use. 
 
 
2.1.9.3 Large-scale purification of plasmid DNA (midi-prep) 
 
To obtain larger amounts of highly purified plasmid DNA for transfection the QIAGEN Plasmid Midi 
Kit (#12145) was used according to the manufacturer’s instructions. 1µl of a bacterial glycerol stock 
was seeded into 3mL LB medium (+ antibiotics, Table 2.9). The culture was grown at 37°C for about 
8 hours under vigorous shaking before it was inoculated in 100ml of fresh LB broth (+ antibiotics) and 
grown overnight at 37°C on a shaker.  The bacterial cells were harvested by centrifugation at 
1,500 x g for 30 minutes at 4°C and the pellet was either stored at -20°C and later processed further or 
immediately resuspended in 4ml buffer P1. After 5 minutes incubation, cells were lysed adding buffer 
P2 and incubating for 5 minutes. Subsequently, 4ml of pre-chilled buffer P3 were added to the lysate. 
Following an incubation time of 15 minutes on ice, the suspension was centrifuged twice for 
30 minutes at 25,000 x g and 4°C. During the second centrifugation step, a QIAGEN-tip column was 
equilibrated with 4ml buffer QBT before the supernatant containing the plasmid DNA was added to the 
column. When the lysate had entered the column matrix by gravity flow and bound to the resin, the 
column was washed twice with 10ml buffer QC, before the DNA was eluted with 5ml buffer QF into a 
Corex
®
 glass centrifugation tube. The eluted plasmid was then precipitated by adding 3.5ml 
isopropanol. The tubes were vigorously vortexed and centrifuged for 30 minutes at 25,000 x g. The 
supernatant was discarded and the plasmid DNA pellet was washed twice in 1ml of 70% ethanol and 
transferred into a 1.5ml tube. After centrifugation for 5-10 minutes at >16,000 x g, all traces of ethanol 
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were removed and the pellet was air-dried, before the DNA was resuspended in 50-70µl H2O and 
stored at -20° until required. 
 
 
2.1.10  DNA quantification using spectrophotometry 
 
     
TE buffer: 10mM Tris-HCl, pH 8.0 
1mM EDTA 
   
     
2µl DNA solution were diluted in 48µl TE buffer and transferred to a UV light-permeable cuvette 
(UVette). DNA concentration was determined using a UV/Vis photometer (BioPhotometer plus, 
Eppendorf). 50 µl TE buffer were used as reference (blank).  
 
 
2.1.11  Sequencing 
 
To verify the correct sequence of constructs after cloning, DNA was purified with either QIAGEN 
QIAprep
®
 Spin Mini Kit or Plasmid Midi Kit, and the concentration was determined 
spectrophotometrically. 500-600ng DNA were pipetted into a 0.5ml tube together with 3.2pmol 
sequencing primer. The total volume was adjusted to 10µl, before the tubes were sealed and sent to 
GSC Genomics lab in Hammersmith. 
 
 
2.1.12  Preparation of bacteria glycerol stocks 
 
650µl of a bacteria culture (grown overnight) were mixed with 300µl 80% (v/v) glycerol and stored at 
-80°C. 
 
 
2.2 Histology 
 
C57BL/6J wildtype or Popdc mutant mice were sacrificed, and muscle tissue was removed. Muscles 
were quickly rinsed with PBS and then directly embedded in Polyfreeze Tissue Freezing Medium 
(Polysciences, #19636) and frozen in 2-methylbutane, which had been cooled down with dry ice. The 
tissue blocks were then stored at -80°C until further use.  
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With a Leica cryostat (CM1850) tissues were sectioned in 10µm thick slices and mounted on 
SUPERFROST
 
PLUS cover slides (Thermo Scientific, #J1800AMNZ). Sections were air-dried and 
carefully encircled using the ImmEdge pen (Vector Laboratories, #H-4000) to create a hydrophobic 
barrier, which helps to keep minimal volumes of buffers on the tissue slices. 
Subsequently, sections were re-hydrated for 10min in PBS, fixed with 2% PFA (2.4.2) for another 
10min. Then, sections were washed three times for 5min with PBS to remove the PFA, and subjected 
to antibody staining as described in chapter 2.4.3. 
 
 
2.3 Cell culture techniques 
 
     
10x PBS: 80g NaCl 
2g KCl 
14.4g Na2HPO4 ∙ 2H2O 
2g KH2PO4 
ad 1000ml H2O 
 pH 7.4 
 1x PBS:   100ml 10x PBS  
ad 1000ml H2O 
 
     
 
 
2.3.1 Culture of established cell lines 
 
All cell culture procedures were carried out under sterile conditions in a laminar flow safety cabinet. 
 
Growth medium for  
Cos-7, H10, C2C12, and Sol-8 cells:  
 
DMEM (Sigma-Aldrich, #D6429)
 
+ 10% (v/v) FCS 
 
+ 1% (v/v) L-glutamine (200mM) (Sigma-Aldrich, #G7513) 
+ 1% (v/v) penicillin-streptomycin (Sigma-Aldrich, #P0781) 
  
Growth medium for MDCK cells: MEM (Sigma-Aldrich, #M4655)
 
+ 10% (v/v) FCS 
 
+ 4% (v/v) L-glutamine (200mM) 
+ 1% (v/v) penicillin-streptomycin 
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Growth medium for HL-1 cells: Claycomb medium (Sigma-Aldrich, #51800C)
 
+ 10% (v/v) FCS 
 
+ 1% (v/v) L-glutamine (200mM) 
+ 1% (v/v) penicillin-streptomycin 
+ 0.1mM norepinephrine (Sigma-Aldrich, #A0937)
 
  
Differentiation medium for C2C12, 
Sol-8, and primary myoblast cells: 
 
DMEM
 
+ 5% (v/v) horse serum
 
+ 1% (v/v) L-glutamine (200mM) 
+ 1% (v/v) penicillin-streptomycin 
  
Cells were maintained in the respective media at 37°C and 5% CO2 in a humidified incubator. When 
they reached 90% to 100% confluence, cells were briefly washed with PBS and incubated with trypsin 
solution until they had detached. Then, medium was added to the cell suspension. Trypsin inhibitors, 
which are present in the FCS, stopped the digestion with trypsin and prevented the cells to be 
damaged by excessive trypsin exposure. A part of the suspension (1/6 to 1/8 of the suspension 
volume) was subsequently transferred to a new tissue culture plate containing fresh medium, and 
placed in a humidified incubator at 37°C and 5% CO2. 
 
 
2.3.2 Cryopreservation of cells 
 
Cells were detached with trypsin. After stopping of the trypsin digestion with medium (FCS), the cells 
were centrifuged at room temperature for 5 minutes at 100 x g. The supernatant was discarded and 
the cell pellet was gently resuspended in culture medium supplemented with 10% (v/v) DMSO as 
cryopreservative agent to reduce the risk of ice crystal formation, which would damage the cells. 
Aliquots of 1ml were transferred to cryotubes (Nunclon) and the vials were placed in a freezing 
container and frozen at -80°C for several days. The freezing container contained isopropanol, which 
ensured the cells to be cooled down very slowly (~1°C/h). For long-term storage, cells were 
subsequently transferred to liquid nitrogen. 
For revival it was important to dilute and remove the DMSO, which would have cytotoxic effects, as 
quickly as possible. Thus, cells were thawed in a 37°C water bath, diluted with pre-warmed growth 
medium and centrifuged as described above. The supernatant was discarded. Cells were 
resuspended in fresh culture medium, seeded into a new tissue culture dish and placed in an 
incubator at 37°C and 5% CO2.   
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2.3.3 Cell transfection 
 
Transfection of eukaryotic cells with plasmid DNA purified by midi-preparation (2.1.9.3) was carried 
out using Lipofectamine 2000 reagent (Invitrogen, #11668) according to the manufacturer’s protocol. 
Briefly, cells were split one day before transfection and kept in antibiotic-containing culture medium. 
Shortly before transfection, the medium was replaced with fresh medium without antibiotics, which 
would damage the cells at the transfection procedure. The required amounts of plasmid DNA, 
Lipofectamine 2000 reagent, and DMEM (serum free medium) is listed in Table 2.10. 
For transfection, the required amount of DNA was diluted with DMEM in a sterile reaction tube. In a 
separate tube the necessary volume of Lipofectamine 2000 reagent was added to DMEM and 
incubated for 5 minutes at RT. Then, both DNA and Lipofectamine were mixed together and incubated 
for another 20 minutes at RT to allow DNA-Lipofectamine complexes to be formed. Finally, the 
solution was added dropwise to the cells. To allow the cells to express the transfected constructs, 
further procedures were carried out after an incubation time of 24 to 48 hours at 37°C and 5% CO2 in 
a humidified cell culture incubator. 
  
Table 2.10: Setup for transfection using Lipofectamine 2000 reagent 
culture plate  
[cm] 
medium [ml] DNA [µg] 
Lipofectamine 
2000 [µl] 
DMEM for 
dilution [µl] 
3.5 (6-well) 2 4 10 250 
6 5 8 20 500 
10 10 24 60 1500 
 
 
 
2.3.4 Isolation of primary neonatal cardiac myocytes 
 
complete medium for neonatal cardiac myocytes: 
 
DMEM (Sigma-Aldrich, #D6429)
 
+ 10% (v/v) FCS 
 
+ 1% (v/v) L-glutamine (200mM)  
+ 1% (v/v) penicillin-streptomycin 
 
Hearts from neonatal (0.5d-1.5d old) mice were excised and washed several times in ice-cold Ca
2+
 
and Mg
2+
 free Hank’s buffered salt solution (CMF-HBSS; Gibco
®
, #14175). The hearts were placed in 
a 3.5cm dish. Aorta and atria were removed and ventricles were minced using scalpels into small 
pieces, which were washed again in CMF-HBSS to remove any traces of blood. After this, 3ml of fresh 
CMF-HBSS were added to the dish containing the minced ventricles. 333µl of trypsin solution 
(Worthington Biochemical Corporation, #TRLSNK) were added and tissue pieces were incubated at 
4°C for 15-16h. The following morning, the partially-digested hearts were transferred to a T25 culture 
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flask, containing 166µl trypsin inhibitor (Worthington Biochemical Corporation, #SICNK) to stop trypsin 
digestion. After incubation for 15min at 37°C, 850µl of collagenase (Worthington Biochemical 
Corporation, #CLSPANK) were added and the flask was incubated in a shaking water bath at 37°C for 
about 40min. Meanwhile, 30ml of serum-free Leibowitz L-15 medium (Sigma-Aldrich, #L1518) were 
equilibrated at 37°C and 5% CO2. After about 40min, collagenase was diluted using about 10ml of 
equilibrated L-15 medium, and remaining pieces were triturated by pipetting up and down with a 10ml 
serological pipette. Then, the suspension was filtered through a 70µm cell strainer and cells were 
collected by centrifugation at 200 x g for 7min. Cardiomyocytes were purified by resuspending the 
cells in complete culture medium and incubating them at 37°C and 5% CO2 for 30 minutes. During this 
time, the fibroblasts were allowed to attach, whereas the majority of cardiac myocytes remained in 
suspension. After 30min the non-attached cells were collected by centrifugation at 200 x g for 7min, 
resuspended in fresh complete medium and plated again in a fresh T25 flask. In this second round of 
preplating, the cells were incubated at 37°C for 40min. Non-attached cells, now enriched for cardiac 
myocytes, were collected as above and seeded into a chamber slide, which had been coated with 
fibronectin (Sigma-Aldrich, #F1141). After 3d incubation at 37°C and 5% CO2, cells were fixed and 
subjected to immunocytochemical staining (2.4). 
 
 
2.3.5 Isolation of primary murine myoblasts 
 
In this work, skeletal myoblasts were isolated using two different methods. The method described in 
2.3.5.1 involves enzymatic digestion of muscle tissue. Enriched myoblast were cultured on collagen-
coated cell culture dishes. For the second method (2.3.5.2) intact muscle fibres from EDL (extensor 
digitorum longus) muscle were isolated.   
 
 
2.3.5.1 Enzymatic digestion of skeletal muscle 
 
primary myoblast growth medium: 
 
DMEM (Sigma-Aldrich, #D6429)
 
+ 20% (v/v) FCS  
+ 5 ng/ml heparin (Sigma-Aldrich, #H3149) 
+ 10 ng/ml HGF (R&D Systems, #2207-HG) 
+ 1% (v/v) L-glutamine (200mM) 
+ 1% (v/v) penicillin-streptomycin 
     
C57BL/6J mice were sacrificed and the diaphragm as well as all hind limb muscles were dissected 
out. Muscles were briefly rinsed in PBS and then minced into small pieces using scissors and scalpels 
to facilitate enzymatic digestion of the tissue. The tissue was incubated with 2mg/ml collagenase type I 
(Sigma-Aldrich, #) in DMEM for about 20 minutes. Samples were centrifuged at 50 x g for 5 minutes 
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and collagenase type I was removed. The partially-digested tissue was resuspended in 5ml of 
Collagenase/Dispase
®
 solution (1mg/ml in PBS) (Roche, #10 269 638 001) and further digested for 
30-40min in a shaking water bath at 37°C. Every 10 minutes, tissue was triturated by pipetting up and 
down with a serological pipette to help dislodging of cells.  
As soon as no big tissue pieces were visible, enzymes were diluted with DMEM containing 20% (v/v) 
FCS and cells were separated by sequential filtration through a 100µm, a 70µm, and a 40µm cell 
strainer. Cells were collected by centrifugation at 200 x g for 5min and resuspended in primary 
myoblast growth medium. After preplating of 1h to enrich for myoblasts, cell suspension was carefully 
transferred to a collagen-coated dish.  
48h later, the growth medium was supplemented with 5ng/ml FGF2 (R&D Systems, #234-FSE). 
To induce differentiation, cells were grown in differentiation medium (2.3.1) containing horse serum 
but no FCS. 
 
 
2.3.5.2 Isolation of primary EDL muscle fibres 
 
single fibre culture medium (SFCM): 
 
DMEM
 
+ 10% (v/v) horse serum  
+ 0.5% (v/v) chick embryo extract 
+ 1% (v/v) penicillin/streptomycin 
     
 
A mouse was sacrificed and EDL muscles were removed carefully. Particular care was taken to keep 
the muscles intact. To separate single fibres, the muscles were digested in 2mg/ml collagenase type I 
(Sigma-Aldrich, #C0130) for about 90min at 37°C. To facilitate digestion, the flask was shaken every 
15 minutes. To stop digestion, fibres were washed twice with DMEM followed by two washes with 
SFCM. Using a glass pipette, muscles were pipetted up and down several times to make single fibres 
to come off. Fibres were either fixed immediately in 2% PFA for 10min (T0 fibres) or cultured in SFCM 
at 37°C and 5% CO2 and fixed later. Fibres were stained as described for cells and tissue slides (2.4). 
For confocal imaging, cells were mounted on a cover slide using Mowiol after immunostaining. 
 
 
2.4 Immunostaining 
 
2.4.1 Preparations for immunocytochemistry 
 
Cells were seeded into a 3.5cmØ cell culture dish containing four round cover glasses (Ø 13mm, 
hydrolytic class 1) and, if needed, transfected using Lipofectamine as described in chapter 2.3.3. 
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When primary myoblast were used, cover glasses were pre-coated with collagen.  
Cover glasses with cells were removed at the required time point and placed for further processing in 
a “humidified chamber”, i.e. a petri dish containing wetted filter paper covered with parafilm, and some 
wetted paper tissue to prevent the samples to dry out. 
 
 
2.4.2 Fixation of cells 
 
     
4% (w/v) paraformaldehyde (PFA): 4g paraformaldehyde  
2 drops of 2M NaOH  
10ml 10x PBS, 
ad 100ml H2O 
 2% (w/v) PFA: 5ml 4% PFA 
5ml 1x PBS 
     
Cells on cover glasses were washed three times with PBS at RT and then incubated with 4% 
paraformaldehyde for 10 minutes at RT. When anti-Popdc1 or anti-Popdc2 antibodies were used, cells 
were fixed in 2% PFA for 10 minutes. After three washes with PBS for 5 minutes, cover glasses were 
covered with about 100µl fresh PBS. Then, the “humidified chamber” was sealed with parafilm and 
stored at 4°C until further use.  
Alternatively, for fixation with methanol, cells were rinsed with ice-cold (-20°C) methanol and incubated 
with fresh -20°C cold methanol for 3 minutes at -20°C. After three washes for 5min with PBS, cells 
were ready for further use. 
 
 
 
2.4.3 Antibody incubation 
 
     
Blocking 
solution: 
1% (w/v) BSA  
5% (v/v) FCS 
0.25% (v/v) Triton X-100 
in 1x PBS 
  
     
Mowiol: 2.4g MOWIOL 4-88 Reagent (Calbiochem, #475904) 
6g glycerol 
6ml H2O 
12ml 0.2M Tris (pH 8.5) 
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As the antigens for all of the antibodies used in this thesis were localised intracellularly, PFA-fixed 
cells or tissue had to be permeabilised prior to antibody incubation to enable the antibodies to 
penetrate the membrane and reach the antigen. Therefore, cover glasses with cells or slides with 
tissue sections were incubated with 100µl 0.25% (v/v) Triton X-100 in PBS for 5 minutes. This step 
was repeated twice. 
 
Then, cells were incubated with 100µl blocking solution for 1 hour at room temperature to saturate 
unspecific antibody binding sites on the glass surface. Subsequently, blocking solution was removed 
and primary antibody diluted in blocking solution (Table 2.11) was added to the cells and incubated for 
1-2 hours at RT or overnight at 4°C. Antibody solution was removed and specimen were washed three 
times with PBS (>100µl).  
 
 
Table 2.11: Antibodies used for immunostaining 
antibody supplier catalogue number dilution 
anti-Ankyrin-B Neuromab  N105/13 1:100 
anti-Caveolin-3 BD Biosciences  610420 1:200 
anti-Dysferlin Leica Biosystems NCL-Hamlet 1:25 
anti-Dystrophin Sigma-Aldrich  D8043 1:100 
anti-Flag Sigma-Aldrich F1804 1:200 
anti-HA Covance MMS-101R 1:200 
anti-MHC (type I fibres) DSHB
*)
 A4.840 1:2 
anti-MHC (type IIa fibres) DSHB
*)
 A4.74 1:2 
anti-MHC2B (type IIb fibres) DSHB
*)
 BF-F3 1:2 
anti-MHC2X (type IIx fibres) DSHB
*)
 6H1 1:2 
anti-myc Abcam  ab32 1:200 
anti-Myogenin DSHB
*)
 F5D 1:2 
anti-NCX Swant  R3F1 1:50 
anti-pan-myosin DSHB
*)
 A4.1025 1:2 
anti-Pax7 DSHB
*)
 PAX7 1:2 
anti-Popdc1 Santa Cruz sc-49889 1:50 
anti-Popdc1 Sigma-Aldrich HPA018176 1:50 
anti-Popdc2 Santa Cruz sc-66588 1:50 
anti-Popdc2 Sigma-Aldrich HPA024255 1:50 
anti-α-Sarcoglycan Leica Biosystems NCL-a-SARC 1:100 
anti-γ-Sarcoglycan Leica Biosystems NCL-g-SARC 1:100 
    
Alexa Fluor
®
 488 donkey 
anti-mouse IgG (H+L) 
Invitrogen A21202 1:200 
Alexa Fluor
®
 555 donkey 
anti-mouse IgG (H+L) 
Invitrogen A31570 1:200 
Alexa Fluor
®
 555 donkey 
anti-goat IgG (H+L) 
Invitrogen A21432 1:200 
Alexa Fluor
®
 594 donkey 
anti-rabbit IgG (H+L) 
Invitrogen A21207 1:200 
FITC-conjugated AffiniPure 
Fab Fragment Donkey Anti-
Mouse IgG (H+L) 
Jackson 
ImmunoResearch 
Laboratories 
715-097-003 1:50 
*
)
DSHB: Developmental Studies Hybridoma Bank 
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Then, the secondary antibody diluted in blocking solution was added to the cover glasses and 
incubated for 1 hour at RT in the dark. The antibody was removed and cover glasses were washed 
twice with >100 µl PBS for 5 minutes and subsequently for 5 minutes with DAPI (Calbiochem, 
#268298) staining solution (1µg/ml DAPI in PBS). The cover glasses were then mounted with Mowiol 
supplemented with 2µg/ml DAPI onto microscope slides and stored at 4°C to allow the Mowiol to set.  
In the case of a double staining with the anti-myc and anti-Flag or anti-HA antibodies, the binding site 
on the first primary antibody (against Flag or HA) was saturated using highly concentrated 
FITC-conjugated Fab fragments (1:50 dilution). After washing with PBS for three times, the next 
primary antibody was added (anti-myc) and incubated for 1h. After washing of cells as above, 
specimen were incubated for 1h with the other secondary antibody (Alexa Fluor
®
 555 donkey 
anti-mouse IgG (H+L), 1:200 dilution). Cover glasses were mounted after final washing to remove 
excess antibody and staining with DAPI. If the primary antibodies directed against different antigens 
were from different species, e.g. produced in mouse and rabbit, or goat and rabbit, samples were 
incubated with both primary antibodies at the same time. Likewise, both secondary antibodies were 
used together at the same time. 
 
 
2.4.4 Fluorescence microscopy  
 
Immunolabelled cells, fibres, or tissue section were examined using Zeiss inverted confocal 
laser-scanning microscopes LSM 510 META or LSM 780. Images were recorded by sequential 
multi-channel scanning to reduce bleed-through and thereby to make sure to capture only the signal 
from a single fluorphor. With the help of Zeiss LSM Image Browser software or the Zeiss Zen lite 2011 
program, the images were further processed. The final figures as presented in this thesis were 
generated using Adobe
®
 Photoshop
®
 CS4 or CS5. 
 
 
2.5 Protein biochemical techniques 
 
2.5.1 Isolation of nuclear proteins 
 
Isolation of nuclear proteins was carried out with the Qproteome
™
 Nuclear Protein Kit from Qiagen 
(#37582) according to the instructions given by the manufacturer. Two 10cm tissue culture plates with 
proliferating primary myoblasts or differentiated primary myotubes were used for nuclear protein 
isolation. To keep protein degradation at a minimum, all steps were carried out at 4°C. After washing 
of the cells with PBS, 10ml ice-cold PBS were added to each plate and cells ware scraped-off using a 
cell scraper. Suspensions from both plates were combined in a 15ml tube, and cells were collected by 
centrifugation for 5min at 450 x g. The supernatant was discarded and the cell pellet was resuspended 
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in 500µl Lysis Buffer NL containing 0.5mM DTT and protease inhibitors. Buffer NL is a hypotonic 
buffer, resulting in swelling of the cells. After 15min incubation on ice, 25µl of Detergent Solution NP 
were added, causing the cells to rupture. By centrifugation for 5min at 10,000 x g, nuclei were 
pelleted, whereas cytosolic proteins remained in the supernatant, which was snap-frozen and kept at 
-80°C until further use. The nuclei-containing pellet was washed by resuspending in 500µl Lysis Buffer 
NL, supplemented with 0.5mM DTT and protease inhibitors. After centrifugation for 5min at 10,000 x g 
at 4°C, the supernatant was carefully removed and the nuclear pellet resuspended in 50µl Extraction 
Buffer NX1 containing protease inhibitors. Buffer NX1 contained high concentration of salt, which 
caused the nuclei to shrink, which lead to separation of “soluble” nuclear proteins from DNA and their 
diffusion through nuclear pores. After 30min incubation in Extraction Buffer NX1, samples were 
centrifuged at 12,000 x g for 10 min. The supernatant containing the “soluble” nuclear fraction was 
snap-frozen and stored until use at -80°C. The pellet was treated for 1h with 100µl Extraction Buffer 
NX2, containing Benzonase
®
, 1mM DTT, and protease inhibitors, to digest nucleic acids and to 
release DNA-bound proteins. Finally, the sample was centrifuged for 10min at 12,000 x g. The 
supernatant containing the “insoluble” nuclear proteins was carefully removed, snap-frozen in liquid 
nitrogen and stored at -80°C. For analysis, cytosolic, “soluble”, and “insoluble” nuclear proteins were 
thawed and subjected to SDS-PAGE (2.5.11) and Western blot analysis (2.5.13). 
 
 
2.5.2 Generation of Cos-7 cell lysates for CoIPs and cAMP precipitation 
experiments 
 
     
lysis buffer for IP: 50mM Tris, pH 8.0 
150mM NaCl 
1% (v/v) Triton X-100 
2mM EDTA 
0.25% (w/v) bovine gelatine (Sigma-Aldrich, #G9391) 
1 tablet/10ml cOmplete, Mini (Roche, #11 836 153 001) 
    
Cells were grown on 10cm or 6cm culture dishes and transiently transfected as described in chapter 
2.3.3. 24h or 48h thereafter, growth medium was removed and cells were washed twice with PBS. 
Subsequently, 700µl lysis buffer for IP were added to the cells, and the plates were incubated on ice 
for about 20 minutes. To prevent degradation of the proteins, cells and lysates were kept on ice or at 
4°C from now on. After the incubation, cells were scraped off using a cell scraper and transferred to a 
1.5ml tube. To enhance lysis and solubilisation of proteins, the lysates were pulled through a 23G 
needle for 4-6 times, followed by sonification at 2mW for 15 seconds. This step was repeated twice 
with 15 second pauses between sonification to allow the samples to cool down.  
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The lysates were then centrifuged twice at >16,000 x g for 30 minutes to remove any debris and 
insoluble components. After the lysates had been cleared in that way, they were used for further 
experiments. 
 
  
2.5.3 CoIP experiments using Cos-7 cell lysates 
 
For CoIPs, cells grown on 10cm culture dishes were transiently transfected and lysates were 
produced as described in 2.5.22.5.1 by adding of 700µl of lysis buffer. 30µl of the by centrifugation 
pre-cleared lysates were taken as an input control and 10µl 4x SDS sample buffer were added. The 
rest of the lysates was subjected to CoIP using the ProFound™ c-Myc Tag IP/co-IP Kit (Thermo 
Scientific, #23620) or the Pierce
®
 HA Tag IP/Co-IP Kit (Thermo Scientific, #26180) and applied to a 
Handee™ Spin Column provided by the kit. After adding of 10µl anti-myc agarose (5µg of antibody) or 
20µl anti-HA agarose (35µg of antibody), the tubes were incubated overnight on a wheel rotator at 4°C 
to allow binding of the immobilised anti-myc or anti-HA antibodies to the antigen. The following day the 
lysates were removed by centrifugation for 10 seconds at full speed and the agarose beads were 
washed five times with 500µl BupH™ TBS, which was also part of the IP/Co-IP kit. Then, the agarose 
beads were resuspended in 30µl 2x SDS sample buffer, and boiled for five minutes at 96°C. By 
centrifugation the agarose beads were removed and the collected samples were mixed with 3µl of 
ß-mercaptoethanol. To add the reducing agent after elution from the agarose beads by boiling reduces 
the amount of antibody heavy and light chains in the samples. Also the input controls were boiled at 
96°C for five minutes. Both input controls and immunoprecipitated samples were then subjected to 
SDS gel electrophoresis and Western blot analysis as described in chapters 2.5.11 and 2.5.13. 
 
 
2.5.4 Generation of heart and skeletal muscle tissue lysates for CoIP 
experiments 
 
Hearts of wildtype and Popdc single mutant mice were excised and flushed with PBS using a syringe 
with needle to remove as much blood as possible. Skeletal muscles were briefly rinsed with PBS. 
Tissues were then immediately snap-frozen in liquid nitrogen and stored at -80°C until use. To 
produce lysates, tissues were pulverised with a pestle and mortar, which was pre-cooled with liquid 
nitrogen. Care was taken to prevent thawing of samples to avoid protein degradation. Tissue powder 
of one whole heart or three TA (tibiales anteriores) muscles were resuspended in 500µl lysis buffer for 
IP (2.5.1). After incubation at 4°C for 30 minutes on a rotator, further mechanical destruction was 
carried out using a small pestle fitting a 1.5ml tube. Thereafter, three sonification steps at 2mW for 30 
seconds were performed with 30 seconds pause in between to keep protein degradation by warming 
up the sample as low as possible. Following sonification, the lysates were centrifuged for 30 minutes 
at >16,000 x g. The supernatant was carefully transferred to a fresh tube. The pellet was resuspended 
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in 500µl lysis buffer for IP and the samples were treated in the same way as described above 
including mechanical destruction with a pestle, sonification, and centrifugation. Finally, supernatants 
from both rounds of tissue lysis were combined and centrifuged again for 2 x 30 minutes to remove all 
traces of insoluble material. The pellet was discarded and the cleared supernatant was snap-frozen in 
liquid nitrogen and stored at -80°C until use for CoIP (2.5.7). 
 
 
2.5.5 Protein extraction using harsh conditions 
 
   
harsh extraction buffer: 50mM Tris, pH 8.0 
4M urea 
10% (w/v) SDS 
2mM EDTA 
  
2.5.5.1 Protein extraction for antibody test 
 
Popdc proteins have been shown to be difficult to extract (Vasavada et al. 2004). Thus, harsh 
extraction conditions were used for antibody test using transfected Cos-7 cell lysates. For this, cells 
grown in 6cm tissue culture dishes were transfected using 8µg of either mPopdc1[WT]-myc, 
mPopdc2[WT]-myc, or mPopdc3[WT]-myc. These constructs had been produced by Andree et al. 
(Andree et al. 2000). Proteins were extracted 24h later using 200µl of the buffer above supplemented 
with 1% (v/v) ß-mercaptoethanol. After brief sonification (3x 15 seconds at 2mW) to help shearing 
DNA and make the lysates less viscous, 21µl of the lysates were taken and mixed with 7µl 4x SDS 
sample buffer and analysed in a Western blot as described in 2.5.11 and 2.5.13.  
 
 
2.5.5.2 Protein extraction for investigating the formation of heteromeric Popdc complexes 
 
Also for investigating the formation of heteromeric Popdc complexes harsh extraction conditions were 
used.  
One 6cm dish of cells was transfected using 4µg hPOPDC1[WT]-CFP + 4µg hPOPDC2[WT]-Flag or 
mPopdc3[WT]-Flag. A second transfection was carried out using 4µg hPOPDC1[WT]-CFP + 4µg 
pcDNA3.1(+). A third sample was transfected with 4µg pECFP-N1 + 4µg hPOPDC2[WT]-Flag. 24h 
later, cells were harvested with 400µl lysis buffer without reducing agent. Cell lysates were three times 
sonificated for 15 seconds at 2mW. After centrifugation for 30 minutes at >16,000 x g 100µl of each 
sample were supplemented with either ß-mercaptoethanol-containing (+BME) SDS sample buffer or 
sample buffer without reducing agent (w/o BME). These samples were incubated at 37°C for 30min to 
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prevent the formation of aggregates and subjected to Western blot analysis as detailed in chapters 
2.5.11 and 2.5.13. 
 
 
2.5.5.3 Protein extraction from human tissue 
 
Using the harsh extraction buffer, proteins were extracted from human tissue. The protocol was 
optimised using murine tissue. However, for legal reasons protein extraction from human tissue was 
carried out by our collaborators in Germany and Italy. A piece of tissue was pulverised with a pestle 
and mortar, which were pre-cooled with liquid nitrogen. Tissue powder was weighted and 
resuspended in 5µl of harsh extraction buffer per 1mg of powder. After incubation at 4°C for 
30 minutes on a rotator, further mechanical destruction was carried out using a small pestle fitting a 
1.5ml tube, and lysates were incubated for another 30min under rotation. Again, a pestle and mortar 
were used to enhance cell lysis mechanically. Three sonification steps at 2mW for 30 seconds were 
performed with 30 seconds pause in between and lysates were again incubated at 4°C for 30min on a 
rotator. Then, the lysates were centrifuged for 30 minutes at >16,000 x g. Protein amounts were 
estimated as outlined in chapter 2.5.6. 50µg of each sample were mixed with SDS sample buffer, 
incubated at 60°C for 15min and subjected to SDS-PAGE (2.5.11) and Western blot analysis (2.5.13) 
for the detection of POPDC1 and POPDC2. To control equal loading, 1µg of the lysates was loaded 
on a separate gel and Western blot was carried out using an anti-Actin antibody. 
 
 
2.5.6 Estimation of protein concentrations 
 
In order to make sure to use equal amounts of protein, the protein concentration was measured using 
the Bio-Rad DC™ Protein Assay. This assay is based on the Lowry method including a reaction of the 
proteins with alkaline copper tartrate (solution A) and a reduction of Folin (solution B) by the copper-
protein complex, which results in a blue coloured product with an absorbance maximum at a 
wavelength of 750nm. The colour intensity is proportional to the amount of protein in the sample. In 
order to quantify the protein concentration of a test sample, absorbance values of known amounts of a 
reference protein like bovine serum albumin (BSA) can be used to establish a standard curve. Then 
absorbance values of the test samples can be matched against the standard curve to obtain an 
estimation of protein concentration of the test sample.  
Here, protein lysates were thawed on ice and centrifuged twice for 30 minutes at 4°C. Samples were 
diluted 1:10 and 1:100 in lysis buffer for IP or in harsh extraction buffer. 5µl of the buffer, diluted 
samples, or standards (Table 2.12) were added to the wells of a 96-well plate in triplicate. 1ml reagent 
A (Bio-Rad, #500-0113) was supplemented with 20µl reagent S (Bio-Rad, #500-0115) and 25µl 
thereof were added to the wells, followed by 200µl reagent B (Bio-Rad, #500-0114). To allow the blue 
colour to develop fully, the plate was left at room temperature for 15 minutes, before absorbance at 
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750nm wavelength was measured using a microplate spectrophotometer (µQuant, BioTek). The 
absorbance values were exported to Microsoft Excel software. Mean values obtained for the protein 
standards were plotted against the known protein concentrations and a standard curve was obtained 
using linear regression. Values of the samples used to match against the standard curve were 
obtained by subtracting the mean value obtained for the buffer from mean values for the samples to 
eliminate the influence of the buffer on the colorimetric reactions. The accuracy of this protein 
estimation was tested by SDS-PAGE followed by Coomassie staining as described in chapters 2.5.11 
and 2.5.12. 
 
 
Table 2.12: Setup for standard curve 
protein concentration [µg/µl] 0 0.2 0.4 0.6 0.8 1.0 1.2 
2mg/ml BSA [µl] 0 5 10 15 20 25 30 
H20 [µl] 50 45 40 35 30 25 20 
 
 
2.5.7 CoIP using murine tissue lysates 
 
Heart or TA tissue lysates were obtained as detailed in chapter 2.5.4, and protein amounts were 
determined according to chapter 2.5.6. 10mg of either wildtype or Popdc1
-/-
, or Popdc2
-/-
 lysates were 
taken and volumes were adjusted with lysis buffer for IP to have equal protein concentrations in the 
samples. 1.5µg of the Sigma rabbit anti-Popdc1 or rabbit anti-Popdc2 antibodies or 10µg of the Santa 
Cruz goat anti-Popdc2 antibody were added to each tube and samples were incubated overnight on a 
rotator at 4°C to allow the antibodies to bind to the antigens. The following morning, 50µl of Protein A 
or G agarose were added. Protein A binds to rabbit IgG immunoglobulins, whereas Protein G has a 
higher affinity for goat antibodies. Due to the binding to Protein A or G, which were covalently bound to 
agarose beads, the previously added antibodies and proteins bound to these antibodies were 
immobilised and could be captured and isolated by centrifugation. After 4h of incubation with Protein A 
or G agarose on a rotator at 4°C, the samples were centrifuged at 500 x g for 5 minutes and 
supernatants were discarded to remove unbound proteins. The agaroses were washed five times with 
500µl BupH™TBS (Thermo Scientific, #28379). Finally, the agaroses were resuspended in 40µl 2x 
NuPAGE
®
 LDS Sample Buffer (Invitrogen, #NP0007) and bound proteins were eluted by boiling the 
samples at 96°C for 5 minutes. Agarose was removed from each sample by centrifugation for 5 
minutes at 500 x g. 4µl of 10x NuPAGE
®
 Sample Reducing Agent (Invitrogen, #NP0004) were added 
and samples were subsequently subjected to SDS-PAGE (2.5.11).  
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2.5.8 Expression of recombinant proteins in E. coli cells 
 
Table 2.13: E.coli strains used for protein expression 
E. coli strain genotype supplier information 
BL21(DE3)pLysS F
–
 ompT hsdSB(rB
– 
mB
–
) gal dcm (DE3)  
pLysS (CamR) 
Novagen
®
, #69388 
Rosetta(DE3)pLysS F
–
 ompT hsdSB(rB
–
 mB
–
) gal dcm (DE3) 
pLysSRARE2 (CamR) 
Novagen
®
, #71403 
 
Plasmids encoding for GST-Popdc1[Ct] or GST (pGEX-5X-3), which were kindly provided by 
Professor David Bader and used previously (Froese et al. 2012), were transformed into 
BL21(DE3)pLysS cells. One single colony was used to inoculate 5ml LB medium supplemented with 
100µg/ml ampicillin and 34µg/ml chloramphenicol. The culture was grown overnight at 37°C under 
vigorous shaking. The following day, 1ml of this culture was poured into a flask containing fresh LB 
medium with ampicillin and chloramphenicol at concentrations described in Table 2.9. The cultures 
were incubated under shaking at 37°C and the growth was regularly controlled by measuring the 
optical density at 600nm wavelength (OD600) with the Eppendorf BioPhotometer plus. LB medium 
served as reference. Once an OD600 of 0.5-0.6 was reached protein expression was induced by 
adding 0.1mM IPTG (isopropyl-ß-D-thiogalactopyranoside). Four hours later, cells were harvested by 
centrifugation at 1,000 x g and 4°C for 30min. Cell pellets were stored at -80°C until use. 
Similarly, for pull-down experiments using GST-TREK-1[Ct] as prey protein, GST-TREK-1[Ct] plasmid 
or the vector pGEX-5X-3 were transformed into chemical competent Rosetta(DE3)pLysS Escherichia 
coli cells (Novagen
®
). Preparation of overnight and expression cultures was the same as delineated 
above. Expression was induced with 0.25mM IPTG at an OD600 of 0.5, and cells were harvested 6-8 
hours later and stored as described above.  
 
 
2.5.9 Glutathione S-transferase (GST) pull-down experiments 
 
2.5.9.1 Generation of bacterial lysates  
     
PBS-based lysis 
buffer:   
10% (v/v) 10x PBS  
50µl 1M MgCl2 
5µl Benzonase
®
   
  (Novagen
®
, # 70746-3) 
1 pinch of lysozyme 
   (AppliChem, #A3711) 
1mM PMSF  
   (AppliChem, #A0999) 
ad 5ml H2O 
 Tris-based lysis 
buffer: 
50mM Tris, pH 7.3  
100mM NaCl  
2mM MgCl2 
5% (v/v) glycerol 
5µl Benzonase
®
  
1 pinch of lysozyme 
1mM PMSF 
ad 5ml H2O 
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The frozen bacteria pellet obtained from 100ml expression culture (2.5.8) was thawed and 5ml of lysis 
buffer were added. In the case of GST-Popdc1[Ct] the PBS-based lysis buffer was used, 
GST-TREK-1[Ct] expressing cells were lysed in the Tris-based lysis buffer. To enhance lysis of the 
cells, three rounds of freeze-thaw cycles were performed by freezing the lysate in liquid nitrogen and 
thawing it in a warm water bath (~37°C). This was followed by three sonification steps for 30 seconds 
at 2mW with 30 seconds cooling in between. 1ml aliquots of lysates were finally snap-frozen in liquid 
nitrogen and stored at -80°C until further use. 
 
 
2.5.9.2 Preparation of glutathione beads 
 
For GST pull-down, thawed bacterial lysates (2.5.9.1) were cleared by centrifugation at >16,000 x g at 
4°C for 30 minutes. In the meantime, 26.7µl of a 75% slurry of glutathione sepharose 4B 
(GE Healthcare, # 17-0756-01) was washed with 400µl of PBS or Tris-based lysis buffer without 
Benzonase
®
 and lysozyme to remove all traces of EtOH, in which the agarose is stored. This was 
done by centrifugation at 500 x g for 5 minutes at room temperature. The agarose was finally 
resuspended in 40µl of the respective buffer and the cleared lysate was added. After incubation on a 
rotator for at least 4 hours, the GST-TREK-1[Ct]-bound agarose was washed three times with 200µl of 
the Tris-based lysis buffer (without Benzonase
®
 and lysozyme), whereas PBS was used in the case of 
GST-Popdc1[Ct]. Bacteria and lysates were treated accordingly, when GST alone was expressed, 
depending on whether GST was used as a control for pull-down with GST-Popdc1[Ct] or 
GST-TREK-1[Ct]. 
 
 
2.5.9.3 Generation of cell lysates for GST pull-down experiments 
 
     
cell lysis buffer 1: 20mM Tris, pH 8.0 
150mM NaCl 
2mM EDTA, pH 8.0 
1% (v/v) Triton X-100 
0.05% (w/v) SDS 
1mg/ml BSA 
1mM dithiotreitol (DTT) 
1 tablet cOmplete, Mini 
ad 10ml H2O 
 cell lysis buffer 2: 50mM Tris, pH 8.0  
150mM NaCl  
2mM EDTA, pH 8.0 
1% (v/v) Triton X-100 
0.05% (w/v) SDS % 
0.25% (w/v) CHAPS 
1mg/ml BSA 
1mM dithiotreitol (DTT) 
1 tablet cOmplete, Mini 
ad 10ml H2O 
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In order to overexpress the prey proteins used in GST pull-down experiments, Cos-7 cells grown on a 
6cm culture dish were transiently transfected with hTREK-1[WT]-Flag or hTREK-1[x]-Flag for 
pull-down with GST-Popdc1[Ct] or with Popdc1[WT]-myc or Popdc1[x]-myc for pull-down with 
GST-TREK-1 as bait protein as detailed in chapter 2.3.3. (The x refers to the number of deleted amino 
acids at the C-terminus of the TREK-1 or Popdc1 protein). 24h later, cells were rinsed with PBS and 
lysed with cell lysis buffer 1 to solubilise TREK-1 proteins or with cell lysis buffer 2 for Popdc1 
proteins. In each case cells were incubated on ice for 20-30 minutes with 1ml of buffer before they 
were scraped off. Lysates were transferred to a 1.5ml tube und further mechanically disrupted by 
pulling them through a 23G needle. Following another incubation step on ice for 20-30 minutes, 
lysates were centrifuged for ≥30 minutes at >16,000 x g. As loading controls 21µl of the supernatants 
were mixed with 7µl of 4x SDS sample buffer and subjected to SDS-PAGE and Western blot analysis 
(2.5.11 and 2.5.13). The rest of the supernatants was added to the washed protein-bound glutathione 
beads, which had been prepared as described in 2.5.9.2. An overnight incubation at 4°C on a rotator 
allowed the prey to bind to the bait proteins. The samples were centrifuged for 5 minutes at 500 x g 
and the supernatants were carefully removed. The agarose pellets were resuspended in 200µl PBS or 
Tris-based lysis buffer without enzymes and centrifuged again with aforementioned parameters. This 
wash step was carried out 5 times, before the agarose was resuspended in 20µl 2x reducing SDS 
sample buffer. Proteins were eluted by boiling at 96°C for 5 minutes and loaded on a SDS protein gel 
alongside the input controls and subjected to SDS-PAGE and Western blot (2.5.11 and 2.5.13). 
 
 
2.5.10  cAMP affinity binding assay 
 
wash buffer A: 10mM HEPES, pH 7.4 
1.5mM MgCl2 
10mM KCl 
500mM NaCl 
0.1% (v/v) Igepal CA-630 
    (Sigma-Aldrich, #I8896) 
1mM DTT 
1mM IBMX 
 wash buffer B: 10mM HEPES, pH 7.4 
1.5mM MgCl2 
10mM KCl 
0.1% (v/v) Igepal CA-630 
1mM DTT 
 
 
Cos-7 cells grown in 6cm culture dishes were transfected to express hPOPDC1[WT]-HA, 
hPOPDC1[R172H]-HA, or hPOPDC1[S201F]-HA (2.3.3). Lysates were obtained using 1ml of lysis 
buffer for CoIP (2.5.1). 30µl of the lysates were mixed with 10µl 4x SDS sample buffer to obtain the 
input controls. 50µl of ethanolamin (EtOH-NH) agarose (BioLog, #E 010) were centrifuged for 5 
minutes at 500 x g and the buffer in which the EtOH-NH agarose was stored was discarded. The 
agarose pellet was washed with 1ml of lysis buffer. After centrifugation as above, the lysis buffer was 
removed and the cell lysate was added to the EtOH-NH agarose and incubated for 1h at 4°C on a 
rotator. This was aimed at reducing unspecific binding to the cAMP agarose, with which the lysates 
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were incubated after this pre-clear step. During incubation of the lysates with EtOH-NH agarose, 
4.8mg of cAMP agarose (Sigma-Aldrich, #A0144) were washed in the same way as the EtOH-NH 
agarose. After 1 hour of incubation with the EtOH-NH agarose the samples were centrifuged at 500 x 
g for 5min at 4°C.  
The pre-cleared supernatant was supplemented with IBMX (3-isobutyl-1-methylxanthine; 
Sigma-Aldrich, #I5879) to a final concentration of 1mM and applied to the washed cAMP agarose. 
IBMX is a PDE inhibitor and was added to prevent phosphodiesterases in the lysate to hydrolyse 
cAMP, which would result in a decreased binding of the POPDC1 proteins to the cAMP agarose. After 
an incubation of 2h with rotation at 4°C, the samples were centrifuged as above. To see how much of 
the POPDC proteins did not bind to cAMP agarose, 30µl of the supernatant were kept for SDS-PAGE 
and Western blot analysis. The rest of the supernatant was discarded and the cAMP agarose was 
washed with 1ml wash buffer A followed by three washes with 1ml wash buffer B. The EtOH-NH 
agarose was kept on the bench at 4°C after pre-clear was finished. It was now washed just like the 
cAMP agarose. This was done to estimate the extent of unspecific binding of the POPDC proteins.  
After washes, both agaroses were boiled in 2x SDS sample buffer. The agarose was removed and the 
eluted proteins were subjected to SDS-PAGE and Western Blot analysis (2.5.11 and 2.5.13). 
 
 
2.5.11  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
     
reducing 
4x SDS sample 
buffer: 
4% (w/v) SDS 
10% (v/v) ß-mercaptoethanol 
40% (v/v) glycerol 
250mM Tris-HCl (pH 6.8) 
0.05% (w/v) bromphenol blue 
ad 10ml dH2O 
  
     
 
 
Table 2.14: Gel formulation 
separation gel 6% 8% 10% 12%  stacking gel 5% 
H2O 2.6 2.3ml 1.9ml 1.6ml  H2O 1.4ml 
1.5M Tris (pH 8.8) 1.3ml 1.3ml 1.3ml 1.3ml  1.0M Tris (pH 6.8) 250µl 
10% (w/v) SDS 50µl 50µl 50µl 50µl  10% (w/v) SDS 20µl 
10% (w/v) APS  50µl 50µl 50µl 50µl  10% (w/v) APS 20µl 
30% acrylamide solution
 1.0ml 1.3ml 1.7ml 2.0ml  30% acrylamide solution 
 
333µl 
TEMED (Merck, #1.10732)
 
4µl 3µl 2µl 2µl  TEMED
 
2µl 
N.B.: The 30% acrylamide solution was a 37.5:1 mix of acrylamide and bisacrylamide (AppliChem, 
#A3626). 
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For SDS-PAGE the Mini-PROTEAN
®
 system from Bio-Rad was used. Glass plates were thoroughly 
cleaned with 70% EtOH to remove any fingerprints and debris, which could impair gel polymerisation. 
The plates were assembled with plastic frames and mounted on a gel cast stand. It was tested with 
water whether the glass plates were tight and the liquid did not run out. The gel solution was prepared 
according to Table 2.14 whereby TEMED, which catalyses the acrylamide polymerisation reaction and 
APS, which is necessary to form free radicals to start the reaction, were added just before it was 
poured in between the glass plates. In order to achieve even polymerisation and a clear transition from 
stacking to separation gel, the gel solution was carefully overlaid with water. Once polymerisation was 
complete, the water was removed and the stacking gel (Table 2.14) was poured over the separation 
gel, and a gel comb was inserted. After polymerisation, the gel was briefly rinsed in water to remove 
any non-polymerised acrylamide. To prevent the gel from drying out it was wrapped in wet tissue and 
plastic foil and stored at 4°C until use. Since prolonged storage would make the differences in pH 
between stacking and separation gel to be indistinct, which would result in poor separation and blurry 
bands, the gel was used within a week after preparation. 
 
 
5x running buffer: 15g Tris 
72g glycine 
5g SDS 
ad 1l H2O 
 1x running buffer: 200ml 5x running buffer 
800ml H2O 
 
 
    
For gel electrophoresis the gel was inserted in the electrophoresis chamber and the chamber was 
filled with running buffer. The comb was removed and the wells were prepared for loading by washing 
with running buffer to remove any traces of not properly polymerised gel.  
Sample buffer containing SDS and a thiol-reducing agent like ß-mercaptoethanol or DTT was added to 
the protein and samples were, if not otherwise stated, boiled at 96°C for 5 minutes in order to facilitate 
the attachment or the SDS to the proteins. This lead to masking of charged amino-acids, resulting in 
denatured proteins with a charge-to-mass ratio proportional to their molecular weights, thus allowing 
separation exclusively according to protein size. Along with a molecular weight marker (PageRuler™ 
Prestained Protein Ladder, Thermo Scientific, #26616), the samples were loaded onto the gel and 
electrophoresed at 50-150V until the dye in the sample buffer had reached the bottom of the gel. The 
electrophoresis apparatus was disassembled. The separation gel was removed from the glass plates 
and used immediately for Coomassie staining (2.5.12) or Western blotting (2.5.13). 
 
For the analysis of samples after CoIP experiments using tissue lysates, commercially available 
NuPAGE
®
 4-12% Bis-Tris Mini Gels (Invitrogen, #NP0321BOX) were used for having maximum 
reproducibility. In this case, NuPAGE
® 
MOPS SDS Running Buffer (Invitrogen, #NP0001) was used. 
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2.5.12  Coomassie staining of polyacrylamide gels 
 
     
fixing solution: 50% (v/v) methanol 
10% (v/v) acetic acid 
   
     
Gels used for mass spectrometry analysis were stained with the Colloidal Blue Staining Kit from 
Invitrogen (#LC6025) according to manufacturer’s instructions. Briefly, gels were incubated in fixing 
solution for 10 minutes at room temperature, followed by a 10 minute incubation in staining solution 
containing 20% (v/v) methanol and 20% (v/v) Stainer A. After adding of 5% (v/v) Stainer B, gels were 
stained for up to 12 hours at room temperature. Destaining of background was accomplished by 
incubating the gels in H2O for several hours. The so prepared gels were photographed, sealed in a 
plastic bag containing H2O, and sent to Dr Marcus Krueger’s lab in Bad Nauheim, Germany, for mass 
spectrometry analysis. 
 
 
2.5.13  Western blot analysis 
 
     
blotting buffer: 10% (v/v) methanol 
25mM Tris-HCl 
150mM glycine 
   
     
10x TBS: 1.5M NaCl 
0.5M Tris-HCl 
 pH 7.4 
 1x TBS: 100mL 10x TBS 
ad 1000ml H2O 
 
     
TBST: 1x TBS 
0.1% (v/v) Tween20 
 blocking 
solution: 
5% (w/v) milk powder in 
TBST 
     
 
Six sheets of Whatman filter paper and 1 piece of nitrocellulose membrane were cut out and trimmed 
to the size of the gel (~8.5cm x 5.5cm). Filter paper, nitrocellulose membrane, and the gel were 
equilibrated in blotting buffer for about 10 minutes. Then, the blot was assembled as depicted in 
Figure 2.2, and the proteins were electrophoretically transferred from the gel to the nitrocellulose 
membrane at 70mA/gel for at least 1 hour.  
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Figure 2.2: Assembly for semi-dry blotting 
Details are outlined in the text. 
 
 
 
Table 2.15: Antibodies used for Western blot analysis 
antibody supplier catalogue number dilution 
anti-Actin Santa Cruz  sc-1616 1:1000 
anti-Ankyrin-B Neuromab  N105/13 1:1000 
anti-Ankyrin-G  Santa Cruz  sc-28561 1:250 
anti-Caveolin-3 BD Biosciences  610420 1:1000 
anti-Dystrophin Sigma-Aldrich  D8043 1:500 
anti-Flag Sigma-Aldrich F1804 1:1000 
anti-GFP Abcam  ab290 1:1000 
anti-HA Covance MMS-101R 1:1000 
anti-histone H1 Millipore 05-457 1:1000 
anti-myc Abcam  ab32 1:1000 
anti-NCX Swant  R3F1 1:500 
anti-Popdc1 Santa Cruz sc-49889 1:200 
anti-Popdc1 Sigma-Aldrich HPA018176 1:200 
anti-Popdc2 Sigma-Aldrich HPA024255 1:200 
    
Peroxidase labeled anti-goat 
IgG (H + L) 
Vector Laboratories  PI-9500 1:1000 
Peroxidase labeled anti-
mouse IgG (H + L) 
Vector Laboratories  PI-2000 1:1000 
Peroxidase labeled anti-
rabbit IgG (H + L) 
Vector Laboratories  PI-1000 1:1000 
 
 
The membrane was then washed with TBS or PBS and incubated with blocking solution for 1 hour at 
room temperature. After blocking, the primary antibody diluted in blocking buffer was added to the 
membrane and incubated overnight at 4°C under gentle rotating. The following morning, the 
membrane was rinsed 3 times shortly with TBST, and then washed 3 times with TBST for 15 minutes 
under shaking to remove all traces of excessive (unbound) antibody.  
The membrane was incubated with secondary antibody conjugated with horseradish peroxidise (HRP) 
for 1 hour at room temperature under rotating and subsequently washed as described above. During 
the last incubation the ECL detection reagent (Millipore, #WBKLS0100) was prepared by mixing of 
both components in a ratio of 1:1, and the membrane surface was covered with ECL detection reagent 
for 5 minutes at room temperature. Excessive reagent was removed and the membrane was wrapped 
in cling film. In a dark room a sheet of X-ray film was exposed to the membrane. The film was then 
incubated in developer solution until bands were clearly visible, then rinsed with tap water and finally 
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immersed in fixer solution for about two minutes. The film was rinsed again with tap water to remove 
fixer solution. When the film was dry, a photograph was taken for quantification (2.5.14) and 
documentation purposes.  
 
If re-probing of nitrocellulose membranes with another pair of antibodies was required, the ECL 
reagent was washed off with TBST before bound antibodies were removed by incubating the 
membranes in a 60°C warm solution of 100mM glycine in PBS, pH 2.5, for 30min. The low pH in the 
buffer resulted in a denaturation of antibodies, and therefore in a loss of binding to their antigens. This 
step was carried out twice to increase efficiency. After 3 washes for 10min with TBST, membranes 
were incubated with blocking solution and primary and secondary antibodies as described above. 
 
 
2.5.14  Quantification of band intensities 
 
Measuring of band intensities of photographed Western blots was performed with ImageJ software. 
The images were converted to greyscale. Rectangular selections were made along the bands, which 
were about to be quantified. Then, the Ctrl and the 1 key were pressed simultaneously to activate the 
menu “Select First Lane” followed by pressing of Ctrl + 3 to activate “Plot Lanes”. This resulted in 
opening of a graph in a window showing the intensities in the selected rectangular area. However, 
since only the intensities of single bands were of interest, which appeared as peaks, and not of the 
entire selected area, the base of the peaks were marked using the line tool. This resulted in “sealing” 
of the peaks so that now the area under the curve could be measured. This was done with the help of 
the wand (tracing) tool by clicking directly in the encircled area under the peaks. In a new window, 
numbers were displayed indicating the area under the curve for each peak as a measure for band 
intensity. These values were copied into Microsoft Excel software, where the data were analysed by 
calculating the ratio of band intensities of cAMP agarose-bound protein and of band intensities of 
unbound protein (bound/unbound ratio). For each mutant mean values of ratios obtained from four 
independent experiments were determined and a graph was created using the GraphPad Prism 5 
software. GraphPad Prism 5 was also used to test statistical significance. 
This method was also used to analyse the ability of the POPDC1[L281P] protein to homodimerise. 
 
 
2.6 Cardiotoxin injections 
 
To investigate Popdc proteins in regenerating skeletal muscle, Cardiotoxin (Ctx) was injected into the 
tibialis anterior (TA) muscle of wildtype C57BL/6 and Popdc2
-/-
 mice. All mice were male and about 
3 months old. The injected Ctx (Sigma-Aldrich, #C9759) was actually a mixture of different 
cardiotoxins isolated from the venom of the Mozambique Spitting Cobra Naja mossambica 
mossambica. Cardiotoxins are proteins of a size of about 7kDa. They are causing depolarisation of 
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muscle fibres, which results in cell death and muscle damage, followed by regeneration. Injections 
were covered by PPL 70/7172 and PIL 70/22526. 
To facilitate injection, mice were anaesthetised with isoflurane. When the mouse was asleep, 2.5µg of 
the analgesic Vetergesic
®
 in a volume of 100µl was subcutaneously applied to ease pain in the first 
hours after injection. Then the legs were shaved and 25µl of PBS were injected into the right TA 
muscle. The left TA was injected with the same volume of 100µM Ctx. After injections, isoflurane 
supply was switched off to let the mouse wake up. To help the mouse to recover, wet diet was 
provided and the cage was kept in a warm incubator for several days. Well-being of Ctx-treated mice 
was monitored closely. 5d or 14d after Ctx injections, mice were sacrificed. TA muscles were carefully 
removed for histological analysis (2.4).  
Cross-sectional area was determined after staining of sections with wheat germ agglutinin (WGA) 
conjugated to FITC (Invitrogen, #W834) or the pan-myosin antibody. Images were taken using a Nikon 
digital camera DXM1200F mounted on a Zeiss Axioskop fluorescent microscope. CSA was measured 
with the NIS-Elements 3.0 software, and GraphPad Prism 5 software was used to create a graph and 
to test statistical significance. 
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3 RESULTS 
 
The discovery of TREK-1 as novel interaction partner of Popdc proteins has provided the first 
evidence that Popdc proteins are regulating ion channels and therefore play a role in 
electrophysiology of excitable tissues (Froese et al. 2012). It has been shown that in the presence of 
Popdc1, -2, or -3 TREK-1 current was increased to about 2-fold. At the same time, membrane 
representation of TREK-1 was doubled.  
TREK-1 is known as a background channel, which is important in setting the membrane potential. In 
the absence of Popdc proteins, as it is the case in the Popdc1 and -2 null mutants, the conductivity of 
this channel should be lower, the membrane potential and therefore the excitability of the cells higher. 
With regard to the heart, this would rather promote a tachycardia-like phenotype. However, a 
stress-induced bradycardia phenotype has been observed in Popdc1 and -2 null mutants (Froese et 
al. 2012). We therefore concluded that there might be other protein interactions by which Popdc 
proteins modulate cardiac pacemaking and other aspects of cardiac electrophysiology.  
In order to identify novel interaction partners, a screen based on co-immunoprecipitation coupled to 
protein mass spectrometry was set up. For this, we first tested some new commercially available 
antibodies against Popdc proteins with regard to their specificity. 
 
 
3.1 Antibody test 
 
Despite having been discovered more than a decade ago, not many reliable antibodies against Popdc 
proteins were commercially available until recently. In 2001 and 2004, papers have been published 
using an antibody against chicken POPDC1 (DiAngelo et al. 2001; Vasavada et al. 2004). This 
antibody is available from Developmental Studies Hybridoma Bank (#3F11). It works very well in the 
chick for both immunohistochemistry and Western blot, and has been used for several publications 
since also by our group (Torlopp et al. 2006); however, it is not suitable for use in other species 
(Stephanie Breher-Esch, personal communication). Another commercially available antibody was from 
Santa Cruz Biotechnology (#sc-49889). It has been shown not to stain tissue from Popdc1 null mutant 
mice, but gives a nice signal with wildtype tissue. It has also been used in Western blotting, however, 
its performance was less satisfying with regard to sensitivity (Breher 2009; Froese et al. 2012).  
For Popdc2 no specific antibody was available until recently. 
Therefore, some effort was undertaken at the beginning of this work to identify novel commercial 
antibodies that are reactive with endogenously expressed Popdc proteins in heart and skeletal 
muscle. According to manufacturer’s experimental data of both, immunohistochemistry and Western 
blot analysis (published online at www.proteinatlas.org), a novel anti-POPDC1 (HPA018176) and an 
anti-POPDC2 (HPA024255) antibody were chosen for further testing with regard to their suitability and 
reliability. These antibodies were purchased from Sigma-Aldrich and are therefore referred to as 
3 Results 77 
Sigma antibodies in this thesis. Both antibodies were first used in a Western blot using lysates of 
Cos-7 cells transfected with myc epitope-tagged murine constructs of Popdc1, Popdc2, or Popdc3. 
Untransfected Cos-7 cells served as negative control. Both antibodies produced a robust and specific 
signal. The antibody raised against Popdc1 recognised only Popdc1, whereas the anti-Popdc2 
antibody specifically detected Popdc2. The immunoreactive bands had a molecular weight of about 
60kDa (Figure 3.1). Doing Western blots with a myc antibody, the same sizes for the recombinant 
proteins have been obtained (Andree et al. 2000; Breher 2009; Froese et al. 2012). Having shown that 
these new antibodies react with recombinant Popdc proteins, we wanted to know whether also 
endogenously expressed proteins are reliably detected. Therefore, a membrane was probed with the 
Popdc1 antibody, on which size-separated protein samples of murine wildtype and Popdc1
-/- 
hearts 
along with lysates obtained from untreated and Popdc1 siRNA transfected rat neonatal myocytes were 
electroblotted. This membrane was provided by Dr Gania Kessler-Icekson, Tel Aviv University. As 
expected for a specific antibody, strong immunoreactivity was detected in the wildtype heart sample, 
whereas for the null mutant only a weak background staining could be observed. In the rat myocyte 
samples, strong signals were obtained with untreated cells, whereas siRNA transfected cells lysates 
showed weaker immunoreactivity in the Western blot.  
 
 
Figure 3.1: Antibody test 
Antibodies directed against Popdc1 (A) or Popdc2 (B) were tested in Western blots using lysates of 
Cos-7 cells transfected with murine myc epitope-tagged Popdc1, Popdc2 or Popdc3. Both antibodies 
specifically detected Popdc1 and Popdc2, respectively. The anti-Popdc1 antibody also detects 
endogenously expressed Popdc1. A strong signal was obtained for heart lysates from wildtype (WT) 
mice, but not from Popdc1
-/-
 (P1
-/-
) mice. Also for non-treated (nt) neonatal cardiac myocytes, strong 
reactivity was observed, which was weaker for lysates of cells treated with Popdc1 siRNA (KD) (C). 
 
 
Therefore, both antibodies are specific as they only detect Popdc1 or Popdc2 in a Western blot. They 
detect recombinant Popdc proteins and Popdc proteins solubilised from tissue and cultured primary 
cells reliably. Also for immunolabelling of Popdc proteins in cells and tissues, these antibodies are 
suitable (Subreena Simrick, personal communication, and data below). 
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3.2 Co-immunoprecipitation to identify novel interaction partners 
 
With these new Popdc1 and Popdc2 antibodies in hand we were able to set up the CoIP using heart 
tissue from about 3 months old wildtype C57BL/6J male mice, and, as controls, hearts obtained from 
Popdc1 or Popdc2 null mutants. 
Frozen hearts were pulverised and lysed in an optimised Tris-based buffer as described in chapter 
2.5.4. Initially, antibodies were cross-linked to protein A or G agarose to prevent contamination of the 
eluted proteins with antibody light and heavy chains. However, it turned out that cross-linking reduces 
the affinity of the antibodies, and therefore, antibodies were incubated with the lysate overnight and 
then captured with protein A or G agarose as described in chapter 2.5.7. In addition to the Popdc2 
antibody from Sigma-Aldrich, we also used an antibody from Santa Cruz Biotechnology (#sc-66588) 
directed against Popdc2, in the following referred to as Santa Cruz anti-Popdc2 antibody. To make 
sure that the amount of solubilised Popdc proteins is not limiting, 10mg protein lysate was used in 
each experiment. 
Proteins eluted from the agarose after several washes with TBS were size-separated using a 4-12% 
gradient gel to allow efficient separation of smaller and larger proteins at the same time. The gel was 
stained in Coomassie solution. Interestingly, only for the Santa Cruz anti-Popdc2 antibody bands 
could be observed in the wildtype sample, which were not present in the precipitate using the  
Popdc2
-/-
 heart lysate (Figure 3.2A).  
 
 
 
Figure 3.2: Coomassie gels after CoIP 
CoIPs from heart lysates of wildtype and Popdc2
-/-
 (P2
-/-
) or Popdc1
-/-
 (P1
-/-
) mice were performed 
using anti-Popdc2 antibodies from Santa Cruz (Scbt antibody, sc-66588) or from Sigma-Aldrich 
(Sigma antibody, HPA024255) (A), and with anti-POPDC1 antibody from Sigma-Aldrich (HPA018176) 
(B). Precipitates were eluted form the agarose by boiling. After size-separation of the proteins, gels 
were stained with Coomassie solution as depicted, and send to Dr Krueger’s lab to be mass 
spectrometrically analysed. Arrows indicate presumptive antibody heavy (IgGH) and light chains 
(IgGL). 
 
 
 
3 Results 79 
As Coomassie staining is not particularly sensitive, it was assumed that also with the Sigma antibody 
differences between WT and Popdc2
-/-
 hearts may be present, although not visible.  
Therefore, also the samples of proteins precipitated with the Sigma antibody were mass 
spectrometrically analysed in Dr Marcus Krueger’s lab in Bad Nauheim, Germany.  
 
For each mass spectrometrically identified protein a score calculated on the basis of intensity and 
amount of specific peptides precipitated with the same antibody from wildtype and Popdc2
-/-
 lysates 
was obtained. Only those were considered as hits or candidates with a score (WT:Popdc2
-/-
) of 2 or 
higher or those were at least two peptides were detected with some intensity (>0) in the wildtype 
sample but not in the null mutant lysates. 
 
In both samples, Popdc2 was detected demonstrating the affinity of the antibodies to their Popdc2 
antigen. The only previously identified interacting protein of Popdc2, Trek-1, was not co-precipitated 
with either antibody. However, Vamp3, which has been shown to interact with Popdc1 (Hager et al. 
2010) was co-precipitated together with the Sigma antibody. In a second round of CoIPs, only the anti-
POPDC2 antibody from Sigma was used (Figure 3.2B). Thus, for the Santa Cruz Popdc2 antibody 
interacting candidates were obtained from one round of CoIP, whereas results for the Sigma antibody 
are from two rounds of CoIP. In total, 204 candidates have been obtained from these two rounds of 
co-precipitation using the Sigma anti-Popdc2 antibody, the majority of them being identical in both 
experimental rounds. 
In a single CoIP experiment using the Santa Cruz antibody 132 candidates were identified. With both 
antibodies, most proteins (55/204 for the Sigma antibody, and 48/132 for the Scbt antibody) were 
blood-related, e.g. antibody chains, etc., and therefore most likely false-positives. Strongly present 
were also mitochondrial proteins and proteins involved in energy metabolism (Sigma: 34/204; 
Scbt: 20/132). As there is no evidence of Popdc2 being expressed in mitochondria, these group may 
be false-positive hits as well. A third strongly represented group of proteins were proteins involved in 
protein biosynthesis or degradation (Sigma: 25/204; Scbt: 23/132). To this group ribosomal proteins 
and constituents of the ubiquitin-proteasome pathway were counted. A large amount of precipitated 
proteins could be classified in a group of cytoskeletal or cytoskeleton-associated and contractile 
proteins, and proteins of the basement membrane, and therefore proteins involved in cell morphology 
and stability (Sigma: 30/204; Scbt: 15/132). Other proteins could be grouped as proteins being 
expressed in the nucleus or in the nuclear envelope (Sigma: 5/204; Scbt: 13/132), playing a role in 
vesicular transport and fusion (Sigma: 14/204; Scbt: 3/132), or ion flux regulation (Sigma: 15/204; 
Scbt: 3/132). Many of the candidates were identified with both antibodies, however, also unique hits 
were obtained with either antibody (Figure 3.3).  
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Figure 3.3: Distribution of proteins co-precipitated with Popdc2 from heart lysates 
CoIP experiments were performed with the Santa Cruz anti-Popdc2 antibody sc-66588 (A) or the 
Sigma HPA 024255 antibody (B). 132 proteins were precipitated with the Santa Cruz antibody, 204 
with the anti-Popdc2 antibody from Sigma. With both antibodies Popdc2 was precipitated showing the 
affinity of the antibodies to their Popdc2 antigen. Many identified candidates were coming from the 
blood and therefore most likely represent false-positives.  
 
 
Analogously, CoIP coupled to mass spectrometry was also performed with the Sigma anti-Popdc1 
antibody using wildtype and Popdc1
-/-
 hearts (Figure 3.2B). 51 proteins were obtained as potential 
interaction partners, of which 26 were from blood, and 9 were mitochondrial proteins or involved in 
energy metabolism. Three others were related to protein synthesis and degradation. One hit was 
obtained for vesicle transport/fusion and one for ion flux regulation, whereas 6 proteins were from the 
cytoskeleton or contractile apparatus and 2 nuclear proteins were obtained (Figure 3.4). As expected 
for precipitation with anti-POPDC1 antibody, Popdc1 was among the precipitated proteins detected. 
None of the known interactors (ZO-1, GEFT, Vamp2, Vamp3, aPKC, NDRG4, TREK-1) was among 
the precipitated proteins.   
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Figure 3.4: Distribution of proteins co-precipitated with Popdc1 from heart lysates 
CoIP experiments were performed with the Sigma anti-Popdc1 antibody HPA018176. 35 proteins 
were precipitated including Popdc1. Most of these were proteins with a function in the blood and 
therefore most likely represent false-positives. Precipitated proteins did not include any of the 
established Popdc1 interacting proteins ZO-1, GEFT, Vamp2, Vamp3, aPKC, NDRG4 or TREK-1. 
 
 
In order to see whether the spectrum of interaction partners is similar in skeletal muscle, CoIP coupled 
to mass spectrometry was performed with TA (tibialis anterior) muscle lysates using the Popdc1 and 
Popdc2 antibodies from Sigma. For Popdc1 133 hits were obtained, whereas 122 proteins were 
precipitated with the anti-Popdc2 antibody. A minority of proteins was from blood (Popdc1: 8/133; 
Popdc2: 6/122). Strongly represented were mitochondrial proteins and proteins involved in metabolic 
processes (Popdc1: 45/133; Popdc2: 30/122). A large number of candidate proteins play a role in 
protein generation and degradation (Popdc1: 16/133; Popdc2: 13/122). 16 proteins precipitated with 
the anti-Popdc1 have known functions in the nucleus, and 8 others, which are related in signalling 
processes, including kinases and phosphatases. 9 candidates are involved in vesicular trafficking, and 
4 in regulating ion flux, e.g. ion channels. In addition to 7 precipitated cytoskeletal components or 
scaffolding proteins, 4 members of the dystrophin-dystroglycan complex were identified (Figure 3.5A).  
With the anti-Popdc2 antibody, 14 nuclear proteins have been co-precipitated. Additionally, 14 of the 
122 candidates are involved in signalling processes. 7 proteins with a role in vesicular trafficking and 
9 regulators of ion fluxes have been obtained. Furthermore, 6 cytoskeletal or scaffolding proteins were 
identified. In addition, 3 members of the dystrophin-dystroglycan complex were among the potential 
interaction partners of Popdc2 (Figure 3.5B).  
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Figure 3.5: Interaction candidates for Popdc1 and Popdc2 in skeletal muscle 
CoIP experiments using TA muscle lysates were performed with the Sigma anti-Popdc1 antibody 
HPA018176 and the Sigma anti-Popdc2 antibody HPA024255. 133 proteins were precipitated with the 
anti-Popdc1 antibody including Popdc1 (A). 122 hits were obtained with the anti-Popdc2 antibody, 
including Popdc2 (B). 
 
 
The candidates being most promising to be true interacting proteins were those, which have been 
picked up independently in the different CoIP experiments. Therefore, we analysed the data with 
regard to overlaps. As blood proteins and those involved in metabolic processes are likely to be  
false-positives, these candidates were excluded. Likewise, uncategorised proteins (“others”) were 
disregarded. Thus, for analysing potential interaction partners of Popdc proteins in the heart we 
compared 12 candidates we got from CoIP coupled to mass spectrometry using the Sigma Popdc1 
antibody, 66 obtained with the Sigma anti-Popdc2 antibody and 36 candidates identified with the 
Santa Cruz anti-Popdc2 antibody. Comparing the potential interaction partners for Popdc2 we found 
9 proteins (including Popdc2), which have been precipitated with both antibodies, from Sigma and 
Santa Cruz. These are therefore most likely true interaction candidates as they were picked up in 
independent experiments using different antibodies and agaroses. Analysing proteins precipitated with 
the Sigma anti-Popdc2 as well as the Sigma anti-Popdc1 antibody, we found 6 identical proteins. 
However, the overlap of candidates obtained with the Santa Cruz anti-Popdc2 and the Sigma 
anti-Popdc1 antibody was only two proteins, Popdc1 and Popdc2 (Figure 3.6A). 
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We next analysed how many candidates for Popdc1 or Popdc2 were identical using heart and skeletal 
muscle lysates. For Popdc1, we found three proteins picked up as potential interaction partners in the 
heart as well as skeletal muscle. These three proteins are Popdc1, Popdc2, and Ankyrin-G. For 
Popdc2, we found 6 proteins, which were precipitated from heart as well as skeletal muscle lysates, 
including Popdc1, Popdc2, Ankyrin-B, and Ankyrin-G (Figure 3.6B).  
Table 3.1 shows proteomics data for Popdc1, Popdc2, Ankyrin-B, Ankyrin-G, and NCX-1 obtained 
from each of the six CoIPs performed in this work.  
 
 
 
Figure 3.6: Overlap of proteins identified by CoIP coupled to mass spectrometry 
Sets of proteins identified by CoIP coupled to mass spectrometry were compared with regard to 
overlaps. Blood proteins and proteins involved in metabolic processes, as well as uncategorised 
proteins (“others”) were disregarded. Figure 3.6A shows distribution of proteins identified by different 
antibodies using heart lysates. In Figure 3.6B, overlap of interaction candidates identified in the heart 
and skeletal muscle are shown for Popdc1 (red), and Popdc2 (green; Sigma antibody only). 
 
 
 
To validate these results, we confirmed some of these candidates in CoIP experiments followed by 
Western blot analysis (chapter 3.3). 
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Table 3.1: Mass spectrometry data obtained for Popdc1 and -2, Ankyrin-B and -G, and NCX-1 
LFQ (label-free quantification) intensites and number of unique peptides for wildtype (WT) and Popdc1 
(P1
-/-
) or Popdc2 null mutant samples (P2
-/-
) are listed. Ratios of intensities (WT/mutant) are given as 
logarithmised (log) values (data provided by Dr Marcus Krueger). 
 
Table 3.1a: CoIP with the anti-Popdc1 antibody from Sigma using heart lysates  
  
LFQ intensity 
significance B 
significant 
 
 
unique peptides 
peptides WT P1
-/-
 log ratio (yes/no) WT P1
-/-
 
Popdc1 3.31 ∙ 10
6
 0 - - - 16 3 
Popdc2 3.89 ∙ 10
6
 0 - - - 13 5 
Ankyrin-B 0 0 - - - 4 3 
Ankyrin-G 3.46 ∙ 10
6
 0 - - - 22 5 
NCX-1 3.87 ∙ 10
6
 0 - - - 8 6 
 
Table 3.1b: CoIP with the anti-Popdc2 antibody from Santa Cruz using heart 
lysates 
  
LFQ intensity 
significance B 
significant 
 
 
unique peptides 
WT P2
-/-
 log ratio (yes/no) WT P2
-/-
 
Popdc1 1.29 ∙ 10
6
 8.83 ∙ 10
5
 0.55 0.58 no 12 5 
Popdc2 8.05 ∙ 10
6
 0 - - - 7 1 
Ankyrin-B 7.48 ∙ 10
5
 5.40 ∙ 10
5
 0.47 0.66 no 6 3 
Ankyrin-G 7.80 ∙ 10
5
 6.33 ∙ 10
5
 0.30 0.84 no 8 3 
NCX-1 9.05 ∙ 10
5
 9.12 ∙ 10
5
 -0.01 0.81 no 4 5 
 
Table 3.1c: First CoIP experiment with the anti-Popdc2 antibody from Sigma using heart lysates 
  
LFQ intensity 
significance B 
significant unique peptides 
peptides WT P2
-/-
 log ratio (yes/no) WT P2
-/-
 
Popdc1 1.16 ∙ 10
9
 3.80 ∙ 10
5
 11.57 7.66 ∙ 10
-145
 yes 18 4 
Popdc2 1.03 ∙ 10
9
 0 - - - 12 1 
Ankyrin-B 3.94 ∙ 10
7
 7.34 ∙ 10
5
 5.75 1.28 ∙ 10
-36
 yes 10 5 
Ankyrin-G 2.96 ∙ 10
8
 4.51 ∙ 10
5
 9.36 4.27 ∙ 10
-95
 yes 37 3 
NCX-1 3.28 ∙ 10
7
 1.30 ∙ 10
6
 4.65 1.91 ∙ 10
-24
 yes 9 7 
 
Table 3.1d: Second CoIP experiment with the anti-Popdc2 antibody from Sigma using heart lysates 
  
LFQ intensity 
significance B 
significant 
 
 
unique peptides 
peptides WT P2
-/-
 log ratio (yes/no) WT P2
-/-
 
Popdc1 8.91 ∙ 10
8
 1.93 ∙ 10
5
 12.17 6.05 ∙ 10
-118
 yes 16 3 
Popdc2 7.32 ∙ 10
8
 6.22 ∙ 10
5
 10.20 3.12 ∙ 10
-83
 yes 14 2 
Ankyrin-B 8.53 ∙ 10
6
 4.27 ∙ 10
5
 4.32 8.78 ∙ 10
-13
 yes 5 2 
Ankyrin-G 1.96 ∙ 10
8
 6.69 ∙ 10
5
 8.19 3.45 ∙ 10
-54
 yes 21 6 
NCX-1 4.01 ∙ 10
7
 9.70 ∙ 10
5
 5.37 5.09 ∙ 10
-24
 yes 9 4 
 
Table 3.1e: CoIP with the anti-Popdc1 antibody from Sigma using skeletal muscle lysates  
  
LFQ intensity 
significance B 
significant 
 
 
unique peptides 
WT P1
-/-
 log ratio (yes/no) WT P1
-/-
 
Popdc1 8.35 ∙ 10
7
 1.12 ∙ 10
6
 6.22 5.13 ∙ 10
-23
 yes 18 8 
Popdc2 5.13 ∙ 10
7
 1.35 ∙ 10
6
 5.24 9.67 ∙ 10
-17
 no 9 7 
Ankyrin-B 5.52 ∙ 10
5
 5.76 ∙ 10
5
 -0.06 0.97 no 4 6 
Ankyrin-G 1.31 ∙ 10
6
 4.70 ∙ 10
5
 1.49 0.04 no 18 24 
NCX-1 0 4.25 ∙ 10
5
 - - - 3 3 
 
Table 3.1f: CoIP with the anti-Popdc2 antibody from Sigma using skeletal muscle lysates  
  
LFQ intensity 
significance B 
significant 
 
 
unique peptides 
WT P2
-/-
 log ratio (yes/no) WT P2
-/-
 
Popdc1 1.25 ∙ 10
8
 2.56 ∙ 10
5
 8.93 3.19 ∙ 10
-42
 yes 18 7 
Popdc2 1.59 ∙ 10
8
 1.95 ∙ 10
6
 6.35 3.91 ∙ 10
-22
 yes 10 6 
Ankyrin-B 9.14 ∙ 10
5
 5.86 ∙ 10
5
 0.64 0.30 no 6 6 
Ankyrin-G 8.43 ∙ 10
7
 5.11 ∙ 10
5
 7.37 2.93 ∙ 10
-29
 yes 46 21 
NCX-1 4.17 ∙ 10
5
 3.93 ∙ 10
5
 0.08 0.83 no 3 5 
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3.3 Validation of Ankyrins as interactions partners of Popdc proteins 
 
To further validate the CoIP coupled to mass spectrometry screen and to confirm some of these 
candidate interacting proteins, the CoIPs were repeated and the proteins were detected by Western 
blot. Proteins were chosen, which were picked up with a high score in more than one round of CoIP 
coupled to mass spectrometry (compare Figure 3.6), and which have been shown previously to play 
important roles in muscle physiology. Among these were Ankyrin-G and -B. Albeit not co-precipitated 
with the Santa Cruz anti-Popdc2 antibody, high scores were obtained for these candidates in 
precipitations performed with anti-Popdc1 and anti-Popdc2 antibodies from Sigma using either heart 
or skeletal muscle tissue.  
 
 
3.3.1 Ankyrin-B interacts with Popdc1 and Popdc2 
 
CoIPs from heart lysates were performed and membranes were probed with an anti-Ankyrin-B 
antibody. Ankyrin-B was detected after immunoprecipitation with the anti-Popdc1 antibody when 
wildtype lysate was used, but not with the Popdc1
-/- 
sample, which served as negative control (Figure 
3.7A). Accordingly, Ankyrin-B was co-precipitated together with Popdc2. As expected, the anti-Popdc2 
antibody did not precipitate Ankyrin-B in the absence of Popdc2 as it was the case in the Popdc2
-/- 
heart lysate (Figure 3.7B).  
 
 
Figure 3.7: Co-precipitation of Ankyrin-B with Popdc1 and Popdc2 from heart lysates 
Immunoprecipitation was performed with the anti-Popdc1 antibody using wildtype and Popdc1
-/-
 (A) or 
with the anti-Popdc2 antibody using wildtype and Popdc2
-/- 
heart lysates (B). Precipitates were 
subjected to Western blotting. Using a specific antibody, Ankyrin-B was detected running at about 
220kDa in both wildtype samples, but not in the null mutant controls. CoIP experiments of Ankyrin-B 
with Popdc1 and Popdc2 from heart lysates were performed twice. 
 
 
Further evidence of interaction was obtained from immunocytochemistry on neonatal murine cardiac 
myocytes where partial co-localisation of Popdc2 and Ankyrin-B could be observed (Figure 3.8). 
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Figure 3.8: Partial co-localisation of Popdc2 and Ankyrin-B in neonatal ventricular myocytes 
Ventricular neonatal myocytes were isolated and immunocytochemically stained for Popdc2 (red) and 
Ankyrin-B (green). The section encircled by the white rectangle in A’’ is depicted as expanded image 
in B-B’’. White arrows indicate towards sites of co-localisation (scale bars: 10µm). Neonatal ventricular 
myocytes were isolated and immunolabeleled in two independent experiments.  
 
 
3.3.2 Popdc proteins partially co-localise with Ankyrin-B in skeletal muscle 
 
Ankyrin-B was co-precipitated from heart lysates. It was also shown that it co-localises with Popdc1 
and Popdc2 in cardiac myocytes. We also tested localisation of Ankyrin-B and co-localisation with 
Popdc proteins in skeletal muscle. Cryosectioned TA or soleus muscles were co-stained for Popdc1 or 
Popdc2 with Ankyrin-B. As shown in Figure 3.9, there was some overlapping distribution of Popdc1 
and Popdc2 with Ankyrin-B. As Ankyrin-B was also co-precipitated with Popdc2 from skeletal muscle 
(see chapter 3.2), it is reasonable to assume interaction of Popdc1 and Popdc2 with Ankyrin-B also in 
skeletal muscle tissue. 
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Figure 3.9: Overlap of Popdc1 and Popdc2 with Ankyrin-B in skeletal muscle 
TA (A) and soleus muscle (B) were excised from wildtype hindlimbs, cryosectioned, and stained for 
Popdc1 (red, A) or Popdc2 (red, B) and Ankyrin-B (green). Both Popdc1 and Popdc2 showed overlaps 
in distribution with Ankyrin-B (scale bars: 10µm). Immunohistochemistry for the detection of Popdc1 or 
Popdc2 and Ankyrin-B was performed twice. 
 
 
3.3.3  Ankyrin-G interacts with Popdc1 and Popdc2 
 
Another interaction candidate, which was detected with high score using the anti-Popdc1 and 
anti-Popdc2 antibodies from Sigma, was Ankyrin-G. For both Popdc1 and Popdc2 interaction with 
Ankyrin-G could be confirmed in Western blots using immunoprecipitated samples from WT and 
Popdc1 or Popdc2 null mutant hearts. Using the anti-Popdc1 antibody, only in the wildtype heart 
sample strong signals occurred, whereas no band being significantly above background could be 
detected when Popdc1 null mutant heart lysates were used (Figure 3.10A). Likewise, in 
immunoprecipitations with the anti-Popdc2 antibody Ankyrin-G could be co-precipitated from wildtype 
heart lysate but not from the Popdc2
-/- 
sample (Figure 3.10B).  
 
 
Figure 3.10: Co-precipitation of Ankyrin-G with Popdc1 and Popdc2 from heart lysates 
Proteins were extracted from whole wildtype and Popdc1 (A) or Popdc2 null mutant (B) hearts, and 
CoIP was performed using an anti-Popdc1 (A) or anti-Popdc2 antibody (B). In both cases, Ankyrin-G 
was co-precipitated from wildtype but not from null mutant heart lysates. The immunoreactive bands 
shown in the Western blot were at about 200kDa, which corresponds to the predicted size of 
Ankyrin-G of 190kDa. Co-immunoprecipitation of Ankyrin-G with Popdc1 and Popdc2 from heart 
lysates was carried out twice. 
3 Results 88 
To further corroborate interaction of Popdc proteins with Ankyrins, Ankyrin-3 cDNA encoding for 
Ankyrin-G was subcloned into the pEYFP-N1 vector to produce Ankyrin-G-YFP.  
This Ankyrin-G-YFP construct was transfected together with pCS2+MT (vector) or Popdc1[WT]-myc 
into Cos-7 cells. 24h later cells were harvested and protein lysates were incubated with 5µg 
immobilised anti-myc antibody. After several washes, precipitated proteins were eluted from the 
agarose by boiling at 96°C and samples were subjected to Western blot analysis. Ankyrin-G-YFP was 
detected using an anti-GFP antibody. Figure 3.11 shows that Ankyrin-G could only be precipitated in 
the presence of Popdc1, but not when the vector alone was co-transfected. This demonstrates a 
specific interaction of Popdc1 with Ankyrin-G after overexpression in Cos-7 cells. Therefore, 
interaction of Popdc proteins with Ankyrins was confirmed in an additional independent experiment. 
 
 
 
Figure 3.11: CoIP of Ankyrin-G with Popdc1 from transfected Cos-7 cells 
Cos-7 cells were transfected with YFP-tagged Ankyrin-G together with either myc-tagged Popdc1 or 
the empty pCS2+MT, and CoIPs were performed 24h later. The Western blot probed with an anti-GFP 
antibody for the detection of Ankyrin-G revealed precipitation of Ankyrin-G only in the presence of 
Popdc1. Co-IP of Ankyrin-G with Popdc1 from transfected Cos-7 cells was performed three times. 
 
 
 
3.4 Popdc2 interacts with the sodium/calcium exchanger NCX-1 
 
The sodium/calcium exchange protein NCX-1 was among the proteins potentially interacting with 
Popdc2. It was picked up in the mass spectrometry analyses in both CoIP experiments performed with 
the Sigma antibody using heart lysates. In both cases, the score was high so that interaction was 
considered to be very likely. We therefore wanted to see whether we can detect NCX-1 co-precipitated 
with Popdc2 also on a Western blot. As shown in Figure 3.12, NCX-1 was clearly detectable in the 
wildtype lysates, but was not present after immunoprecipitation using protein lysate from Popdc2 null 
mutant mice. It can therefore be concluded that NCX-1 is indeed a protein interacting with Popdc2.  
In contrast to Popdc2, NCX-1 could not be established as interaction partner for Popdc1. 
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Figure 3.12: Co-precipitation of NCX-1 with Popdc2 from heart lysates 
Proteins extracted from wildtype and Popdc2
-/-
 hearts were subjected to immunoprecipitation with the 
Sigma anti-Popdc2 antibody. Precipitated proteins were size-separated on a SDS gel and blotted onto 
nitrocellulose membrane. Strong immunoreactivity for NCX-1 (between 100 and 130kDa) could be 
detected in the wildtype sample, but not in the Popdc2
-/-
 control. Co-precipitation of NCX-1 with 
Popdc2 from heart lysates was performed twice. 
 
 
By immunocytochemistry performed on isolated adult cardiac myocytes by Dr Subreena Simrick, 
strong co-localisation of NCX-1 with Popdc1 and -2 at the plasma membrane and in t-tubules was 
observed, supporting the CoIP data.  
 
Taken together, we could confirm the interaction of Popdc1 and -2 with Ankyrin-G, and -B. 
Furthermore, also an interaction with the sodium/calcium exchanger NCX-1 could be corroborated.  
 
 
3.5 Popdc proteins interact with the voltage-gated sodium channel 
SCN5A/Nav1.5 
 
One of the candidates of interacting proteins for both Popdc1 and Popdc2 was the sodium channel 
subunit Scn4a/Nav1.4, which was found to be co-precipitated with both Popdc1 and Popdc2 from 
skeletal muscle lysates. Interestingly, an electrophysiology-based screen for Popdc-interacting 
channels in Professor Niels Decher’s lab in Marburg, Germany, resulted in identifying of Scn5a/Nav1.5 
as interaction partner. Scn5a is an isoform of the voltage-gated sodium channel closely related to 
Scn4a and expressed in cardiac muscle, whereas Scn4a is primarily found in skeletal muscle. 
Co-expression of SCN5A with Popdc2 in Xenopus oocytes resulted in an inhibition of the sodium 
current (Niels Decher, personal communication). 
To further corroborate interaction with the sodium channel, SCN5A cDNA was fused to a HA epitope 
tag by PCR and subcloned into a mammalian expression vector (pECFP-N1). This construct was 
transfected into Cos-7 cells together with Popdc1[WT]-myc. For a negative control cells were 
transfected with Popdc1[WT]-myc and the empty pECFP-N1 vector. 24 hours later cells were 
harvested for CoIP using the Pierce HA Tag IP/Co-IP Kit from Thermo Scientific. After incubation of 
the lysates with the anti-HA agarose overnight and several washes with TBS, bound proteins were 
eluted by boiling in SDS sample buffer and subsequently used for Western blot analysis. 
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Co-precipitation of Popdc1[WT]-myc was observed only in the presence of SCN5A-HA. It was not 
precipitated by the anti-HA antibody in the absence of SCN5A-HA.  
 
 
 
Figure 3.13: Co-precipitation of Popdc1[WT]-myc with SCN5A-HA 
Cos-7 cells were transfected with Popdc1[WT]-myc together with either the empty pECFP-N1 vector 
or the SCN5A-HA construct, and CoIPs were performed 24h later. The Western blot probed with 
anti-myc antibody revealed precipitation of Popdc1 only in the presence of SCN5A. CoIP of 
Popdc1[WT]-myc with SCN5A-HA was carried out four times. 
 
 
To visualise subcellular distribution of SCN5A-HA in presence and absence of Popdc1[WT]-myc in 
Cos-7 cells, immunocytochemical staining was performed.  
In the absence of SCN5A-HA, Popdc1[WT]-myc was mainly localised to the ER but also to the plasma 
membrane of transfected Cos-7 cells, as revealed by co-transfection with the ER marker plasmid 
pCDNA3-CD4-EGFP-KKXX (Zerangue et al. 1999), which was kindly provided by Dr Blanche 
Schwappach, Heidelberg (Figure 3.14).  
 
 
Figure 3.14: Subcellular localisation of Popdc1[WT]-myc in transfected Cos-7 cells 
Cos-7 cells were transfected with Popdc1[WT]-myc and the ER marker construct 
pCDNA3-CD4-EGFP-KKXX. 24h later, cells were fixed and immunohistochemistry for the detection of 
Popdc1[WT]-myc was performed using an anti-myc antibody (red). Confocal images demonstrate 
strong overlap with the ER marker, which was visualised through its GFP fluorescence (green). Figure 
3.14B shows the digitally zoomed section encircled by the white rectangle in A’’. Arrows indicate 
overlaps of Popdc1 labelling and the ER marker (scale bars: 10µm). Comparable results were 
obtained for cells analysed in three independent experiments.  
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A distribution similar to Popdc1[WT]-myc was revealed when SCN5A-HA was transfected alone into 
Cos-7 cells with SCN5A-HA being present predominantly in the ER and to a minor extent at the 
plasma membrane (Figure 3.15A).  
 
Co-transfection revealed both proteins to be extensively co-localised, providing further evidence for 
interaction (Figure 3.15B).  
 
We therefore conclude that the effect of Popdc proteins on SCN5A conductivity observed in Xenopus 
oocytes could be due to direct physical interaction of Popdc proteins with the voltage-gated sodium 
channel. 
 
 
 
Figure 3.15: Co-localisation of Popdc1[WT]-myc and SCN5A-HA in transfected Cos-7 cells 
Immunolabelling of Cos-7 cells transfected with SCN5A-HA alone (A) or together with 
Popdc1[WT]-myc (B-B’’) showed localisation of SCN5A in the ER and at the plasma membrane (A), 
and overlapping distribution of both proteins after co-transfection (B’’) (scale bars: 10µm). Similar 
subcellular distributions were seen for cells analysed in two different experiments. 
 
 
 
3.6 Popdc1 interacts with Caveolin-3 via a C-terminal binding site 
 
In the group of Dr Gania Kessler-Icekson, Petah-Tikva, Israel, Caveolin-3 has recently been identified 
as a further interaction partner of Popdc1 (Alcalay et al. 2013). They found that in the absence of 
Popdc1 caveolae in the hearts were altered in number and size. These might contribute to the 
observed ischemia-reperfusion vulnerability of Popdc1 null mutant hearts. Although Caveolin-3 was on 
the list of interaction partners identified by CoIP coupled to mass spectrometry, the score, which is 
calculated on the basis of intensity and amount of specific peptides precipitated from wildtype and 
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Popdc null mutant tissue, was below 2. Therefore, Caveolin-3 would not have been regarded as 
interactor in our screen. However, Popdc1 was co-sedimented with Caveolin-3 from membrane 
fractions and a binding site for Caveolin-3 was predicted in the C-terminus of Popdc1 (Figure 3.16A). 
According to a tertiary structure prediction, this binding site is located within an α-helix, which is part of 
the cAMP binding domain. We used our CoIP protocol to test whether this binding site is functional. 
For this purpose a series of C-terminal deletions of Popdc1 as indicated in Figure 3.16A were used. 
Most interesting were Popdc1[92]-myc, which retained the putative Cav3 binding site, and 
Popdc1[116]-myc, where the binding site was deleted. The binding of Caveolin-3 was much lower to 
Popdc1[116]-myc compared to Popdc1[92]-myc and the full-length Popdc1 construct 
(Popdc1[WT]-myc). Thus, it was demonstrated that the predicted binding site is functional and 
contributes significantly to Cav3 binding. 
 
 
Figure 3.16: Popdc1 interacts with Caveolin-3 via a C-terminal binding site 
A Caveolin-3 binding site was predicted in the C-terminus of Popdc1 (A). Deletion-mutated 
myc-tagged Popdc1 constructs or the empty pCS2+MT vector (Cav3 only) were co-transfected with 
Caveolin-3 into Cos-7 cells. 48h later immunoprecipitations were performed using an anti-myc 
antibody. Binding of Cav3 to the Popdc proteins was analysed in a Western blot. Only when the 
constructs harbouring the predicted binding site (WT and 92) were present strong immunoreactivity 
for Cav3 could be detected, whereas the lack of this site as represented in the 116 mutant lead to a 
drastic reduction in Cav3-binding (B), suggesting that the predicted binding site is indeed functional. 
Figure 3.16C indicates the presumptive location of the Cav3 binding site within the structure of the 
Popdc1 C-terminus (figure modified from (Alcalay et al. 2013)). For each Popdc1 construct CoIP with 
Caveolin-3 was carried out at least twice.  
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3.7 Popdc1 interacts with Dysferlin 
 
Caveolin-3 was not found as candidate by the screen for interacting proteins using CoIP coupled to 
mass spectrometry, but yet interaction with Popdc1 could clearly be determined (3.6). Dysferlin is a 
membrane-bound protein involved in repair processes of muscle fibres. Mutations in the Dysferlin 
encoding gene in humans are associated with autosomal-recessive muscular dystrophies 
(Demonbreun et al. 2011). Dysferlin is a known interaction partner of Caveolin-3 (Matsuda et al. 
2001). We therefore tested the possibility of Dysferlin also interacting with Popdc1. A plasmid 
encoding HA-tagged human Dysferlin (Dysferin-3HA) was obtained from Addgene (Covian-Nares et 
al. 2010). Myc-tagged wildtype murine Popdc1 was transfected alone or together with the empty 
pCDNA3.1(+) vector into Cos-7 cells and CoIP was performed using the Pierce
®
 HA Tag IP/Co-IP Kit 
from Thermo Scientific. Precipitates were subjected to Western blot for the detection of Popdc1 using 
an anti-myc antibody. As shown in Figure 3.17A, Popdc1 was only co-precipitated in the presence of 
Dysferlin, but not with an empty vector alone, which is indicative of specific interaction between these 
two proteins. We wondered whether this interaction is mediated by caveolins. We therefore repeated 
the CoIP experiments with a deletion-mutated Popdc1 construct lacking the Caveolin-3 binding site 
(Popdc1[116]-myc). As an additional control, a mutant was used harbouring a deletion C-terminally 
of the Caveolin-3 binding site, but keeping the Caveolin-3 binding site itself intact (Popdc1[107]-myc) 
(Figure 3.17C). Both mutants were co-precipitated with Dysferlin, suggesting that Caveolin-binding is 
not necessary for Popdc1-Dysferlin interaction (Figure 3.17B). 
 
 
 
Figure 3.17: Interaction of Popdc1 with Dysferlin 
Myc-tagged wildtype Popdc1 (WT) was transfected into Cos-7 cells together with the empty 
pCDNA3.1(+) vector or with Dysferlin-3HA (Dysf) (A). Likewise, the deletion-mutated Popdc1 
constructs Popdc1[107]-myc (harbouring Caveolin-3 binding site) or Popdc1[116]-myc (lacking 
Caveolin-3 binding site) were transfected either with the empty vector or with Dysferlin-3HA (B). The 
localisation of the deleted regions of Popdc1 is depicted in C. Binding of all Popdc1 constructs was 
observed, suggesting that binding for Dysferlin does not require the Caveolin-3 binding site. For each 
Popdc1 construct CoIP with Dysferlin was carried out three times. 
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In addition, co-localisation studies were performed by immunocytochemistry using Cos-7 cells 
transfected with Dysferlin-3HA alone or in combination with Popdc1[WT]-myc. Overexpression of 
Dysferlin resulted in the protein to be mainly localised in the ER, but also vesicles and the plasma 
membrane were stained (Figure 3.18A). After co-transfection with Popdc1, both proteins were largely 
co-localised (Figure 3.18B). Thus, evidence for interaction of Popdc proteins with Dysferlin has been 
obtained from an independent approach. 
 
 
 
Figure 3.18: Co-localisation of Popdc1 and Dysferlin after co-transfection into Cos-7 cells 
A HA epitope tagged Dysferlin construct was transfected alone (A) or together with myc-tagged 
Popdc1 (B). Immunocytochemistry was performed for the detection of Dysferlin using an anti-HA 
antibody (green), and for Popdc1 with an anti-myc antibody (red). Arrows indicate overlapping 
distribution of Popdc1 and Dysferlin in vesicles, whereas arrowheads show co-localisation at the 
plasma membrane (scale bars: 10µm). Similar subcellular localisation of Popdc1 and Dysferlin was 
observed in two independent experiments.  
 
 
 
3.7.1 Popdc1 interacts with Dystrophin 
 
In the screen for interaction partners (3.2), one of the candidates was Dystrophin. In order to test 
whether Dystrophin is indeed an interacting protein we first investigated whether Popdc proteins are 
co-localised with Dystrophin in skeletal muscle. Immunohistochemistry of cryosectioned TA muscle 
revealed strong co-localisation of both Popdc1 and Popdc2 with Dystrophin (Figure 3.19). 
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Figure 3.19: Co-localisation of Popdc1 and Popdc2 with Dystrophin 
10µm cryosections of TA muscles were immunostained for Dystrophin (green) and either Popdc1 (A) 
or Popdc2 (B). Representative confocal images obtained from two experiments show extensive 
co-localisation of Dystrophin and Popdc proteins (scale bars: 100µm). 
 
 
Next, we performed a CoIP experiment to demonstrate association of Popdc proteins with Dystrophin. 
We used two different dystrophin constructs, a mini-dystrophin construct (Becker dystrophin) and a 
micro-dystrophin (Jorgensen et al. 2009). These constructs were kindly provided by Dr Rolf Stucka, 
Munich. They were transfected together with the empty pCS2+MT vector or with Popdc1-myc into 
Cos-7 cells. Cell lysates were subjected to anti-myc immunoprecipitation 24h later. As shown in Figure 
3.20, both constructs were co-precipitated with Popdc1. It can therefore be concluded that Dystrophin 
is associated with Popdc proteins. 
 
 
 
Figure 3.20: Co-precipitation of Dystrophin with Popdc1 
CoIP experiments were performed using lysates of Cos-7 cells transfected with Becker 
mini-dystrophin (A) or M2 micro-dystrophin (B) together with Popdc1-myc or with the empty pCS2+MT 
vector as negative control. Western blot with an anti-Dystrophin antibody revealed co-precipitation of 
both dystrophin constructs with Popdc1-myc in three independend experiments. Precipitation with the 
vector control alone resulted in significantly less reactivity, indicating that Popdc1-dystrophin 
interaction is specific. 
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3.8 Identification of a domain important for TREK-1 binding 
 
Recently, our group has identified TREK-1 as interaction partner for Popdc1, -2, and -3 (Froese et al. 
2012). It was the first identified ion channel interacting with Popdc proteins, and the first interacting 
protein for Popdc2, and -3 at all. To further characterise this protein-protein interaction, deletion 
analyses of both proteins, Popdc1 and TREK-1 were performed aiming at narrowing the binding sites.  
In previous pull-down experiments we could detect two TREK-1 bands of about 41kDa and 47kDa in a 
Western blot (Froese et al. 2012), both of them supposedly being isoforms of TREK-1 produced by 
alternative translation initiation as described by Thomas and colleagues (Thomas et al. 2008). The 
41kDa isoform has an only very short amino terminus, which makes the N-terminus unlikely to harbour 
the interaction site for Popdc proteins. Assuming that the carboxyl terminus mediates interaction, three 
TREK-1 constructs with deletions of the C-terminus were produced. These mutants were fused to a 
Flag epitope tag.  
 
 
Figure 3.21: Localisation of the putative Popdc1 binding site on TREK-1 
GST pull-down experiments were performed using GST-Popdc1[Ct] as bait proteins (A). As prey 
proteins served deletion-mutated Flag-tagged TREK-1 constructs, which have been produced in 
accordance with previously described mutants used by Sandoz et al., (2006) (B). All three TREK-1 
mutants showed binding to Popdc1, but not to GST alone or to GST-E12 (A), indicating that the 
binding site for Popdc1 is located adjacent to the M4 transmembrane domain of TREK-1 (B, C). The 
green rectangle indicates the location of the different portions of TREK-1 which have been deleted. 
The red circle marks the putative binding site for Popdc1. Note that in Western blots two bands were 
detected for each TREK-1 mutant, which are likely two isoforms generated by alternative translation 
initiation. For each TREK-1 deletion mutant GST pull-down with GST-Popdc1[Ct] was performed at 
least three times.  
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The resulting constructs TREK-1[51]-Flag, TREK-1[76]-Flag, and TREK-1[100]-Flag, which have 
truncations of 51, 76, or 100 amino acids respectively (Figure 3.21B,C), were used as prey proteins in 
a GST pull-down with a GST-fused C-terminus of Popdc1 (GST-Popdc1[Ct]) as bait protein. Binding of 
all three of these mutants to GST-Popdc1[Ct] was observed (Figure 3.21A). This suggests that the 
binding site may be towards the fourth transmembrane domain of TREK-1 in the juxtamembrane 
region (Figure 3.21C red circle). 
 
Transfected into Cos-7 cells, these three TREK-1 deletion mutants revealed similar subcellular 
localisation as full-length TREK-1, for which the induction of filopodia has been described (Lauritzen et 
al. 2005), and like full-length TREK-1 (Froese et al. 2012), these three TREK-1 deletion mutants did 
co-localise with full-length Popdc1 after transient transfection (Figure 3.22). 
 
 
 
Figure 3.22: Co-localisation of Popdc1[WT]-myc with TREK-1 deletion mutants 
Flag-tagged deletion mutated TREK-1 constructs were co-transfected together with myc-tagged 
wildtype Popdc1 and co-localisation was studied using confocal microscopy after immunolabelling with 
anti-myc antibody for Popdc1 (A,B,C, red) and an anti-Flag antibody for the TREK-1 mutants (A’,B’,C’, 
green) (scale bars: 10µm). For each mutant co-localisation was studied in two or three independent 
experiments. 
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To allow mapping of the binding site of Popdc1, another GST pull-down assay was established. At 
first, an appropriate bait construct was produced by cloning the C-terminal portion of TREK-1 into the 
pGEX-5X-3 vector (GE Healthcare), resulting in GST-TREK-1[Ct], which was used to express a 
protein of a calculated size of about 40kDa. The protocol for protein expression demanded some 
optimisation including the usage of Rosetta(DE3)pLysS bacteria cells (Novagen) harbouring a plasmid 
encoding for tRNAs, which are common in eukaryotic (human) but not in bacterial genes, an adjusted 
amount of IPTG (0.25mM IPTG at OD600 = 0.5), and a suitable time of expression (6-8h) at 37°C.  
Next, different deletion mutants of Popdc1 were generated by PCR and subcloned into the same 
vector as the full-length cDNA (i.e. pCS2+MT). This resulted in a library of different myc-tagged 
Popdc1 deletion mutants, in the following indicated with Popdc1[x]-myc with x standing for the 
number of truncated amino acids at the very C-terminal end of the protein. These constructs were 
used as prey proteins in GST pull-down assays. 
Some of these mutants were chosen for pull-down assays: Popdc1[92]-myc, Popdc1[107]-myc, 
Popdc1[116]-myc, and Popdc1[127]-myc. 
 
Subsequently, the buffers for GST pull-down were developed to ensure efficient solubilisation of both, 
bait and prey proteins, close to their normal 3-dimensional structures. Finally, the conditions as 
described in chapter 2.5.9 were used, and it could be shown that full-length Popdc1 (Popdc1[WT]-
myc) binds to GST-TREK-1[Ct], showing the usefulness of this assay. Also the tested deletion mutants 
of Popdc1, including Popdc1[127]-myc, were able to bind to GST-TREK-1[Ct] (Figure 3.23A). This 
shows that the C-terminal part of the Popeye domain is not necessary for interaction with TREK-1. As 
TREK-1 is interaction partner for all three Popdc protein family members, the binding site for TREK-1 
was hypothesised to be located in the juxta-M3 region of the intracellular portion of Popdc1 in close 
neighbourhood to the third transmembrane domain (M3) (Figure 3.23C, red circle), since there is a 
highly conserved region, which is outside of the cAMP-binding domain.  
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Figure 3.23: GST pull-down of Popdc1 proteins with GST-TREK-1[Ct]  
A bacterially expressed C-terminal portion of TREK-1 was used as prey protein in a GST pull-down 
assay. As prey proteins served in Cos-7 cell expressed wildtype and deletion mutated Popdc1 
proteins, lacking different portions of the C-terminal end as indicated in B and C (green rectangle). 
Binding of all Popdc proteins to TREK-1 was observed (A), suggesting the binding site to be in the 
juxta-M3 region of Popdc1 (C, red circle). Note that some of the input controls are overexposed, which 
demonstrates clearly the presence of the respective Popdc protein in the pull-down sample. For each 
Popdc1 deletion mutant GST pull-down with GST-TREK-1[Ct] was performed three times. 
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By GST pull-down, the binding site could not be narrowed down further, since Popdc1 mutants with 
even larger deletions showed binding to GST (negative control) alone. Therefore, another 
experimental approach was employed involving the co-transfection of full length TREK-1 cDNA 
(TREK-1[WT]-Flag) together with full-length Popdc1 or Popdc1 deletion constructs. As shown in 
Figure 3.24 TREK-1 is still able to interact with a Popdc1 protein lacking 172 amino acids at its  
C-terminal end. However, further deletion eliminated binding practically completely. Therefore, these 
experiments could corroborate the hypothesis that the binding site for TREK-1 is in the N-terminal 
region of the Popeye domain (Figure 3.24C,D). 
 
 
 
Figure 3.24: CoIP of TREK-1 with myc-tagged Popdc1 proteins 
Flag-tagged wildtype TREK-1 was transfected into Cos-7 cells together with the empty pCS2+MT 
vector or myc-tagged-Popdc1 (WT) (A), or with deletion mutated myc-tagged Popdc1 proteins (B). The 
localisation of the deleted region is indicated in C. Binding of TREK-1 was significantly weaker when 
the 219 or 236 mutants were used (B), suggesting that the binding site for TREK-1 is located at the 
N-terminal region of the Popeye domain (C,D). Note that in agreement with isoforms generated by 
alternative translation initiation (Thomas et al. 2008), two bands for TREK-1 were detected in Western 
blots. CoIP of TREK-1 was performed two or three times for each Popdc1 construct. 
 
 
Also subcellular localisation of these Popdc1 deletion mutants with full-length TREK-1 was examined 
in transiently transfected Cos-7 cells. As shown in Figure 3.25, a clear co-localisation in cellular 
protrusions was seen for all of these mutants including Popdc1[219]-myc and Popdc1[236]-myc. 
This indicates that recruitment into TREK-1-induced filopodia may be independent of Popdc1-TREK-1 
interaction. 
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Figure 3.25: Co-localisation of Popdc1 deletion mutants with TREK-1 in Cos-7 cells 
Popdc1[172]-myc (A,D), Popdc1[219]-myc (B,E) or Popdc1[236]-myc (C,F) were transfected 
either alone (A-C), or together with TREK-1[WT]-Flag (D,E,F). Cells were immunostained for the myc 
epitope (Popdc constructs, red) and the Flag epitope to detect TREK-1 (green). Representative 
confocal images are shown (scale bars: 10µm). For each Popdc construct comparable results were 
obtained from two independent co-localisation experiments.  
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3.9 Popdc2 and -3 interact with TREK-1 but do not co-localise after 
transfection 
 
The same GST pull-down method was used to demonstrate physical interaction of TREK-1 with 
Popdc2 and -3. It was shown before using electrophysiological methods that Popdc2 and -3 influence 
TREK-1 similarly to Popdc1 by nearly doubling its current (Froese et al. 2012).  
As expected, both Popdc2 and Popdc3 were co-precipitated by GST-TREK-1[Ct]. Thus, interaction of 
Popdc2 and -3 with TREK-1 could be confirmed biochemically by GST pull-down.  
 
 
 
Figure 3.26: Pull-down of Popdc2 and Popdc3 with GST-TREK-1[Ct] 
GST pull-down of Popdc2[WT]-myc (upper panels) or Popdc3[WT]-myc (bottom) as prey and 
GST-tagged C-terminal TREK-1 (GST-TREK-1[Ct]) as bait proteins is shown. Binding to GST 
(negative control) was significantly lower, indicating specific binding of Popdc2 and Popdc3 to 
TREK-1. Three GST pull-down experiments were performed for Popdc2[WT]-myc and two for 
Popdc3[WT]-myc. 
 
 
Similar to a previously developed bi-molecular FRET sensor based on the interaction of Popdc1 and 
TREK-1, we wanted to generate novel sensors consisting of YFP-TREK-1 and Popdc2-CFP and 
Popdc3-CFP, respectively. These sensors should be used to determine cAMP affinity of Popdc and 
Popdc3, respectively, as it has been done for Popdc1 (Froese et al. 2012). Therefore, cDNAs for both 
Popdc2 (WT, isoform C) and Popdc3 were subcloned into the pECFP-N1 vector to obtain C-terminal 
fusions to a CFP moiety. The resulting constructs were transfected together with TREK-1-Flag into 
Cos-7 cells. However, in contrast to Popdc1, which was extensively co-localised with TREK-1 in 
filopodia, only poor co-localisation could be seen in the case of Popdc2 (Figure 3.27A) and Popdc3 
Figure 3.27C). The co-localisation was not sufficient to produce a robust FRET signal (Viacheslav 
Nikolaev, personal communication). The weak co-localisation was independent of the CFP protein and 
was also seen when myc-tagged Popdc2 and Popdc3 proteins were used (data not shown). 
Transfection of another isoform of Popdc2 with a different C-terminus, Popdc2A/B, resulted in a strong 
localisation in the ER (Figure 3.27B). The same was true for a deletion mutant lacking the last 
C-terminal 28 amino acids (Figure 3.27C). Also after co-transfection of Popdc1-myc, Popdc2 
isoform C and Popdc3 were predominantly present in the ER (Figure 3.27E,F). 
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Figure 3.27: Subcellular localisation of Popdc2 and Popdc3 constructs in Cos-7 cells 
Several different CFP-tagged Popdc2 and Popdc3 constructs were transfected into Cos-7 cells either 
alone (B,C), or together with TREK-1-Flag (A, C), which was detected using an anti-Flag antibody, or 
together with mPopdc1[WT]-myc (E,F). 
Popdc2[WT]-CFP (mPopdc2C) (A) was present in the ER and did not co-localise with TREK-1 (red) 
after co-transfection (A’’). Similar ER localisation was seen for mPopdc2A/B-CFP (B) or when the last 
28 amino acids were deleted (mPopdc2[28]-CFP, C). Similarly to Popdc2-CFP, co-transfection of 
Popdc3-CFP (D) with TREK-1-Flag (red, D’) did not result in co-localisation. Co-transfection of 
Popdc2C-CFP (E) or Popdc3-CFP (F) with Popdc1 (not detected) did not significantly change their 
subcellular localisation (scale bars: 10µm). Each transfection was carried out twice. 
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3.10 Popdc proteins form heteromeric complexes 
 
3.10.1 Popdc1 is co-precipitated together with Popdc1 from murine heart 
lysates 
 
Having identified a couple of Popdc interacting proteins it became evident that many of them interact 
with both Popdc1 and Popdc2, e.g. Ankyrin-B, Ankyrin-G, and SCN5A, and, as previously 
demonstrated by Froese and colleagues for TREK-1, also with Popdc3 (Froese et al. 2012). It was 
also considered that Popdc proteins may interact with each other. First results confirming this 
hypothesis came from the CoIP experiments coupled to mass spectrometry (3.2). In all experiments 
using heart or skeletal muscle lysates with all three anti-Popdc1 and anti-Popdc2 antibodies, both 
Popdc1 and Popdc2 were precipitated, regardless of antibody being used. We therefore repeated the 
immunoprecipitation with heart lysates from wildtype and Popdc2
-/-
 mice using the Sigma anti-Popdc2 
antibody. The precipitated proteins were analysed in a Western blot for co-precipitation of Popdc1 
using an anti-Popdc1 antibody. As shown in Figure 3.28, Popdc1 was co-precipitated together with 
Popdc2 from wildtype lysates, but not in the absence of Popdc2, suggesting that there is indeed a 
specific interaction between the two members of the Popdc protein family. 
 
 
Figure 3.28: Co-precipitation of Popdc1 with Popdc2 from wildtype heart lysates 
Heart lysates from wildtype and Popdc2
-/-
 mice were subjected to IP with an anti-Popdc2 antibody. 
Precipitates were analysed for the presence of Popdc1 in a Western blot. Co-precipitation of Popdc1 
only occurred in the wildtype lysate. CoIP experiments of Popdc1 with Popdc2 from wildtype heart 
lysates were performed twice. 
 
 
In order to confirm Popdc1-Popdc2 interaction, human POPDC2 cDNA was cloned in frame with a 
Flag epitope into the pCDNA3.1(+) vector. The construct was transfected together with pCS2+MT or 
Popdc1[WT]-myc into Cos-7 cells, which were lysed 24h later. Immunoprecipitation with anti-myc 
agarose was performed and, after several washes with TBS, precipitates were subjected to Western 
blot using an anti-Flag antibody to detect (co-)precipitated POPDC2. Confirming the results obtained 
for endogenously expressed Popdc proteins in heart lysates, POPDC2 was co-precipitated in the 
presence of Popdc1 only, but not with the vector control (Figure 3.29A). Thus, interaction of Popdc1 
and Popdc2 was confirmed. Similarly, interaction of Popdc2 with Popdc3 was tested using a 
myc-tagged Popdc3 construct for CoIP with POPDC2. As depicted in Figure 3.29A, POPDC2 was not 
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co-precipitated with Popdc3, suggesting that there is no interaction with between the used isoforms of 
Popdc2 and Popdc3. Although Popdc3 was not picked up by mass spectrometry after CoIP, neither 
when heart nor when TA muscle lysates were used, the high similarity between Popdc2 and Popdc3 
prompted us to test a possible Popdc1-Popdc3 interaction. In this case, we used the Popdc3[WT]-myc 
construct co-transfected with HA-tagged POPDC1 and did CoIP with anti-myc agarose. As negative 
control served cells transfected with PODPC1[WT]-HA and the pCS2+MT vector. By this approach, we 
could confirm Popdc1-Popdc3 interaction, as POPDC1 was only co-precipitated together with Popdc3. 
It was, however, not precipitated when the empty vector was co-transfected (Figure 3.29B).  
 
 
Figure 3.29: Interaction of Popdc1 with Popdc2 and Popdc3 
Flag-tagged POPDC2 was co-transfected together with pCS2+MT (vector), myc-tagged Popdc1 or 
Popdc3 (A). Cells were lysed 24h later and CoIP was performed. Precipitated POPDC2 was detected 
in a Western blot using an anti-Flag antibody. POPDC2 was co-precipitated with Popdc1, but not with 
the vector or Popdc3. Likewise, HA-tagged POPDC1 was co-transfected together with pCS2+MT 
(vector) or myc-tagged Popdc3 (B). CoIP followed by Western blot revealed interaction of Popdc3 and 
POPDC1. Each CoIP experiment was performed at least twice. 
 
 
 
3.10.2 Popdc proteins form heteromeric complexes 
 
It has been shown many years ago that Popdc1 forms homodimers (Knight et al. 2003; Vasavada et 
al. 2004). Having shown interaction of Popdc1 with Popdc2 and Popdc3 we wondered whether Popdc 
proteins may also form heterodimers. At first we tested conditions for Western blots, which allowed us 
to differentiate with certainty between monomers, homodimers, and heterodimers. Importantly, Popdc 
proteins tend to form aggregates when boiled in SDS-PAGE sample buffer (Figure 3.30). Therefore, to 
analyse the formation of multimeric complexes, protein lysates were not boiled at 96°C, but incubated 
in SDS-PAGE sample buffer for 30min at 37°C prior to loading on a polyacrylamide gel.  
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Figure 3.30: Clustering of Popdc1 
Cos-7 cells were transfected with myc-tagged and Flag-tagged Popdc1 and harvested 24h or 48h in 
the same buffer, which was used for CoIP experiments. SDS-PAGE sample buffer was added and 
lysates were incubated at 37°C for 30min, 60°C for 15min, or 96°C for 5min. The Western blot 
depicted was for the detection of the myc fusion protein. Protein aggregates were formed by the 96°C 
treatment, and to lesser extent by incubating at 60°C. The arrow directs towards the usual 60kDa 
triplet of isoforms. 
 
 
As Popdc1 and Popdc2 have about the same size (~ 42kDa predicted size + glycosylation adding 
10-15kda), heterodimers are not distinguishable from homodimers, when proteins are isolated from 
heart lysates. Therefore, we used recombinant proteins tagged with CFP (fused to POPDC1) and Flag 
epitopes (fused to POPDC2 or Popdc3), respectively, and overexpressed them in Cos-7 cells. Thus, 
the protein complexes became distinguishable as the CFP tag itself has got a size of about 30kDA, 
whereas the Flag epitope adds just about 1kDa to the protein it is fused to.   
Cells were either transfected with POPDC1[WT]-CFP alone, POPDC2[WT]-Flag or Popdc3[WT]-Flag 
alone, or both POPDC1 and POPDC2 or Popdc3 were expressed together. 24h later, cells were 
harvested in a harsh extraction buffer containing 10% (w/v) SDS and 4M urea to ensure efficient 
solubilisation. Samples were divided into two reaction tubes, and one of them was supplemented with 
ß-mercaptoethanol (BME) to reduce disulfide bonds.  
 
Both samples were electrophoresed on a 6% SDS polyacrylamide gel and electroblotted onto a 
nitrocellulose membrane. Western blot was performed using an anti-GFP antibody to detect the 
POPDC1 fusion protein.  
When POPDC1-CFP was transfected alone (pCDNA3.1(+) plasmid was used to match amounts of 
transfected DNA) the strongest band in the Western blot appeared just below 70kDa, which is the 
predicted size for monomeric POPDC1-CFP (Figure 3.31). There was also a much fainter band of 
about 140kDa, which is likely to be a homodimer, as it disappeared through BME treatment. Similar 
results have been reported previously (Knight et al. 2003; Vasavada et al. 2004). When POPDC1-CFP 
was co-transfected with POPDC2-Flag (Figure 3.31A), the strongest band was also at about 70kDa, 
suggesting that most of the recombinant protein overexpressed in Cos-7 cells did not form complexes 
at all. However, also a band occurred running between 100kDa and 130kDa indicating that this band 
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represented a heterodimer of POPDC1-CFP and POPDC2-Flag. Interestingly, also a band of much 
higher size was detected, which run at the size of what would be expected for a heterotetrameric 
complex consisting of two CFP-tagged POPDC1 and two Flag-tagged POPDC2 proteins. Importantly, 
the presumptive heterotetramer was not detectable in the BME-treated sample, whereas even higher 
levels of the POPDC1/POPDC2 heterodimer were apparently present (Figure 3.31A).  
Similar results were obtained when Popdc3-Flag was co-transfected with POPDC1-CFP (Figure 
3.31B). Interestingly, the heterodimeric and heterotetrameric complexes were even stronger as in the 
case of POPDC1/POPDC2, and both were present also in BME-treated samples, suggesting that 
Popdc1-Popdc3 complexes are formed with strong avidity and are very stable (Figure 3.31B). 
 
 
Figure 3.31: Formation of heteromeric complexes of Popdc proteins 
Cos-7 cells were transfected with POPDC1-CFP alone or together with POPDC2-Flag (A) or 
Popdc3-Flag (B). Proteins were extracted 24h later. Half of the lysates were mixed with non-reducing 
SDS sample buffer (w/o BME), whereas BME was present in the SDS sample buffer, which was 
added to the rest of the lysates. After incubation at 37°C for 30min lysates were subjected to Western 
blot. Using an anti-GFP antibody for the detection of POPDC1, monomers (x), homodimers (*), 
heterodimers (o), and heterotetramers (#) could be detected. The formation of heteromeric 
POPDC1-POPDC2 complexes (A) was studied in five independent experiments. To analyse 
POPDC1-Popdc3 complexes (B) two experiments were performed.  
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3.10.3 The N-terminus of Popdc1 is sufficient for interaction with POPDC2 
 
Having established Popdc1-Popdc2 and Popdc1-Popdc3 interaction, we wondered which portion of 
the protein mediates this interaction. Therefore, different deletion mutated myc-tagged Popdc1 
constructs (Figure 3.32B) were co-transfected with full-length Flag-tagged POPDC2 und subjected to 
CoIP and subsequent Western blot analysis for the detection of POPDC2 using an anti-Flag antibody.  
POPDC2 was co-precipitated with all tested mutants, even the 245 mutant, which lacks the entire 
intracellular portion. This indicates that the N-terminus including the transmembrane domains is 
sufficient for interaction. 
 
 
 
Figure 3.32: CoIP of POPDC2 with deletion mutants of Popdc1 
Deletion mutants of Popdc1 lacking parts of the C-terminal portion as indicated in (B) were used for 
CoIP of full-length Flag-tagged POPDC2. POPDC2 was co-precipitated with all mutants (A), indicating 
that the N-terminus alone is sufficient for mediating the interaction of Popdc1 with POPDC2. For each 
Popdc1 mutant a minimum of two CoIPs were performed. 
 
 
 
3.10.4 Both amino and carboxyl termini contribute to Popdc-Popdc interaction 
 
Having shown that the N-terminus of Popdc1 is sufficient to mediate Popdc1-Popdc2 interaction 
(Figure 3.32) and that there is no or only a very weak interaction between Popdc2 and Popdc3 (Figure 
3.29), it was tested whether replacing the amino terminus of POPDC2 with that of POPDC1 (P1P2 
chimera) is sufficient to achieve Popdc2-Popdc3 interaction. Also the other way round, the effect of 
Popdc2 transmembrane domains fused to the C-terminus of Popdc1 (P2P1 chimera) was tested with 
regard to interaction with Popdc2 and Popdc3. The respective chimeric constructs were generated 
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with the help of the OE-PCR technique as described in 2.1.2.2, and fused to a Flag epitope for 
detection in transfected cells or in a Western blot. Schematics of the resulting constructs are depicted 
in Figure 3.34. First, the subcellular localisation of the chimeras was tested after Cos-7 cell 
transfection and both constructs showed similar distribution with predominant localisation in the ER 
but also at the cell surface indicating correct folding of the proteins (Figure 3.33).  
 
 
Figure 3.33: Subcellular localisation of Popdc chimeras in Cos-7 cells 
Flag-tagged POPDC chimeric proteins were produced by fusion of the amino terminus of POPDC1 to 
the carboxyl terminus of POPDC2 (P1P2 chimera, A) or by combining the N-terminus of POPDC2 with 
the intracellular portion of POPDC1 (B, P2P1 chimera). Immunolabelling using an anti-Flag antibody, 
nuclear counterstaining with DAPI, and confocal microscopy were used to detect subcellular 
localisation of the proteins after transfection into Cos-7 cells. Representative images of two 
experiments are shown (scale bars: 10µm).  
 
 
Next, both chimeras were used for CoIP with Popdc1[WT]-myc and Popdc3[WT]-myc. As expected, 
the POPDC1/POPDC2 (P1P2) chimera did interact with both Popdc1 and Popdc3. However, the 
POPDC2/POPDC1 (P2P1) chimera harbouring the transmembrane domains of POPDC2 did also bind 
to both Popdc1 and Popdc3 (Figure 3.34). Thus, also lacking the transmembrane domains of 
POPDC1, the chimera was able to interact with Popdc3, suggesting that it is not the N-terminus alone, 
which is mediating interaction. There may also be a cytoplasmic motif contributing to  
Popdc1-Popdc2/3 interaction. 
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Figure 3.34: CoIP of chimeric POPDC proteins with Popdc1 and Popdc3 
Flag-tagged Popdc chimeric proteins were produced by fusion of N-terminus of POPDC1 to the 
C-terminus of POPDC2 (P1P2 chimera, A) or by combining N-terminus of POPDC2 with the 
intracellular portion of POPDC1 (B, P2P1 chimera). Both chimeras were co-transfected with the 
pCS2+MT vector, or myc-tagged Popdc1 or Popdc3. Anti-myc immunoprecipitation was performed 
followed by Western blot analysis of precipitates and input controls for the detection of the chimeras 
using an anti-Flag antibody. Both chimeras did bind to Popdc1 as well as to Popdc3. CoIP 
experiments of each chimeric POPDC protein with Popdc1 and -3, as well as the vector control were 
performed twice. 
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3.10.5 The transmembrane domains modulate affinity of Popdc proteins to each 
other 
 
Although an additional binding site must be present in the intracellular portion, the N-terminus was 
sufficient for heteromeric Popdc protein interaction. The role of the transmembrane domains for 
Popdc1-Popdc2/3 interaction was further investigated using a previously identified Popdc3 isoform, 
which lacks the second half of the first, the entire second, and the first half of the third transmembrane 
domain, but retains the entire intracellular portion of Popdc3 (Figure 3.35A,B). In order to make sure 
that this isoform is properly translated subcellular localisation was studied in transfected Cos-7 cells. 
In contrast to Popdc3[WT] (isoform A), which was mainly found in the ER, Popdc3 was predominantly 
present at the nuclear membrane, and to a lesser extent in the ER. A small fraction of Popdc3c was 
also detected in the nucleus (Figure 3.35C,D). Despite of these significant differences, there was 
some overlap with Popdc3[WT] (isoform A) as well as with Popdc1 with regard to subcellular 
distribution. Therefore, the Popdc3c isoform was used in a CoIP experiment to see any differences in 
binding to Popdc1 compared to Popdc3 isoform A. 
 
 
Figure 3.35: Subcellular localisation of Popdc3c after transfection into Cos-7 cells 
Popdc3[WT] (isoform A) consists of three transmembrane domains and the intracellular C-terminus 
containing the Popeye domain (A). Popdc3c (isoform C) lacks two transmembrane domains since the 
second half of the first (orange), the entire second (black) and the first half of the third transmembrane 
domain (blue) are missing. However, the intracellular portion is unaltered (B). Popdc3 isoforms A and 
B were fused to a HA epitope tag and transfected into Cos-7 cells. Confocal imaging of anti-HA 
immunostained cells (green) revealed localisation of isoform A predominantly in the ER, but also, at a 
smaller fraction, to the plasma membrane, and in the nuclear envelope (C) (nuclei labelled in blue). 
Isoform C was mainly found in the nuclear membrane, but also in the ER, and, to lesser extent in the 
nucleus (D) (scale bars: 10µm). Subcellular localisation of Popdc3 isoforms was studied in two 
independent experiments with comparable results. 
 
 
 
3 Results 112 
For CoIP experiments, the cDNAs for Popdc3 isoforms A and C were subcloned into the pECFP-N1 
vector, and co-transfected with Popdc1-myc or the pCS2+MT vector as control. Lysates were 
produced 24h later and subjected to anti-myc immunoprecipitation. After several washes with TBS and 
elution of bound-proteins, samples were subjected to Western blot for the detection of Popdc3 
proteins using an anti-GFP antibody. Both Popdc3 isoforms bound specifically to Popdc1. However, 
isoform C had a much higher affinity, as a strong signal was obtained already with short exposure of 
the membrane to a X-ray film (Figure 3.36B). Only when exposure time was increased, a signal was 
also seen for isoform A (Figure 3.36A). 
 
 
 
Figure 3.36: CoIP of Popdc3[WT]-CFP and Popdc3c-CFP with Popdc1-myc 
Cos-7 cells were transfected with Popdc3[WT]-CFP (isoform A, A) or Popdc3c-CFP (B) together with 
pCS2+MT (vector) or Popdc1[WT]-myc, and subjected to CoIP followed by Western blot analysis.  
Blots with precipitated samples were exposed for a short time (short exp, panels in the middle) or a 
longer time (long exp, panels at the bottom). Blots in A and B were exposed simultaneously to ensure 
same exposure time. CoIP of Popdc3[WT]-CFP (isoform A) and Popdc3c-CFP with Popdc1-myc was 
repeated three times. 
 
 
 
3.11 Expression of Popdc proteins in skeletal muscle 
 
3.11.1 Expression of Popdc1 in skeletal muscle 
 
Popdc1 and -2 expression in skeletal has been widely studied using different methods, including LacZ 
staining of transgenic mice (Andree et al. 2002; Froese and Brand 2008). With the new specific 
antibodies in hand we wanted to have a look at the subcellular localisation of Popdc proteins in 
skeletal muscle.  
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The subcellular localisation of Popdc1 showed that the protein was mainly localised to the 
sarcolemma membrane, however, a significant amount of protein is also present in the fibre bodies. 
The intensity of intracellular staining was inhomogeneous and differed from fibre to fibre. It was 
hypothesised that these differences are not random, but may correlate with different fibre types. 
Therefore, tibialis anterior (TA) muscle cross-sections were co-stained with anti-Popdc1 together with 
antibodies for fibre type-specific myosin heavy chain isoforms (Figure 3.37). No correlation was seen 
with type IIa and type IIx fibres. However, in all type IIb fibres, intracellular expression of Popdc1 was 
increased (Figure 3.37B). 
 
 
 
Figure 3.37: Popdc1 expression in TA muscle 
TA muscle of a male C57BL/6J mouse of about 3 months of age was excised for cryosectioning. 
Sections of 10µm thickness were co-stained for Popdc1 (red) and antibodies labelling type IIa (green, 
A), type IIb (green, B) or type IIx fibres (green, C). Highest Popdc1 expression was observed in type 
IIb fibres (B). Fibres encircled by white rectangles are depicted in A’’, B’’, and C’’. For better 
visualisation, fibres positive for the respective fibre type marker are labelled with asterisks (scale bars: 
100µm). Fibre type-specific differences of Popdc1 expression in TA muscle was analysed in two 
experiments obtaining equivalent results. 
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3.11.2  Expression of Popdc2 in skeletal muscle 
 
The correlation of Popdc1 levels and type IIb fibres raised the question whether also Popdc2 is higher 
expressed in this fibre type. Immunohistochemistry of cryosectioned TA muscle tissue showed an 
expression pattern, which was quite different to Popdc1. The intracellular localisation was nearly 
absent, whereas the sarcolemmal localisation was prominent. Also Popdc2 levels were 
inhomogeneous. However, the expression in type IIb fibres was not stronger but weaker compared to 
other fibre types (Figure 3.38B). In contrast, most fibres with the highest Popdc2 levels were positive 
for the type IIa marker (Figure 3.38A). No correlation of protein levels with type IIx fibres could be 
established (Figure 3.38C).    
 
 
 
Figure 3.38: Popdc2 levels in TA muscle 
TA muscle tissue of a male C57BL/6J mouse of about 3 month of age was cryosectioned and stained 
for Popdc2 (red), and markers for type IIa (green, A), type IIb (green, B), and type IIx fibres (green, C). 
Popdc2 levels were particularly high in non-type IIb fibres (B). Fibres encircled by white rectangles are 
depicted in A’’, B’’, and C’’. For better visualisation, fibres positive for the respective fibre type marker 
are labelled with asterisks (scale bars: 100µm). Fibre type-specific differences of Popdc2 expression 
in TA muscle was analysed in two experiments obtaining equivalent results. 
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Subcellular localisation of Popdc2 was also studied in soleus muscle (Figure 3.39). Interestingly, in 
this muscle a higher fraction of Popdc2 seems to be intracellular in the fibre body compared to what 
was observed in TA muscle. Again, highest expression was observed in type IIa fibres (Figure 3.39B), 
whereas expression in type IIb fibres was very low (Figure 3.39C).  
 
 
 
Figure 3.39: Popdc2 expression in soleus muscle 
Soleus muscle of a male C57BL/6J mouse of about 3 months of age was cryosectioned and stained 
for Popdc2 (red) together with antibodies labelling type I (green, A), type IIa (green, B) or type IIb 
fibres (green, C). Popdc2 expression was higher in type IIa fibres (B), and particularly low in type IIb 
fibres (C). Fibres encircled by white rectangles are depicted in A’’, B’’, and C’’. Fibres positive for the 
respective fibre type marker are labelled with asterisks. For better visualisation of differences in 
fluorescence intensity among fibre types, Popdc2 staining is slightly overexposed (scale bars: 100µm). 
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3.11.3 Popdc proteins co-localise with α- and γ-Sarcoglycan  
 
Having demonstrated interaction and co-localisation of Popdc proteins with Dystrophin (chapter 3.7.1), 
also other components of the dystrophin-dystroglycan complex were tested with regard to  
a) co-localisation with Popdc proteins and b) potential alterations of protein distribution in the absence 
of Popdc1 and Popdc2 (3.11.4).  
First, the localisation of α-Sarcoglycan was tested. Co-localisation was seen with Popdc1 and Popdc2 
mainly in the sarcolemma (Figure 3.40).  
 
 
 
Figure 3.40: Co-localisation studies of Popdc proteins and α-Sarcoglycan 
TA muscle from a wildtype C57BL/6J mouse was dissected and cryosectioned. Immunohistochemistry 
for Popdc1 (A, red) or Popdc2 (B, red) together with α-Sarcoglycan (green) revealed overlapping 
distribution at the sarcolemma (scale bars: 10µm). Comparable results for overlapping distribution of 
Popdc proteins with α-Sarcoglycan were obtained from two experiments.  
 
 
 
Next, we tested co-localisation of Popdc1 and Popdc2 with γ-Sarcoglycan and found extensive 
overlap at the sarcolemma. However, a more alternating localisation pattern of Popdc1 or Popdc2 with 
γ-Sarcoglycan was seen at the t-tubules (Figure 3.41). 
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Figure 3.41: Co-localisation studies of Popdc proteins and γ-Sarcoglycan 
Cryosectioned soleus muscle was stained for Popdc1 (red) and γ-Sarcoglycan (green) (A). 
Co-localisation was seen at the sarcolemma. The area outlined by the white rectangles in A’’ is shown  
as expanded image in B, revealing that Popdc1 staining (arrows) is alternating rather than overlapping 
with γ-Sarcoglycan (arrow heads) at the striations. For the Popdc2 immunostaining shown in C and D, 
TA muscle tissue was used. Again, Popdc2 (red) was co-localised with γ-Sarcoglycan (green) at the 
sarcolemma (C). The area outlined by the white rectangle in C’’ is depicted in D as expanded image. 
In the striations Popdc2 (arrows) was not co-localised with γ-Sarcoglycan (arrow heads) (D) (scale 
bars; 10µm). Co-localisation studies of Popdc proteins with γ-Sarcoglycan were performed twice 
leading to similar results. 
 
 
3.11.4 Comparison of expression levels in wildtype and P12dKO mice 
 
In order to determine whether in the absence of Popdc1 and Popdc2 any changes with regard to 
expression levels or subcellular localisation of proteins interacting or co-localising with Popdc proteins 
occur, cryosections of TA muscles obtained from wildtype and Popdc1/Popdc2 double knockout 
(P12dKO) mice were labelled with antibodies against Caveolin-3, Dysferlin, Dystrophin, 
α-Sarcoglycan, or γ-Sarcoglycan, and sections were analysed using a confocal microscope.  
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Pictures were taken using the same settings for all wildtype and P12dKO samples (Figure 3.42). 
Obvious differences with regard to subcellular localisation could not be detected. However, slight 
differences in expression levels in wildtype and P12dKO mice occurred for some of the analysed 
proteins. For Dysferlin, a slight increase in expression was seen in the P12dKO sample (Figure 
3.42C,D), whereas Dystrophin expression appeared to be somewhat reduced (Figure 3.42E,F). A 
reduction was also observed for γ-Sarcoglycan (Figure 3.42I,J). No obvious differences could be seen 
for Caveolin-3 (Figure 3.42A,B) and α-Sarcoglycan (Figure 3.42G,H). 
 
 
Figure 3.42: Comparison of expression levels  
TA muscles from wildtype (WT) mice and Popdc1/Popdc2 double null mutants (P12dKO) were 
cryosectioned and labelled for Caveolin-3 (A,B), Dysferlin (C,D), Dystrophin (E,F), α-Sarcoglycan 
(G,H), or γ-Sarcoglycan (I,J). Pictures were acquired using the same settings for wildtype and 
P12dKO samples (scale bars: 10µm). Similar relative expression levels were obtained from two 
experiments. 
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3.12 Regeneration of TA muscles in young Popdc2 null mutant mice 
 
It was described by Andrée and colleagues that Popdc1
-/-
 mice exhibit a retarded muscle regeneration 
upon Ctx-induced injury (Andree et al. 2002). Given the fact that Popdc1 and Popdc2 did not only 
show overlapping subcellular distribution but also formed heteromeric complexes, it was investigated 
whether the lack of Popdc2 also affects muscle regeneration. For this purpose, the snake venom 
Cardiotoxin (Ctx) was injected into the TA muscle of 3 months old male wildtype and Popdc2 null 
mutant mice. Five or 14 days later, mice were sacrificed and TA muscles were removed for 
histological analysis. Cross-sectional area (CSA) of regenerating fibres was determined after 
pan-myosin immunostaining of muscles harvested 5d after Ctx injection, or by membrane labelling 
using wheat germ agglutinin (WGA) for muscles harvested 14d after Ctx injection. Assuming the 
presence of an impaired regenerative capacity in the Popdc2
-/-
 mice, we expected a smaller CSA in 
the null mutants. However, in newly formed myotubes of muscles harvested 5d after Ctx injection a 
statistically significantly larger CSA was observed in Popdc2
-/-
 compared to wildtype controls. 
Moreover, also 14d after injection, the CSA of regenerating fibres, which have been identified by their 
centralised nuclei, was significantly higher in muscles of Popdc2
 
null mutants compared to wildtype 
mice (Figure 3.43). 
 
 
 
Figure 3.43: Cross-sectional area of regenerating muscle fibres of wildtype and Popdc2
-/-
 mice 
Regeneration was induced by Cardiotoxin injection into TA muscles of wildtype (A,C) or Popdc2 null 
mutant (P2KO) mice (B,D) and muscles were harvested 5d (A,B) or 14d (C,D) later. Muscles were 
cryosectioned and immunolabelled using an antibody against pan-myosin (A,B) or stained with WGA 
(C,D). Regenerating fibres were identified by their centralised nuclei (scale bars: 50µm). 
Cross-sectional areas (CSAs) were determined by measuring CSA of 78 single fibres of 2-4 different 
regions of the muscles of 3 different mice for each time point and genotype (E). Statistical significance 
was analysed with the Mann-Whitney test (*: p≤0.05; ***: p≤0.01).  
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3.13  Nuclear localisation of Popdc1 and Popdc2 
 
3.13.1 Nuclear localisation of Popdc1 and Popdc2 in myoblasts 
 
Andrée and co-workers showed that expression of a Popdc1-LacZ reporter in isolated primary 
myoblasts is strongly up-regulated upon activation and down-regulated when the cells start to fuse to 
myotubes (Andree et al. 2002). We hypothesised that Popdc proteins may play a role in the 
differentiation process. We therefore wanted to have a look at the subcellular distribution of Popdc 
proteins in primary myoblasts and myotubes.  
 
 
Figure 3.44: Nuclear localisation of Popdc1 in primary myoblasts 
Myoblasts isolated from hindlimb muscles of WT mice were immunolabelled for Popdc1 with two 
different antibodies, either sc-49889 from Santa Cruz (A,B) or HPA018176 from Sigma (C,D). Nuclei 
were counterstained with DAPI (blue). Both antibodies revealed nuclear localisation of Popdc1, 
independent of the fixation of the cells with PFA (A,B) or methanol (B,D) (scale bars: 2µm in A, 10µm 
in B,C,D). Equivalent subcellular localisation was seen in more than three immunostainings for 
Popdc1 after PFA fixation and two after MeOH fixation of satellite cells from four isolations. 
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To our surprise, both anti-Popdc1 antibodies (from Sigma-Aldrich and Santa Cruz Biotechnology) did 
not reveal protein localisation at the plasma membrane, as it was observed for adult muscle fibres 
(Figure 3.37). Instead, vesicular structures were stained. In addition, both antibodies also resulted in a 
strong nuclear staining, which was weaker in nucleoli. These patterns were largely undistinguishable 
when different fixation methods (MeOH or PFA) were used (Figure 3.44). 
 
Similar to Popdc1, nuclear localisation in activated myoblasts was also observed for Popdc2, although 
MeOH fixation seemed to result in overall weaker signals (Figure 3.45).  
 
 
 
Figure 3.45: Nuclear localisation of Popdc2 in primary myoblasts 
Myoblasts isolated from hindlimb muscles of WT were fixed with PFA (A) or methanol (B), and 
immunolabelled for Popdc2 with the HPA024255 antibody from Sigma. Nuclei were counterstained 
with DAPI (blue). Independent of the method of fixation, strong nuclear staining was obtained (scale 
bars: 10µm). Immunocytochemistry for the detection of Popdc2 was carried out three times after PFA 
fixation and twice after MeOH fixation of satellite cells obtained from three isolations with comparable 
results. 
 
 
 
The nuclear expression seemed to be quite strong, however, these observed staining patterns could 
be due to a change of the cells by isolation, and may not play a physiological role in primary 
myoblasts. We therefore employed a more physiological protocol of myoblast activation by isolation of 
mouse EDL (extensor digitorum longus) muscle fibres. In activated myoblasts grown on muscle fibres 
significant nuclear staining could be seen (Figure 3.46A). Although Popdc1 was mainly localised in the 
cytoplasm there is some evidence that nuclear localisation may be of physiological importance.  
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Figure 3.46: Popdc1 localisation in primary myoblasts of EDL fibres and C2C12 cells 
EDL fibres were isolated and fixed 48h later. Immunostaining for Popdc1 showed significant nuclear 
localisation of Popdc1 in activated myoblasts (arrows) (A). Similarly, in the C2C12 myoblast cell line, 
Popdc1 was located in the nucleus (B, nuclei indicated by asterisks). Also in C2C12-derived 
myotubes, Popdc1 was detected in the nucleus (C) (scale bars: 10µm). Popdc1 immunostaining was 
carried out on EDL fibres isolated from three different WT mice. Immunostaining of Popdc1 on C2C12 
myoblasts as well as myotubes was performed three times.  
 
 
 
Nuclear localisation was found to be differentiation dependent. Upon the formation of myotubes, 
Popdc1 could no longer be detected in the nucleus (Figure 3.47A). Likewise, also Popdc2 was not 
present in the nuclei of primary myoblasts (Figure 3.47B). 
 
 
Figure 3.47: Subcellular localisation of Popdc1 and -2 in differentiated primary myotubes 
PFA-fixed primary myotubes were stained for Popdc1 (A) or Popdc2 (B), and nuclei were 
counterstained with DAPI (blue). Confocal images are shown. In contrast to proliferating myoblasts, 
Popdc1 and Popdc2 were not detected in the nucleus of primary myotubes (scale bars: 10µm). 
Immunocytochemistry for the detection of Popdc1 and Popdc2 was performed at least three times 
using primary myotubes derived from three satellite cell isolations. 
 
 
 
To shed more light on the time course of nuclear localisation of Popdc proteins in myoblasts, EDL 
fibres were isolated and fixed immediately after isolation (T0), or 24h (T24) or 72h (T72) thereafter and 
stained for Popdc1 or Popdc2. To identify myoblasts, fibres were co-stained with an anti-Pax7 
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antibody (T0 and T24) or with an anti-Myogenin antibody (T72). Popdc1 and Popdc2 expression in 
quiescent satellite cells in T0 fibres only revealed a very low expression of both Popdc1 and Popdc2 
(not shown). However, as soon as satellite cells were activated, even in T0 fibres, both Popdc proteins 
could clearly be detected.  
A small fraction of the protein was also present in the nucleus (Figure 3.48A,B,E,F). When myoblasts 
were undergoing differentiation, as indicated by the Myogenin marker expression, Popdc1 and Popdc2 
were still found in the nucleus, albeit most of the protein expressed was not nuclear (Figure 3.48C,G). 
 
 
 
Figure 3.48: Time course of Popdc1 and Popdc2 expression in activated primary myoblasts 
and during regeneration 
EDL fibres were fixed immediately after isolation (T0), or 24h (T24) or 72h (T72) later and stained for 
Popdc1 (red, A,B,C) or Popdc2 (red, E,F,G). Myoblasts were co-labelled for either Pax7 (green, A,B, 
and E,F) or Myogenin (green, C,G). Nuclear localisation was observed for Popdc1 and Popdc2 at all 
time points (scale bars in A,B,C, and E,F,G: 5µm). TA muscles were injected with Cardiotoxin (Ctx) to 
induce regeneration and harvested 5d later. The tissues were cryosectioned and stained for Popdc1 
(green, D), or Popdc2 (green, H). Nuclei are labelled in blue (scale bars in D and H: 10µm). For each 
time point Popdc protein expression was analysed using EDL fibres obtained from at least two 
isolations. Expression of Popdc1 and Popdc2 in regenerating muscle (D, H) was investigated in three 
experiments. 
 
 
 
In myotubes newly formed during regeneration induced by Cardiotoxin injection, Popdc1 was found to 
be mainly in the cytoplasmic compartment. In many fibres Popdc1 showed also presence at the cell 
surface membrane (Figure 3.48D). Popdc2 showed prominent localisation at the cell surface, even in 
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small tubes (Figure 3.48H). In comparison to undamaged fibres, both Popdc1 and Popdc2 levels were 
lower in the newly formed myotubes. 
 
 
 
To see whether nuclear localisation occurs also in vivo after Cardiotoxin-induced injury, skeletal 
muscle was excised 5d after Ctx injection and stained for Popdc1 and the myoblast marker Myogenin. 
As shown in Figure 3.49, cells were present showing Myogenin expression and nuclear Popdc1 
localisation. 
 
 
 
Figure 3.49: Nuclear localisation after Cardiotoxin-induced muscle regeneration 
Regeneration was induced by Cardiotoxin (Ctx) injection into the TA muscle of a wildtype C57BL/6 
mouse and 5d later the muscle was dissected out and subjected to cryosectioning. Sections were 
labelled for Popdc1 (red) and nuclei were counter-stained with DAPI (blue). For the identification of 
myoblasts, sections were co-labelled with an anti-Myogenin antibody (green). Depicted is a 
Myogenin-positive cell showing nuclear localisation of Popdc1 (scale bar: 5µm). Three experiments 
were performed to investigate nuclear localisation of Popdc1 after Ctx-induced muscle regeneration. 
 
 
 
Popdc proteins are predicted to be transmembrane proteins with an intracellularly localised 
C-terminus. To find out how big the nuclear localised portion of Popdc proteins is, cell fractionation 
was performed using the Qproteome Nuclear Protein Kit (Qiagen). Three protein fractions were 
obtained: cytosolic proteins, soluble nuclear proteins (e.g. transcription factors), and insoluble nuclear 
proteins (e.g. histone proteins). The fractions were subsequently subjected to SDS-PAGE and 
Western blot analysis. 
Using the Sigma antibody (HPA018176) in each fraction, several bands could be detected (Figure 
3.50A). Many of them appear in different fractions obtained from differentiated and undifferentiated 
cells, and therefore seem to be unspecific. However, a band of about 15kDa was detected specifically 
in the insoluble nuclear protein fraction of undifferentiated myoblasts, and not detectable in the 
insoluble fraction of differentiated cells. As a control, the membrane was re-probed with the Santa 
Cruz antibody (sc-49889), and again, a 15kDa band could be detected in the insoluble fraction of 
undifferentiated myoblasts, and with much less intensity in differentiated cells (Figure 3.50A), 
indicating that these bands were specific for Popdc1. As both antibodies are recognising epitopes 
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located at the C-terminus of Popdc1, these fragments are presumably portions of the intracellular part 
of Popdc1. 
Interestingly, Western blot using the Popdc2 antibody from Sigma (HPA024255), also resulted in a 
15kDa band in the insoluble nuclear protein fraction of undifferentiated myoblasts, and a only faint 
band in the corresponding fraction from differentiated cells (Figure 3.50B). Therefore, Popdc1 and -2 
seem to give rise to a nuclear fragment of the same size of about 15kDa. The efficiency of 
fractionation was examined by Western blot analysis using an anti-histone H1 antibody, which 
confirmed the presence of histones in the insoluble nuclear protein fraction (Figure 3.50C). 
 
 
 
Figure 3.50: A protein fragment of about 15kDa is present in the nucleus of primary myoblasts 
Proteins from primary myoblasts were fractionated into cytosolic, soluble nuclear, and insoluble 
nuclear proteins. Western blot for the detection of Popdc1 (A) or Popdc2 (B), or histone H1 (C) was 
performed. A specific band of about 15kDa was detected with two different antibodies for Popdc1 
(A, upper panel: Sigma antibody HPA018176, lower panel; Santa Cruz antibody sc-49889) in 
undifferentiated myoblasts, which was significantly weaker when differentiated cell preparations were 
used (B). Similarly, a 15kDa Popdc2 fragment was detected in undifferentiated cells, but at much 
lower intensity in protein fractions obtained from differentiated cells (B). Probing of the membranes for 
histone H1 shows the efficiency of nuclear protein fractionation (C). The fractionation experiment was 
performed twice. 
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To facilitate further testing of nuclear localisation of Popdc proteins, we wanted to find a cell line with 
endogenously expressed Popdc proteins showing a similar subcellular distribution as in primary 
myoblasts. Therefore, a few cell lines were tested with regard to expression and subcellular 
localisation of Popdc1 and Popdc2. C2C12 cells did express Popdc1 and Popdc2, but they appear to 
have a different subcellular distribution than in primary myoblasts. This is particularly evident in 
myotubes formed by C2C12 myoblasts. Whereas in primary myotubes nuclei were devoid of Popdc1, 
C2C12-derived myotubes still revealed nuclear localisation of Popdc1 (Figure 3.46C). Another 
myoblast-like cell line are Sol-8 cells. Also there, Popdc1 and Popdc2 are expressed. Similar vesicular 
distribution was seen in comparison to primary myoblasts. Also nuclear staining was obtained, which 
was rather diffuse and not distinct as it was seen in primary myoblasts (Figure 3.51).  
 
 
 
Figure 3.51: Subcellular localisation of Popdc1 and Popdc2 in Sol-8 myoblasts 
Proliferating Sol-8 myoblasts were fixed in PFA and subjected to immunolabelling for Popdc1 (A) and 
Popdc2 (B). DAPI was used to stain nuclei (blue). Confocal images revealed cytoplasmic and nuclear 
expression (scale bars: 10µm). Subcellular localisation of Popdc1 and Popdc2 in Sol-8 myoblasts was 
analysed in two experiments obtaining comparable results.  
 
 
 
 
3.13.2 Subcellular localisation of Popdc proteins in cardiac myocyte-derived 
cell lines 
 
Having shown that Popdc proteins localise to the nucleus in myoblasts, subcellular localisation of 
Popdc proteins in cardiac myocyte-like cell lines was assessed.  
First, the H10 cell line derived from atrial rat myocytes was tested with regard to expression of Popdc1 
and Popdc2. H10 cells are normally cultivated at 33°C to keep them in an undifferentiated state. When 
grown at 39°C, H10 cells exhibit a more differentiated phenotype (Jahn et al. 1996). Although Popdc1 
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has been found to be strongly expressed in the heart and particularly in atrial cardiac myocytes of 
mice (Breher 2009), staining of H10 cells for Popdc1 did not result in any signal, suggesting that in this 
cell line Popdc1 is not expressed, neither when they are grown at 33°C nor when temperature is 
shifted to 39°C. In contrast, immunolabelling for Popdc2 revealed expression in a subpopulation of 
cells grown at 33°C and 39°C. Popdc2 showed a predominant vesicular distribution, but was not 
localised to the plasma membrane. Also the nuclei were devoid of Popdc2 (Figure 3.52A,B).  
Another cardiac myocyte-derived cell line are HL-1 cells. These cells are derived from murine atrial 
myocytes (Claycomb et al. 1998). Again, Popdc1 was not detectable, and Popdc2 was only present in 
a subset of cells. However, these cells revealed strong staining of the plasma membrane at cell-cell 
contacts. A fraction of the protein may also be in the nucleus, however, nuclear staining was not 
prominent (Figure 3.52C). 
 
 
 
Figure 3.52: Immunocytochemistry of Popdc2 in H10 and HL-1 cells 
H10 cells were grown at 33°C (A) or 39°C (B). Antibody staining for Popdc2 revealed Popdc2 
expression in a subset of cells with a mainly vesicular distribution. In HL-1 cells Popdc2 was 
prominently found at cell-cell contacts (C). Nuclei were labelled with DAPI (blue) (scale bars: 10µm). 
Subcellular localisation of Popdc proteins in H10 cells was studied in three experiments, distribution in 
HL-1 cells was analysed in two experiments. 
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3.13.3 Nuclear localisation of Popdc1 and Popdc2 in epithelial cells 
 
In previous publications Madin-Darby canine kidney (MDCK) cells have been used to study Popdc1 
function, where the protein was shown to be endogenously expressed (Osler et al. 2005). Therefore, 
the subcellular localisation was studied using antibodies specifically detecting Popdc1 and Popdc2, 
respectively. In confluent cells, both Popdc proteins were localised in the cytoplasmic compartment, 
but also at the plasma membrane. The strongest signal, however, was seen in the nucleus (Figure 
3.53). Therefore, also in this epithelial cell line Popdc proteins revealed nuclear localisation. 
 
 
 
Figure 3.53: Localisation of endogenously expressed Popdc1 and Popdc2 in MDCK cells 
PFA-fixed MDCK cells were immunolabelled with an anti-Popdc1 (A) or anti-Popdc2 antibody (B). 
Nuclei were stained using DAPI. Confocal images revealed membrane localisation (arrows), 
cytoplasmic staining, and strong nuclear localisation of both proteins (scale bars: 10µm). Subcellular 
localisation of Popdc1 and Popdc2 in MDCK cells was investigated in two experiments both leading to 
similar results. 
 
 
 
3.13.4 Regulation of nuclear localisation 
 
Nuclear localisation has been detected in different cell types. Thus, we were interested to find out how 
nuclear localisation is achieved by Popdc1 and Popdc2 as transmembrane proteins. For both Popdc 
proteins a 15kDa nuclear fragment has been detected (Figure 3.50). Several explanations for the 
generation of these fragments could be possible, e.g. alternative splicing, alternative translation 
initiation, or posttranslational cleavage.  
We first wanted to see whether a Popdc1 protein lacking the transmembrane domains is imported into 
the nucleus when overexpressed in primary myoblasts. In order to avoid any unspecific binding of 
antibodies, a Popdc1 construct was produced with an YFP fused to its C-terminus (Popdc1[Ct]-YFP], 
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which could be directly visualised with a fluorescence microscope. This construct was transfected into 
primary myoblasts and its subcellular localisation was analysed using confocal laser scanning 
microscopy. In Figure 3.54A a representative transfected cell is depicted showing that most of the 
recombinant protein was localised to the ER. However, also in the nucleus, YFP fluorescence could 
be detected, which was much weaker in the nucleoli (Figure 3.54A). This pattern was reminiscent to 
what was revealed for endogenously expressed Popdc1. It can therefore be concluded, that the 
recombinantly expressed C-terminus of Popdc1 was indeed imported into the nucleus.  
Additionally to the C-terminal Popdc1 construct, also a full-length YFP-tagged Popdc1 construct was 
produced, containing both, C-terminal and N-terminal portion including the transmembrane domains. 
When this construct was transfected into primary myoblasts the expressed protein was mainly present 
in the ER. Importantly, a fraction of this protein was also found to be in the nucleus, but to a minor 
extent in nucleoli (Figure 3.54B). Thus, a protein has been produced by this construct, which was able 
to enter the nucleus and therefore did not have the transmembrane domains. This suggests that 
alternative splicing is not necessary to achieve nuclear localisation of Popdc1. 
 
 
Figure 3.54: Subcellular localisation of transfected Popdc1 constructs in primary myoblasts 
Primary myoblasts isolated from wildtype C57BL/6J mice were transfected with the C-terminal portion 
of Popdc1 lacking the transmembrane domains (Popdc1[Ct]-YFP) (A) or full-length Popdc1[WT]-YFP 
(B). Cells were fixed and stained with DAPI to label nuclei (blue). Confocal images of representative 
cells are shown, indicating nuclear localisation of both constructs (scale bars: 10µm). Transfection of 
primary myoblasts was carried out twice for both C-terminal and full-length constructs. 
 
 
 
3.13.5 Identification of a region in the Popdc1 C-terminus, which is important 
for nuclear localisation 
 
Figure 3.54 shows that transfection of a C-terminal construct of Popdc1 into primary myoblasts results 
in nuclear localisation. In order to find out which domains are involved in this, the intracellular portion 
was further deleted C-terminally (mutant Ct[116]) or N-terminally (mutants Ct[149] and Ct[186]) 
(Figure 3.55A). The constructs were transfected into Cos-7 cells, because these are easier to cultivate 
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and to transfect than primary myoblasts. Subcellular localisation was analysed with confocal laser 
scanning microscopy. Representative pictures are shown in Figure 3.55B. Cells were categorised into 
two groups according to the distribution of fluorescence. Cells showing nuclear fluorescence, which 
was greater or equally intense compared to cytoplasmic fluorescence were counted to one group, 
whereas cells showing lower nuclear than cytoplasmic fluorescence were counted to the other group. 
As shown in Figure 3.55C, N-terminal mutants resulted in highly significant more cells with lower 
nuclear than cytoplasmic fluorescence compared to the entire C-terminus (Ct[WT]). Particularly strong 
was the effect of Ct[186], where most cells revealed lower nuclear versus cytoplasmic fluorescence 
(Figure 3.55B,C). 
 
 
Figure 3.55: Identification of a region in the Popdc1 C-terminus involved in nuclear localisation 
The intracellular portion of Popdc1 was C-terminally (mutant Ct[116]) or N-terminally (mutants 
Ct[149] and Ct[186]) truncated and fused to an YFP tag (A). Cells were transfected into Cos-7 cells 
and analysed using confocal laser scanning microscopy. Representative fields of transfected cells and 
single cells (inlets) are depicted. The scale bars represent 10µm (B). Relative number of cells with 
higher or equal nuclear localisation (yellow), or lower nuclear than cytoplasmic fluorescence (blue) 
were counted from several fields in at least three different transfections for each construct. Numbers of 
analysed cells are given in the bars. Fisher’s exact test was performed using GraphPad Prism 5 
software, and statistical significance was determined after post-hoc Bonferroni correction of values  
(***: p≤0.01).  
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3.14 Mutations in POPDC genes found in human patients 
 
3.14.1 S201F mutation in the POPDC1 gene 
 
By our collaborator Professor Alessandra Ferlini, Ferrara, Italy, and her laboratory, a mutation in the 
POPDC1 gene has been discovered in a familial case of muscular dystrophy characterised by high 
creatinine kinase (CK) levels, and AV conduction disorders (Alessandra Ferlini, personal 
communication).  
The mutation is a missense mutation where a cytosine is changed to thymine. This leads to an altered 
codon (TTT instead of TCT) and to an amino acid exchange of serine to phenylalanine on position 201 
of the protein. Serine 201 is part of the DSPE motif which is present in all Popdc members and highly 
conserved. Three members of the family are homozygous for this mutation and all of them are 
affected, two brothers (Figure 3.56, individuals 4 and 5) and their grandfather (Figure 3.56, individual 
1). As expected, Sanger sequencing revealed that the brothers’ parents (Figure 3.56, individuals 2 and 
3) are both heterozygous for this mutation, so they have one wildtype allele with a cytosine and one 
mutated allele with a thymine. The parents do not have a phenotype (Alessandra Ferlini, personal 
communication). 
 
 
Figure 3.56: Family pedigree of the POPDC1[S201F] family 
Cytosine to thymine mutation leads to a serine to phenylalanine exchange at position 201 of the 
protein. The mutation is homozygous in all affected patients (individuals 1, 4, and 5). Note that the 
asymptomatic individuals 2 and 3 are carriers of this mutation on one allele (Figure provided by 
Alessandra Ferlini).  
 
 
Sequences and protein patterns have been obtained for several other known genes causing similar 
phenotypes like LaminA/C, Emerin, alpha-Dystroglycan, etc. No abnormalities in these genes and 
proteins have been observed, suggesting that the POPDC1 mutation is the cause of the phenotype in 
this family (Alessandra Ferlini, personal communication).  
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It was shown previously that the aspartate residue at position 200 (D200) of the Popdc1 protein is 
essential for cAMP binding, and mutation to alanine resulted in a strongly decreased affinity (Froese et 
al. 2012). However, the effect of serine (S200) substitution by phenylalanine on cAMP binding was not 
clear. Therefore, the t602c (S201F) mutation was introduced into the POPDC1 cDNA and subcloned 
into a mammalian expression vector to obtain POPDC1[S201F]-HA. Alongside with wildtype POPDC1 
(Popdc1[WT]-HA) this construct was transfected into Cos-7 cells and lysates were subjected to cAMP 
precipitation assay as described in 2.5.10. Thereby, a significantly reduced binding affinity of 
POPDC1[S201F] compared to wildtype hPOPDC1 was observed, demonstrating a strong effect of this 
mutation on an important feature of the protein (Figure 3.57). 
 
 
 
Figure 3.57: cAMP affinity binding of POPDC1[WT], POPDC1[R172H], and POPDC1[S201F] 
For cAMP affinity binding assays protein extracts obtained from Cos-7 cells transfected with 
POPDC1[WT]-HA, POPDC1[R172H]-HA or POPDC1[S201F]-HA were incubated with EtOH-NH 
agarose and subsequently with cAMP agarose. A sample of unbound protein was taken for Western 
blot detection of POPDC1. Both agaroses were washed several times and bound proteins were eluted 
by boiling in SDS sample buffer. An aliquot of the cell lysates served as input control. Representative 
blots using an anti-HA antibody are shown (A). Band intensities were determined for each construct. 
Ratio of cAMP agarose-bound protein to input were calculated and normalised to the wildtype sample. 
The mean values obtained from 4 independent rounds of cAMP affinity pull-down are depicted (B). 
Statistical significance was determined using one-way ANOVA followed by Bonferroni post-hoc test. 
 
 
 
In order to test that the reduced binding is not due to misfolding of the protein, the constructs were 
transfected into Cos-7 cells either alone or together with TREK-1[WT]-Flag, and immunocytochemistry 
was performed. Representative pictures taken with a confocal microscope are shown in Figure 3.58. 
No obvious differences could be seen for the S201F mutant compared to the wildtype protein when 
transfected alone. Furthermore, both proteins co-localised with TREK-1, suggesting that protein 
interaction was not impaired by the mutation. 
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Figure 3.58: Subcellular localisation of POPDC1[WT], POPDC1[R172H], and POPDC1[S201F] 
POPDC1[WT]-HA (A,D), POPDC1[R172H]-HA (B,E) or POPDC1[S201F]-HA (C,F) were transfected 
either alone (A-C), or together with TREK-1[WT]-Flag (D,E,F). Cells were immunostained using an 
anti-HA antibody for the detection of POPDC1 (red) and an anti-Flag antibody to label TREK-1 
(green). Nuclei are stained with DAPI (blue). Representative confocal images show similar subcellular 
distribution of all POPDC1 constructs (scale bars: 10µm). Transfection of Cos-7 cells with either 
POPDC1 constructs alone or together with TREK-1 was carried out twice.  
 
 
 
Next, the expression of POPDC1[S201F] in a tissue sample from one of the affected family members 
(individual 4) was assessed by Western blot. The proteins were extracted in Italy according to the 
protocol described in chapter 2.5.5.3. Protein amount was determined and 50mg were size-separated 
using a SDS gel and blotted onto nitrocellulose. One part of the membrane was probed for POPDC1, 
the other for POPDC2. For a loading control, an additional gel was loaded with 1µg of each sample, 
and subjected to Western blot for the detection of ACTIN. 
 
POPDC1 protein could be detected in both, patient and control samples. No obvious difference in 
protein amount could be detected in both samples. Surprisingly, however, we found a down-regulation 
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of POPDC2, as the bands in control and patient sample appeared nearly identically intense, whereas 
the ACTIN control was clearly stronger in the S201F sample, indicating a relatively less amount of 
POPDC2 protein (Figure 3.59A). 
We also assessed POPDC1 and -2 expression in dermal fibroblasts of both patients (Figure 3.56, 
individuals 4 and 5) in the same way. Again, we could not find down-regulation of POPDC1. Also 
POPDC2 was unaltered in comparison to control fibroblasts (Figure 3.59B).  
These experiments suggest that the mutant POPDC1 protein is being produced and maintained at 
levels comparable to wildtype POPDC1.  
 
 
 
Figure 3.59: Expression levels of POPDC1 in human muscle and dermal fibroblasts 
Proteins were extracted from muscle biopsy samples of a healthy control and of one of the 
POPDC1[S201F] patients (A). Likewise, protein lysates were obtained from cultured dermal fibroblasts 
obtained from healthy controls and two patients (B). The samples were subjected to Western blot 
analyses for the detection of POPDC1 (upper panels) or POPDC2 (middle panels). To control equal 
loading, a Western blot was performed using an anti-ACTIN antibody (lower panels).  
 
 
Importantly, immunohistochemical analyses done by Dr Subreena Simrick revealed an altered 
subcellular distribution of POPDC1[S201F]. Compared to the wildtype control, the protein was found to 
a significant lesser extent at the sarcolemmal membrane, whereas its presence in intracellular 
vesicular structures was increased (Alessandra Ferlini and Subreena Simrick, personal 
communication). 
 
 
3.14.2 R172H mutation in the POPDC1 gene 
 
In the laboratory of Professor Hendrik Milting, Bad Oyenhausen, Germany, another missense mutation 
in POPDC1 has been identified in a patient affected by dilative cardiomyopathy (DCM). This mutation 
leads to a change of arginine to histidine at position 172 of the protein (R172H). Analysis of about 200 
other known candidate genes revealed an additional mutation in the LaminA/C gene. Both mutations 
could contribute to the phenotype. To analyse a potential effect of the R172H mutation on the function 
of the POPDC1 protein, the recombinant POPDC1[R172] protein was tested with regard to cAMP 
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binding affinity. Although some experiments showed a slight reduction in binding, no significant 
difference compared to the wildtype protein could be observed (Figure 3.57). Likewise, no difference 
to the wildtype protein was seen with regard to subcellular localisation and co-localisation with TREK-1 
(Figure 3.58B,E). 
  
Also the expression of POPDC1[R172H] in the explanted patient’s heart was assessed. As controls, 
non-failing hearts and hearts with DCM caused by other reasons were used. The protein extraction 
was carried out in Professor Milting’s lab in Bad Oyenhausen according to the protocol described in 
chapter 2.5.5.3. In all hearts, two bands at about 55kDa and 60kDa were detected with the 
anti-POPDC1 antibody. However, compared to non-failing controls the POPDC1[R172H] and the other 
DCM hearts showed a changed band patterns. Whereas the upper band (~60kDa) was slightly 
reduced in intensity, the lower band running at about 55kDa was increased. Similarly, also for 
POPDC2 bands were stronger in the diseased heart samples compared to non-failing hearts. 
Particular high expression was seen in the POPDC1[R172H] sample. For example, a band running 
just below 70kDa, which was only faint in non-failing hearts, was much more intensive in the 
POPDC1[R172H] sample. 
 
 
 
Figure 3.60: Expression levels of POPDC1 and POPDC2 in human hearts 
Proteins were extracted from tissue samples of non-failing, DCM, and POPDC1[R172H] patient hearts 
and subjected to Western blot analysis for the detection of POPDC1 (upper panel) or POPDC2 
(middle panel). To control equal loading, a Western blot was performed using an anti-ACTIN antibody 
(lower panel).  
 
 
 
3.14.3 L281P mutation in the POPDC1 gene 
 
Another mutation of POPDC1 had recently been identified by Professor Ferlini in a patient with mild 
dystrophy characterised by high CKemia and toe walker phenotype. This missense mutation leads to 
an amino acid change of leucine to proline at position 281 in the protein (L281P). Secondary structure 
predictions revealed a C-terminal shift of an alpha-helix, which is part of a previously described 
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homodimerisation motif (Kawaguchi et al. 2008) (Figure 3.61A). It was therefore assumed that 
homodimerisation of the POPDC1[L281P] protein may be impaired. To test this hypothesis, a 
POPDC1[L281P]-HA construct was produced, and binding to C-terminal Popdc1 was tested in GST 
pull-downs. There was no reduction in binding, but rather an increase, which was, however, not 
significant.  
 
 
 
Figure 3.61: Analysis of homodimerisation of hPOPDC1[L281P] 
Psipred analysis suggested that mutation of leucine 281 to proline (red letters) results in a shift of an 
alpha-helical segment (orange barrel, arrow). In the wildtype protein, this helix is part of the previously 
identified homodimerisation domain (blue; critical lysine residues are labelled in dark blue). Thus, the 
possibility of abnormalities in homodimerisation was tested by GST pull-down with C-terminal Popdc1 
(B). Quantification of band intensities did not reveal significant differences between wildtype and 
L281P-mutated POPDC1 (C).Significance was analysed using one-tailed t-test. 
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3.14.4 W188X mutation in the POPDC2 gene 
 
Also in the POPDC2 gene mutations were found in patients. Two families were identified harbouring 
the same nonsense mutation resulting in a truncated POPDC2 protein, which consists only of the first 
187 amino acids. Interestingly, the affected patients suffer from cardiomyopathy in one family, in the 
other family cardiac pacemaker and conduction phenotypes are predominant (Thomas Brand, 
personal communication).  
To start deeper investigation into the phenotype, human POPDC2 cDNA was obtained from Source 
Bioscience and subcloned into the pCDNA3.1(+) vector in frame with a Flag epitope tag. For studying 
the effect of the W188X mutation, a deletion-mutated version of POPDC2 was generated by PCR and 
cloned into the same vector. Thus, a protein construct was obtained consisting of the first 187 amino 
acids of POPDC2 followed by a Flag epitope. Although the construct is not a point mutant, it is 
designated in the following as POPDC2[W188X]-Flag. 
We first checked whether this truncated protein is efficiently translated and stable. We therefore 
transfected both wildtype and mutated POPDC2 into Cos-7 cells and detected subcellular localisation 
of the recombinant proteins using an anti-Flag antibody. POPDC2[W188X]-Flag was normally 
translated and its subcellular localisation was comparable to the wildtype construct. Both proteins 
were found mainly intracellularly localised in the ER (Figure 3.62). 
 
 
 
Figure 3.62: Subcellular localisation of POPDC2[WT]-Flag and POPDC2[W188X]-Flag  
Cos-7 cells were transfected with either POPDC2[WT]-Flag (A) or POPDC2[W188X]-Flag (B). 24h 
later, cells were fixed and immunocytochemically labelled using an anti-Flag antibody. Nuclei were 
counterstained using DAPI (blue) (scale bars: 10µm). Both POPDC2[WT]-Flag and 
POPDC2[W188X]-Flag were analysed with regard to their subcellular distribution in two experiments. 
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Expression was also analysed by Western blotting. Cos-7 cells were transfected with either 
POPDC2[WT]-Flag or POPDC2[W188X]-Flag alone or with both constructs together, and proteins 
were extracted 24h later. Samples were size-separated on a SDS gel and blotted onto a nitrocellulose 
membrane, followed by immunodetection using an anti-Flag antibody.  
Transfection of the W188X mutant resulted in a strong band between 15kDa and 25kDa, which is in 
agreement with the predicted size of 21kDa. Importantly, also a band double of this size was detected, 
which is indicative for a homodimer (Figure 3.63, first lane). For POPDC2[WT], which has a predicted 
size of about 41kDa, several bands could be detected, which may be due to posttranslational 
modifications. The main bands were detected running between 40kDa and 55kDa. Significantly, also a 
band being approximately double of this size could be detected (Figure 3.63, second lane). When both 
WT and W188X were expressed together, an additional band occurred at a molecular weight between 
55kDa and 70kDa, suggesting that both proteins are competent for dimer formation (Figure 3.63, third 
lane). Importantly, these dimers persisted in the presence of the reducing agent ß-mercaptoethanol.  
 
 
 
Figure 3.63: Western blot analysis of POPDC2[WT]-Flag and POPDC2[W188X]-Flag  
Cos-7 cells were transfected with POPDC2[WT]-Flag or POPDC2[W188X]-Flag alone or in 
combination. Proteins were extracted 24h later and lysates were subjected to Western blot using an 
anti-Flag antibody. Note that when both constructs were transfected, only 50% of each plasmid DNA 
was used for transfection (+: W188X monomer, ^: W188X dimer, x: WT monomer, *: WT dimer, 
o: presumptive W188X/WT dimer). Western blot analysis of POPDC2[WT]-Flag and 
POPDC2[W188X]-Flag was done twice. 
 
 
Apparently, POPDC2[W188X] is still able to form homodimers. We wondered whether it can also 
interact with Popdc1. Therefore, the Flag-tagged POPDC2[W188X] construct was co-transfected 
together with myc-tagged Popdc1 and cells were harvested 24h later. CoIP was performed using an 
immobilised anti-myc antibody. After several washes, samples were eluted by boiling in SDS ample 
buffer and subjected to Western blot analysis for the detection of POPDC2[W188X] using an anti-Flag 
antibody. As control, Cos-7 cells were used transfected with POPDC2[W188X] and the empty 
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pCS2+MT vector. Co-precipitation was only seen after co-transfection with Popdc1, suggesting that 
there is a specific interaction between Popdc1 and the truncated Popdc2 protein (Figure 3.64).  
It can therefore be concluded that POPDC2[W188X] is able to interact with both POPDC1 and 
POPDC2. 
 
 
Figure 3.64: CoIP of hPOPDC2[W188X]-Flag with Popdc1[WT]-myc 
Flag-tagged POPDC2[W188X] was transfected into Cos-7 cells together with pCS2+MT (vector) or 
myc-tagged Popdc1, and subjected to anti-myc CoIP followed by Western blot analysis for the 
detection of POPDC2[W188X] using an anti-Flag antibody. POPDC2[W188X] was precipitated only in 
the presence of Popdc1. CoIP of hPOPDC2[W188X]-Flag with Popdc1[WT]-myc was carried out 
twice. 
 
 
. 
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4 DISCUSSION 
 
In this work the role of members of the Popeye domain containing protein family in striated muscle 
tissue was investigated. Several novel interaction partners could be identified, which shed new light on 
the biological context in which Popdc proteins work. Moreover, it was found that Popdc proteins 
interact with each other and form heteromeric complexes, which further elucidates the complexity of 
this protein family. In addition, a novel feature of Popdc proteins was discovered, the nuclear 
localisation of Popdc1 and Popdc2, which may be particularly important in activated myoblasts. 
Furthermore, abnormalities of skeletal muscle regeneration in Popdc2 null mutant mice were 
observed.  
Several mutated POPDC1 proteins found in patients with heart and skeletal muscle diseases were 
functionally characterised. For one of these, the S201F mutant, a reduction in cAMP binding was 
observed, which seems to be crucial for the pathology observed in these patients.  
 
 
4.1 All Popdc antibodies used in this work are specific 
 
All experiments performed in this thesis involving endogenously expressed Popdc proteins relied on 
the availability and specifity of anti-Popdc protein antibodies. Thus, initial efforts were focused on 
testing new commercially available antibodies to characterise their affinity and specifity. In total,  
4 different anti-Popdc antibodies were used in this work for immunoprecipitation, immunofluorescence, 
and Western blot analysis. Besides an anti-Popdc1 antibody from Santa Cruz (#sc-49889), which has 
been shown previously to be specific for the detection of Popdc1 (Breher 2009; Froese et al. 2012), 
we found that another antibody for the detection of Popdc1 (Sigma-Aldrich, #HPA018176) and one for 
Popdc2 (Sigma-Aldrich, #HPA024255) proved to be particularly useful to study Popdc proteins. In 
Western blots, both antibodies were specific for their respective antigen (Figure 3.1). Specificity was 
also analysed using murine heart tissue from wildtype and Popdc null mutant mice. Signals could only 
be detected if wildtype tissue was used (Subreena Simrick, personal communication). Similar results 
have been obtained for an antibody against Popdc2 from Santa Cruz (#sc-66588). Immunolabelling 
using this antibody also resulted in staining only when wildtype tissue was used, but not with Popdc2
-/- 
hearts (Subreena Simrick, personal communication). Thus, all Popdc antibodies used in this work are 
specific for Popdc1 and Popdc2, respectively. Taken together, these antibodies do not cross-react, 
despite of the high degree of homology between members of the Popdc protein family. We can 
therefore conclude that the results obtained using one of these antibodies against Popdc1 or Popdc2 
were not blurred by cross-reactivity or the undesired co-detection of other Popdc family members, but 
were specific for either Popdc1 or Popdc2. 
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4.2 Several novel Popdc interacting proteins were discovered 
 
Popdc genes have been discovered about one and a half decades ago (Reese et al. 1999; Andree et 
al. 2000). They are predominantly expressed in heart and skeletal muscle (Andree et al. 2002; Froese 
and Brand 2008). It has recently been shown that inactivation of either Popdc1 or Popdc2 in mice 
leads to stress-induced cardiac arrhythmias characterised by the occurrence of sinus pauses (Froese 
et al. 2012). Furthermore, depletion of Popdc1 resulted in impaired muscle regeneration (Andree et al. 
2002) Despite the identification of several interaction partners for Popdc proteins including ZO-1, 
GEFT, Vamp2, Vamp3, NDRG4, aPKC, and TREK-1 (Osler et al. 2005; Smith et al. 2008; Hager et al. 
2010; Froese et al. 2012; Wu et al. 2012; Benesh et al. 2013) the molecular mechanisms underlying 
the observed phenotypes in striated muscle tissue could not be explained satisfactorily yet.  
 
 
4.2.1 Several classes of Popdc interaction proteins were identified by CoIP 
coupled to mass spectrometry  
 
In this work, several novel potential interaction partners could be identified by CoIP coupled to mass 
spectrometry (chapter 3.2).  
Many identified proteins were coming from the blood and are most likely false-positives. They can 
therefore be disregarded. Another highly represented group were mitochondrial proteins. Until now, 
Popdc proteins have never been implicated with mitochondrial localisation or function. Therefore, this 
group may be false-positives as well. However, due to the high number of hits, it may be worthwhile to 
isolate mitochondria and investigate whether Popdc proteins are indeed expressed in these 
organelles.  
Interestingly, a prominent number of identified candidates have known functions in protein translation, 
modification, or degradation. Some of these candidates may represent proteins, which are modifying 
Popdc proteins. Therefore, deeper investigation of this group may shed light on possible 
posttranslational modifications of Popdc proteins. Until now, the only known posttranslational 
modification of Popdc proteins is glycosylation (Knight et al. 2003; Vasavada et al. 2004), but it is likely 
that also other types of modification exist, such as posttranslational cleavage (discussed in chapter 
4.13), which may have strong impact on Popdc protein localisation and function.  
Highly represented were also proteins playing roles in vesicular transport or fusion processes. This 
group is of high significance given that the SNARE proteins Vamp2 and -3 have been established as 
interaction partners for Popdc proteins before (Hager et al. 2010). There might also be proteins in this 
group by which Popdc proteins are transported to the different subcellular compartments such as the 
plasma membrane, t-tubules, or the nuclear envelope.  
Similarly strongly represented were proteins, which have a role in cell form and stability like 
cytoskeletal proteins or components of the basement membrane. This group is likely to contain a 
number of true interaction partners as Popdc1 has been described to regulate the organisation of the 
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actin cytoskeleton by interaction with the Rho-GTPase GEFT (Smith et al. 2008). It is therefore not 
unlikely that also other mechanism exist by which Popdc proteins regulate cytoskeletal components.  
Furthermore, several proteins involved in signalling processes have been discovered. Given the 
interaction of Popdc1 with Caveolin-3 and their role for structure and function of caveolae, which have 
important roles in signalling events (Alcalay et al. 2013) and the fact, that Popdc proteins are 
modulated by the signalling molecule cAMP (Froese et al. 2012), deeper analysis of this group of 
interaction candidates may give important insights into the function of Popdc proteins.  
Importantly, there were many false-negatives, i.e. known interaction partners, which were not picked 
up by our screen. Examples for these are Caveolin-3 and Dysferlin. It is particularly apparent, that only 
relatively few integral membrane proteins were among the candidates. As both Popdc1 and Popdc2 
are transmembrane proteins themselves, and they are present at the cell surface and in t-tubules 
(Froese et al. 2012; Simrick et al. 2013), one would assume that many interaction partners are also 
integral membrane proteins and present at the cell surface. The relative low abundance may be due to 
the CoIP methodology used. The buffer conditions to extract protein complexes were very mild, 
however, it was previously reported for Popdc1 that the protein is only efficiently solubilised using 
harsh buffers containing 8M urea (Vasavada et al. 2004). It is therefore likely, that a significant fraction 
of Popdc proteins and its interaction partners were not extracted but discarded as insoluble pellet after 
clearing of the lysates by centrifugation. As harsh buffer conditions would most likely not allow keeping 
complexes of interaction partners intact, proteins could be cross-linked using a reversible cross-linker 
such as DSP before extraction with strong buffers. This principle has been used by Alcalay and 
colleagues to demonstrate interaction of endogenously expressed Popdc1 and Caveolin-3 in rat 
cardiac myocytes (Alcalay et al. 2013), and could therefore also work for other Popdc interacting 
proteins. However, it has to be considered that for some protein complexes, cross-linking could reduce 
efficiency of immunoprecipitation.  
Moreover, some protein-protein interactions may result in the antigen to be inaccessible for the 
antibody or antibody binding may impair interaction with other proteins. To overcome this, the 
utilisation of different antibodies may be required. Thus, to explore the Popdc protein interactome in its 
entirety it would be necessary to combine different techniques and reagents. 
 
 
4.3 Popdc proteins interact with each other 
 
4.3.1 Popdc proteins do not only homodimerise but also form heteromeric 
complexes 
 
It was striking that Popdc1 as well as Popdc2 were precipitated from heart and skeletal muscle lysates 
with the Popdc1 as well as with both Popdc2 antibodies. Also from Cos-7 cell lysates, POPDC2 was 
co-precipitated with Popdc1. Moreover, we demonstrated that Popdc1 and -2 form heteromeric 
complexes (chapters 3.2 and 3.10). In addition, in isolated adult ventricular myocytes Popdc1 and -2 
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showed highly overlapping subcellular distribution (Subreena Simrick, personal communication). 
Similar results have been obtained for Popdc3, which also does not only interact with Popdc1 but also 
forms heteromeric complexes with it (chapter 3.10). It has been described previously that Popdc1 is 
able to homodimerise (Knight et al. 2003; Vasavada et al. 2004; Kawaguchi et al. 2008). In this work, 
some evidence was obtained for homodimerisation of Popdc2 as well. However, heterodimerisation 
was previously supposed to be unlikely, since the C-terminal motif involved in Popdc1 
homodimerisation is not conserved among Popdc proteins (Brand 2005; Breher 2009). Thus, this work 
provides the first evidence of heteromerisation. Interestingly, we did not only find heterodimers, but 
also complexes, which are supposedly heterotetramers suggesting that Popdc proteins form higher 
order complexes. Interestingly, interaction between Popdc2 and Popdc3 could not be detected, 
indicating that Popdc1 is a hub with regard to Popdc complexes, connecting all three Popdc proteins. 
However, it cannot be excluded that other isoforms of Popdc2 and Popdc3 may be interacting. 
In this work, a Western blot-based in vitro approach was used to determine the presence of  
homo- and heteromeric complexes. It appears that the formation of heteromers was even preferred 
compared to homodimer formation, as the bands for POPDC1 homodimers were much weaker.  
Although being members of the same protein family, there are significant differences between different 
Popdc proteins, e.g. with regard to overall size (Popdc1: 358aa, Popdc3: 291aa). Thus, it is very likely 
that heteromeric complexes have different properties compared to homodimers, e.g. with regard to the 
modulation of other proteins. However, those differences and their functional impact have yet to be 
elucidated. Since depletion of Popdc1 or of Popdc2 in mice causes the nearly identical phenotype of 
an age-dependent stress-induced bradycardia (Froese et al. 2012), it is tempting to assume that 
heteromeric Popdc1-Popdc2 complexes may play a major role in cardiac pacemaking. This hypothesis 
is supported by the fact that the phenotype in Popdc1/Popdc2 double null mutants is not exaggerated 
(Subreena Simrick, personal communication). However, whereas in single null mutants the phenotype 
is observed only in older animals (≥5.5 months), the stress-induced bradycardia in the double null 
mutants is already present in younger mice (3 months old), suggesting that also Popdc1-Popdc3 and 
homomeric Popdc3 complexes have a pacemaking function and can partially compensate for the loss 
of either Popdc1, Popdc2 or both. It will be interesting to analyse SAN function in Popdc3 null mutants 
as well as in Popdc1/Popdc3 and Popdc2/Popdc3 double and Popdc1/Popdc2/Popdc3 triple null 
mutant mice to get deeper insight into the relative contribution of each gene and the functional 
significance of different homo- and heteromeric complexes.  
 
 
4.3.2 The transmembrane domains modulate Popdc-Popdc protein interaction 
 
We have shown that the C-terminal (intracellular) portion of Popdc proteins is not required for 
interaction, as the transmembrane domains including the very short extracellular part of Popdc1 were 
able to interact with Popdc2 (Figure 3.34).  
It was first assumed that the transmembrane domains alone are responsible for heteromerisation. To 
prove this concept, CoIPs were performed using chimeric constructs consisting of the N-terminal 
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portion of POPDC1 and the C-terminus of POPDC2 (P1P2 chimera) or the N-terminus of POPDC2 
and the C-terminal portion of POPDC1 (P2P1 chimera). We assumed that P1P2 would be able to 
interact with Popdc3, but not P2P1 as it is lacking the POPDC1 transmembrane domains. However, 
both constructs were co-precipitated with Popdc3, suggesting that heteromeric interaction is not only 
mediated by the transmembrane domains alone.  
Interestingly, also Popdc1 homodimerisation seems to be mediated by two different domains localised 
in the cytoplasmic portion and the transmembrane domains, respectively. In addition to the C-terminal 
homodimerisation motif discovered by Kawaguchi et al. (Kawaguchi et al. 2008), which is located at 
the C-terminal, non-conserved end of the Popeye domain, another homodimerisation motif is present, 
most likely in the transmembrane domains, since homodimerisation also occurred when almost the 
entire intracellular portion of Popdc1 including the C-terminal homodimerisation motif was deleted 
(Russ et al. 2011). Also for Popdc2, the C-terminal part of the Popeye domain is not necessary, as the 
W188X mutant was still able to form dimers with itself and with wildtype POPDC2 (Figure 3.63).  
 
Despite of the suspected presence of an intracellular interaction domain, the importance of the 
transmembrane domains for modulation of Popdc-Popdc interaction could be demonstrated using the 
Popdc3c isoform. Compared to the Popdc3 isoform A, which was generally used in this work, isoform 
C showed an even higher affinity for Popdc1 (Figure 3.36), although the intracellular portions of both 
isoforms are identical. However, in contrast to isoform A harbouring three transmembrane domains, in 
isoform C only a single transmembrane domain is present (Figure 3.35A,B). It can therefore be 
concluded that the transmembrane domains are important in regulating the affinity of Popdc proteins 
to each other, which could have a profound impact of the ratio of different homo- and heteromeric 
complexes in vivo. However, it can be assumed that the formation of heteromeric complexes is not 
only regulated by the presence of different isoforms but also by expression levels of Popdc proteins.   
Interestingly, the isoforms showed different subcellular distribution, with isoform C predominantly 
found in the nuclear envelope (Figure 3.35C,D). It can therefore be concluded, that the 
transmembrane domains do not only modulate interaction but also subcellular localisation of Popdc 
proteins. Moreover, there is some evidence of Popdc3 isoform expression to be tissue-specific 
(Stefanie Wiegand, student research project, 2005).  
Therefore, through the modulation of splicing affecting the transmembrane domains of Popdc proteins 
the subcellular localisation and function of Popdc proteins can be regulated.  
 
 
4.4 Popdc proteins interact with Ankyrins 
 
In this work Ankyrin-B and Ankyrin-G were established as novel interaction partners for Popdc 
proteins. They were discovered using the CoIP coupled to mass spectrometry screen. Significantly, 
with antibodies directed against Popdc1 and Popdc2 Ankyrin-G was co-precipitated in all performed 
experiments using either heart or muscle lysates. Ankyrin-B was only co-precipitated with the Popdc2 
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antibody in all rounds of CoIP coupled to mass spectrometry but not with the Popdc1 antibody. 
However, Western blot detection after CoIP clearly showed that Ankyrin-B was co-precipitated with 
Popdc1 as well (Figure 3.7). This interaction may be indirect via Popdc1-Popdc2 interaction. To test 
this hypothesis, CoIP should be repeated using tissue lysates from wildtype and Popdc2
-/-
 hearts as 
control in addition to lysates obtained from Popdc1
-/-
 tissue. If the interaction is direct, then Ankyrin-B 
would be co-precipitated from wildtype as well as Popdc2
-/-
 lysates, however, in the case of an indirect 
Popdc2-mediated interaction, no signal should occur when Popdc2
-/-
 or Popdc1
-/-
 hearts are used. 
Alternatively, CoIPs could be performed using lysates of Cos-7 cells, which do not endogenously 
express Popdc proteins, transfected with Ankyrin-B and Popdc1 constructs. 
In comparison to Ankyrin-B, interaction with Ankyrin-G seems not to be mediated by Popdc2, as it was 
robustly co-precipitated in all rounds of CoIP coupled to mass spectrometry or Western blot analysis 
(Figure 3.10). Furthermore, Ankyrin-G was co-precipitated together with Popdc1 from  
Cos-7 cell lysates in the absence of Popdc2 (Figure 3.11). As it was also reproducibly precipitated with 
the Popdc2 antibody, direct interaction with Popdc2 is also likely, although this is not formally proven. 
Further evidence for interaction of Popdc proteins with Ankyrins was obtained from immunostaining 
performed on neonatal cardiac myocytes and skeletal muscle sections, where Ankyrin-B was shown to 
partial co-localise with Popdc2 (Figure 3.8 and Figure 3.9). In adult cardiac myocytes, Popdc1 and -2 
have been shown to be distinctively localised at the plasma membrane and in transverse tubules 
(Breher 2009; Froese et al. 2012). Neonatal myocytes, however, are lacking t-tubules, and their 
membrane organisation as a whole is less complex (Ibrahim, 2011). Therefore, co-localisation studies 
in isolated adult cardiomyocytes have been performed by Dr Subreena Simrick. For Ankyrin-B strong 
immunoreactivity over the M-line was observed, but also at the t-tubules/Z-lines, where it is 
co-localised with Popdc1 and Popdc2. Furthermore, the effect of loss of Popdc1 and Popdc2 on the 
subcellular localisation of Ankyrin-B was studied by immunocytochemistry on isolated Popdc1/Popdc2 
double knockout (P12dKO) murine cardiac myocytes, and a significant alteration of Ankyrin-B and -G 
localisation was seen (Subreena Simrick, personal communication). Interestingly, preliminary analyses 
of subcellular localisation of Popdc1 and Popdc2 in cardiac myocytes isolated from Ankyrin2 null 
mutant mice lacking the Ankyrin-B protein indicate that subcellular localisation of Popdc proteins does 
not depend on Ankyrin-B (Jerry Curran and Peter Mohler, personal communication). Thus, it can be 
concluded that Popdc proteins contribute to the regulation of Ankyrin localisation rather than the 
converse. Ankyrins in turn are crucial for proper subcellular localisation and function of several other 
proteins (reviewed in (Nilsson and Bennett 2009)). It is therefore reasonable to assume that via 
interaction with Ankyrins Popdc proteins are able to modulate several physiological processes.  
Ankyrins are adaptor proteins involved in organising the transport and localisation of 
membrane-associated proteins to specific microdomains and linking these to the cytoskeleton (Nilsson 
and Bennett 2009; Cunha and Mohler 2011). Canonical ankyrins are composed of four domains, the 
membrane-binding domain, the spectrin-binding domain, the death domain, and the C-terminal 
regulatory domain (Cunha and Mohler 2006). The C-terminal regulatory domain is involved in 
protein-protein interactions. It has been shown for Ankyrin-B that this domain contains the binding site 
to obscurin, which contributes to the localisation of the Ankyrin protein to the M-line of cardiac 
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myocytes and in skeletal muscle (Cunha and Mohler 2008; Randazzo et al. 2013). The death domain 
is involved in the regulation of apoptosis by binding to the proapoptotic Fas protein (Del Rio et al. 
2004). The spectrin-binding domain is crucial for binding of Ankyrins to the actin/spectrin cytoskeleton 
(Davis et al. 2009; Stabach et al. 2009). Through binding to spectrin Ankyrins anchor several 
interacting proteins to the cytoskeleton, including the sodium/calcium exchanger. At the same time the 
spectrin-binding domain also contributes to organisation and stabilisation of the actin/spectrin 
cytoskeleton (reviewed in (Nilsson and Bennett 2009)). The membrane-binding domain contains 
binding motifs for several membrane-associated proteins including ion channels like Scn5a/Nav1.5 
(Lowe et al. 2008), the sodium/calcium exchanger (Cunha et al. 2007), as well as cell adhesion 
molecules like E-cadherin (Kizhatil et al. 2007). In addition, this domain may be involved in 
mechanotransduction (Lee et al. 2006).  
Interestingly, we could also identify known Ankyrin-interacting proteins to be interactors of Popdc 
proteins including NCX-1, Scn5a, and Dystrophin. It would be important for the understanding of the 
physiological role of Popdc proteins to find out whether these interactions are mediated directly or 
indirectly via Ankyrins.  
 
 
4.5 Popdc proteins interact with NCX-1 
 
A further interaction partner of Popdc proteins is the sodium/calcium exchange protein NCX-1. 
Identified by CoIP coupled to mass spectrometry, Western blot analysis could confirm co-precipitation 
with Popdc2 from wildtype heart lysates (Figure 3.12). Moreover, extensive co-localisation of both 
proteins was seen in ventricular myocytes isolated from adult wildtype hearts (Subreena Simrick, 
personal communication). Significantly, the subcellular localisation of NCX-1 in adult cardiac myocytes 
isolated from P12dKO mice was altered compared to wildtype cells (Subreena Simrick, personal 
communication). Strikingly, NCX localisation is also altered in Ankyrin-B
+/- 
mice, where NCX is absent 
from Z-lines/t-tubules (Mohler et al. 2005). Therefore, Popdc2 seems to be a constituent and anchor of 
a larger complex consisting of Ankyrin-B, NCX, and others Ca
2+
 regulating molecules like the InsP3 
(inositol triphosphate) receptor (Mohler et al. 2005). Popdc1 presumably only indirectly interacts with 
NCX-1 through binding to Popdc2, which may explain the unsuccessful precipitation of NCX-1 with the 
anti-Popdc1 antibody.  
NCX-1 is an important molecule for cardiac pacemaking. NCX-1 is activated by spontaneous Ca
2+
 
release from the sarcoplasmic reticulum, and, by transferring 3 Na
+
 ions into myoycytes and 1 Ca
2+
 ion 
out, it generates a net inward current, which contributes to membrane depolarisation (Lakatta et al. 
2010; Maltsev and Lakatta 2012). Specific inactivation of NCX-1 in cardiac pacemaker cells revealed a 
bradyarrhythmic phenotype (Herrmann et al. 2013). Other studies suggest an important role for heart 
rate adaptation under stress (Gao et al. 2013). Moreover, it is important for excitation-contraction 
coupling as it contributes to the end of contraction by extrusion of Ca
2+
 from the cell (Bers 2002).  
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Due to these substantial roles of NCX as well as of Popdc2 in cardiac electrophysiology, particularly in 
pacemaking (Froese et al. 2012), it will be important to reveal the impact of regulation of NCX-1 by 
Popdc2 with regard to precise localisation and function of NCX.  
 
 
4.6 Popdc proteins interact with voltage-gated sodium channels 
 
Interaction of Popdc proteins with voltage-gated sodium channels was discovered independently in 
this work by the CoIP coupled to mass spectrometry screen as well as by an electrophysiological 
screen based on the co-expression of Popdc proteins with different ion channels in Xenopus oocytes 
performed in Professor Niels Decher’s lab in Marburg, Germany. Interaction was confirmed by CoIP 
from Cos-7 cells after overexpression of Popdc1 and SCN5A (Figure 3.13). Thus, after TREK-1 
SCN5A/Nav1.5 is the second ion channel shown to be interacting with Popdc proteins. However, the 
effect of Popdc proteins on both channels is different. Whereas conductivity of TREK-1 is increased 
(Froese et al. 2012), SCN5A/Nav1.5 is inhibited in the presence of Popdc proteins (Niels Decher, 
personal communication).  
Scn5a is the predominantly expressed Nav channel α-subunit in the heart. Cardiac expression has 
also been reported for α-subunits, which are primarily found in neurons such as Nav1.1, Nav1.3, and 
others, and in skeletal muscle, such as Nav1.4, whose α-subunit is encoded by the Scn4a gene. For 
these channels, differences to Nav1.5 with regard to their localisation and cellular function have been 
described (Maier et al. 2002; Pereon et al. 2003; Lei et al. 2004). Interestingly, Scn4a was the isoform 
which was identified by our CoIP coupled to mass spectrometry screen, suggesting that Popdc 
proteins can interact with several different Nav α-subunits. In this regard it is noteworthy that Popdc1 
is also expressed in neurons (Brand 2005). Therefore, modulation of voltage-gated sodium channels 
by Popdc proteins my also play a role in these cells.  
In mice, genetic inactivation of Scn5a leads to embryonic lethality in homozygous Scn5a
-/-
 animals 
accompanied by morphological alterations, and to several electrophysiological phenotypes in the 
heterozygotes including impaired atrioventricular and intramyocardial conduction as well as ventricular 
tachycardia. Scn5a is also important in the pacemaker as Scn5a
+/-
 mice showed sinus bradycardia, 
slowed SA conduction, and sinoatrial exit block (Papadatos et al. 2002; Lei et al. 2005; Huang et al. 
2012).  
Interestingly, also in Popdc1
-/-
 and Popdc2
-/-
 mice, sinus bradycardia has been reported (Froese et al. 
2012). It would be important to examine sodium currents in these mice to reveal whether the observed 
phenotypes are partially caused by Scn5a/Nav1.5 being dysregulated in the absence of either Popdc1 
or Popdc2.  
In man, mutations in the SCN5A gene have been linked to several diseases including the Brugada 
syndrome, which is associated with high mortality and sudden cardiac death (Brugada et al. 2000). 
Interestingly, there are Brugada syndrome-causing mutations in SCN5A/Nav1.5, which have been 
described to result in loss of Ankyrin-G binding and therefore altered membrane localisation of the 
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sodium channel (Mohler et al. 2004). It is tempting to speculate whether Brugada syndrome-like 
diseases are also caused by mutations in SCN5A or POPDC genes, which lead to a loss of  
POPDC-SCN5A interaction, since Popdc proteins seem to be organisers of Ankyrin-containing 
macromolecular complexes. 
It would be interesting to determine the Popdc binding site for SCN5A. As all three Popdc proteins 
seem to be able to interact with SCN5A (Niels Decher, personal communication), a binding site within 
the Popeye domain is likely, as the Popeye domain shows the highest degree of conservation (Brand 
2005). Interestingly, in the Xenopus system, POPDC2[W188X] was still able to interact with SCN5A, 
indicating that the C-terminal part of the Popeye domain does not mediate interaction. However, in 
contrast to wildtype POPDC2, the SCN5A/Nav1.5 current was not decreased, but increased in the 
presence of the W188X mutant, suggesting that the C-terminal part of the protein has important 
regulatory functions (Niels Decher, personal communication). 
 
 
4.7 TREK-1 and Caveolin-3 binding sites do not overlap 
 
In this work, we could narrow down the binding site of TREK-1 to a region in the N-terminal part of the 
Popeye domain (Figure 3.24). In contrast, Caveolin-3 binding is predominantly mediated by a motif, 
which is located towards the C-terminus of the Popeye domain (Figure 3.16). As the binding sites are 
not overlapping, binding of both proteins at the same time might be possible, however, TREK-1 was 
found to be localised mainly outside of caveolae (Calaghan 2011).  
Caveolae are centres of regulating cAMP-mediated signalling processes (Xiang 2011; Stary et al. 
2012). In Popdc1
-/-
 mice, fewer caveolae were found, which were larger in size compared to wildtype 
controls (Alcalay et al. 2013). Interestingly, after beta-adrenergic stimulation the protein composition of 
caveolae changes (Wypijewski et al. 2013). It is reasonable to hypothesise that Popdc proteins are 
involved in these regulations, since they are not only able to interact with a variety of proteins, but they 
are also modulated by cAMP. This may in part explain the alteration in Ca
2+
 transients and increased 
vulnerability of the heart to ischemia-reperfusion injury in Popdc1
-/-
 mice (Alcalay et al. 2013). So far, a 
Popdc-dependent modulation of protein complexes by cAMP binding has only been demonstrated for 
TREK-1 (Froese et al. 2012), but it is likely that interaction with many other proteins is cAMP 
regulated. Importantly, the Cav3 binding site is predicted to form the lid structure of the cAMP binding 
domain (Rehmann et al. 2007). This is a region, which is supposed to undergo prominent 
conformational changes upon cAMP binding, which could have a significant effect on Caveolin-3. 
Thus, investigating the composition of caveolae in Popdc null mutant mice under normal conditions 
and after ß-adrenergic stimulation deserves more detailed studies in order to reveal the role of Popdc 
proteins for caveolae number, shape, and function.  
For a better understanding of Popdc protein function, it would also be necessary to determine binding 
sites for interacting proteins, which are not localised to caveolae, and to test, whether several proteins 
can bind to Popdc proteins simultaneously. It would also be helpful to see whether these interactions 
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are modulated by cAMP binding to Popdc proteins. As Popdc proteins form higher order complexes, it 
is likely that many of these interaction partners are regulated at the same time.  
 
 
4.8 Popdc1 interacts with Dystrophin 
 
In this work, interaction of Popdc1 with Dystrophin could be demonstrated by CoIP using mini- and 
micro-dystrophin constructs (Figure 3.20).  
Dystrophin is a member of a large complex containing several different glycoproteins that links the 
cytoskeleton with the extracellular matrix, thereby mechanically stabilising the muscle membrane 
(Dalkilic and Kunkel 2003). Mutations in the DMD gene encoding for Dystrophin in humans are 
associated with both, muscle dystrophies as well as with cardiomyopathy, as muscle membranes 
become fragile and leaky (Goldstein and McNally 2010; Ferlini et al. 2013).  
Importantly, POPDC1[S201F] patient have high CKemia, which is indicative of leaky membranes. As 
no mutation in DMD or other dystrophy-associated genes are present, it seems that POPDC1 also 
contributes to membrane integrity, which may partially be explained on the basis of interaction with 
Dystrophin. It appears that in the patients sarcolemmal Dystrophin levels were slightly reduced 
(Subreena Simrick and Alessandra Ferlini, personal communication). Therefore, impairment of 
membrane trafficking may cause alteration of Dystrophin localisation and therefore impaired 
membrane integrity. Additionally, POPDC1[S201F] may show a decreased affinity to Dystrophin 
compared to the wildtype protein, which may lead to a destabilisation of the dystrophin-dystroglycan 
complex at the membrane, independent of membrane trafficking. However, this has yet to be tested. 
It is noteworthy that Dystrophin levels were also slightly reduced in muscle from Popdc1/Popdc2 
double null mutant mice (P12dKO) compared to age-matched wildtype control tissue. Likewise,  
γ-Sarcoglycan, another constituent of the dystrophin-dystroglycan complex, was weaker expressed in 
P12dKO mice, whereas α-Sarcoglycan was not affected (Figure 3.42). It would be interesting to know 
whether Popdc proteins are directly interacting with γ-Sarcoglycan and other components of the 
dystrophin-glycoprotein complex. This would give further evidence that Popdc proteins may stabilise 
components of the dystrophin-glycoprotein complex and thereby contribute to mechanical integrity of 
muscle membranes.  
Interestingly, it has been shown that Scn5a/Nav1.5 and other sodium channels are interacting with 
syntrophins and are therefore part of the dystrophin-dystroglycan complex (Gee et al. 1998; Gavillet et 
al. 2006). Strikingly, Dystrophin has also been found in caveolae and could be co-precipitated together 
with Caveolin-3 (Doyle et al. 2000).  
Thus, it is possible that SCN5A/Nav1.5, dystrophin, Caveolin-3, and Popdc proteins are in close 
spatial and most likely also functional relationship.  
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4.9 Popdc1 is co-precipitated with Dysferlin 
 
Co-precipitation and co-localisation studies have provided evidence for interaction of Popdc1 with 
Dysferlin (Figure 3.17A). It has been demonstrated previously that Dysferlin requires Caveolin-3 for 
membrane trafficking but once at the membrane, Dysferlin seems not to be associated with Caveolin-3 
(Hernandez-Deviez et al. 2006). Binding of Popdc1 and Dysferlin appears to be independent of 
caveolins, since Dysferlin was also co-precipitated with a Popdc1 deletion mutant lacking the 
Caveolin-3 binding motif (Popdc1[116], Figure 3.17B,C). 
Dysferlin has been shown to be involved in repairing of membrane damages caused by mechanical 
stress. These repair mechanisms prevent degradation of muscle fibres. Mutations in the  
Dysferlin-encoding DYSF gene in man are associated with Miyoshi myopathy and limb-girdle muscular 
dystrophy type 2B (LGMD2B) (Glover and Brown 2007; Han and Campbell 2007). Although Dysferlin 
shows a broad expression pattern, mutations cause only skeletal muscle phenotypes. However, 
usually membrane stability is not affected (Glover and Brown 2007).   
Interestingly, in the P12dKO muscle Dysferlin staining appeared to be more intense (Figure 3.42E,F), 
which may be indicative of a higher degree of muscle repair due to a mild degree of muscle 
membrane instability. Importantly, up-regulation of Dysferlin has been described for muscular 
dystrophy before (Waddell et al. 2011), and seems to be a more general feature of dystrophic 
muscles. 
Thus, we conclude that Popdc1 provides a link between Dysferlin and the dystrophin-dystroglycan 
complex, suggesting that Popdc proteins are involved in the maintenance of muscle membrane 
integrity by regulation membrane stability and repair. It is therefore possible that mutations in or 
depletion of Popdc proteins results in both, impaired membrane stability and defective repair. 
 
 
4.10 Mutations in POPDC1 and POPDC2 are associated with cardiac and 
skeletal muscle diseases 
 
4.10.1 POPDC1[S201F] shows reduced cAMP affinity  
 
Patients with a POPDC1[S201F] mutation showed clinical signs of muscular dystrophy including high 
creatinine kinase (CK) levels in the blood, as well as an impaired AV conduction in the heart.  
The S201F mutation has a significant impact on cAMP binding as demonstrated by affinity binding 
(Figure 3.57). This result was confirmed by FRET analyses using a bi-molecular sensor consisting of 
POPDC1-CFP and YFP-TREK-1 (Viacheslav Nikolaev, personal communication). Furthermore, 
regulation of TREK-1 was altered in the Xenopus system. In accordance with previous data (Froese et 
al. 2012), TREK-1 current was augmented with wildtype POPDC1 and currents were even higher 
when the S201F mutation was co-expressed. Importantly, increase of cAMP levels by theophylline 
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abolished the effect of wildtype POPDC1, however, POPDC1[S201F] resulted in a significant increase 
in TREK-1 current even in the presence of theophylline. Thus, the S201F mutation resulted in reduced 
affinity to cAMP and in altered effects on TREK-1 (Niels Decher, personal communication). Popdc 
proteins regulate membrane localisation of TREK-1 in a cAMP-dependent manner with cAMP to have 
an inhibitory effect (Froese et al. 2012). This inhibition is compromised for POPDC1[S201F] resulting 
in an increased TREK-1 current. 
 
Moreover, in a muscle biopsy from one of the affected patients, POPDC1 levels seemed to be 
unaltered (Figure 3.59). However, the subcellular localisation was changed as the amount of POPDC1 
at the sarcolemmal membranes was strongly reduced, whereas vesicular structures in the fibre bodies 
were more intensively labelled (Alessandra Ferlini and Subreena Simrick, personal communication).  
Popdc1 has been shown to be involved in vesicular transport and fusion (Hager et al. 2010; Benesh et 
al. 2013). Therefore, this alteration in vesicular labelling may be an important contribution to the 
pathology in the patients. To some extent, also indirect effects caused by this mutation could 
contribute to the observed phenotypes. It has been shown that Popdc proteins can bind cAMP with 
high affinity (Froese et al. 2012). Given the relative high expression levels, an effect on the buffering 
capacity of local cAMP concentrations is possible. To what extent a decreased cAMP affinity, as it was 
observed for POPDC1[S201F] or a complete loss of Popdc proteins in Popdc null mutant mice results 
in increased levels of free cAMP, which may cause enhanced activation of other cAMP-modulated 
proteins like PKA, is still unknown. 
To fully explore the underlying pathomechanisms, it will be important to reveal the relative 
contributions of the protein interactions, particularly with Dystrophin, Dysferlin, and Caveolin-3, as 
mutations in all of these proteins have been implicated in muscular dystrophy before. 
Interestingly, immunohistochemical staining revealed up-regulation of Caveolin-3 in the patient 
(Subreena Simrick, personal communication). Up-regulation of Caveolin-3 is also seen in Duchenne 
muscular dystrophy (Repetto et al. 1999; Galbiati et al. 2001). Conversely, overexpression of 
Caveolin-3 in mice reduced Dystrophin and ß-Dystroglycan levels (Galbiati et al. 2000). Therefore, the 
pathomechanism in POPDC1[S201F] patients may involve the up-regulation of Caveolin-3 as well as 
down-regulation of Dystrophin. In addition the S201F mutation may have direct effects on POPDC1 
interactions with Caveolin-3, Dystrophin, and Dysferlin, thereby contributing to the phenotype. 
 
 
4.10.2 POPDC1 levels are increased in DCM compared to non-failing human 
hearts 
 
Our collaborator Professor Milting and his team have discovered patients with dilated cardiomyopathy, 
harbouring a R172H mutation in the POPDC1 gene. However, another mutation is present in these 
patients affecting the LaminA/C encoding LMNA gene. Therefore, it is presently unclear if or to what 
extent the POPDC1[R172H] mutation is involved in the pathogenesis of the disease in these patients, 
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requiring further experiments to define the relative contributions of either of these mutations to the 
phenotype.  
In this work, first analyses were done aiming to reveal the impact of the R172H mutation on cAMP 
binding of the POPDC1 protein. No differences were detected using the cAMP affinity binding assay, 
suggesting that cAMP binding is not affected (Figure 3.57). Thus, the pathomechanism in these 
patients will need to be explored in further experiments.  
Since affected patients in this family had to undergo heart transplantation, we were able to analyse the 
effect of this mutation on POPDC1 and -2 expression in cardiac tissue. We found that total POPDC1 
as well as POPDC2 levels were increased compared to normal control hearts (Figure 3.60). Moreover, 
the relative distribution of different isoforms was altered in the case of POPDC1. One isoform detected 
as a band in the Western blot running at about 60kDa was slightly reduced in intensity, whereas 
another band running at about 55kDa was clearly increased. For POPDC2, all isoforms appeared to 
be up-regulated. This was particularly visible for a band running just below 70kDa, which was hardly 
above detection limit in non-failing control hearts but much more intense in the POPDC1[R172H] 
sample. Importantly, also in DCM cases with other causes POPDC1 and POPDC2 were up-regulated 
in a similar fashion. This is in contradiction to previously published data showing that POPDC1 is 
down-regulated in failing human hearts on the transcript as well as the protein levels (Gingold-Belfer et 
al. 2011). The differences are currently unexplained. Gingold-Belfer and colleagues mainly 
investigated ischemic heart disease samples and only a very few DCM hearts. Thus, regulation of 
POPDC1 expression may be dependent on the aetiology of heart failure. Additionally, also usage of 
other reagents, including the antibody for the detection of POPDC1, and different methodologies might 
contribute to these differences.  
In this work, particular diligence was taken to achieve efficient protein extraction by using a harsh 
buffer as well as to avoid clustering of POPDC proteins by incubating the samples at 60°C for 15min in 
SDS sample buffer instead of boiling, which could have distorted the results. Furthermore, we used 
anti-POPDC antibodies, which have been tested extensively. Moreover, in this thesis 4 DCM samples 
have been investigated, and all of them showed up-regulation of POPDC1 and POPDC2 levels, 
providing further evidence for an up- rather than a down-regulation of POPDC proteins in DCM. 
Therefore, the hypothesis of a general down-regulation of POPDC1 in failing human hearts 
(Gingold-Belfer et al. 2011) may need to be refined by the addition of the aetiology of heart failure. To 
further test whether POPDC proteins are generally up-regulated in DCM hearts, expression analyses 
could be done using hearts of MLP
-/-
 mice, which are an animal model for DCM in humans (Arber et al. 
1997).  
Furthermore, it has to be determined, whether these alterations of POPDC1 and -2 expression affect 
the pathology of DCM. An important step towards the understanding of the role of POPDC proteins in 
this context would be to identify the nature of these isoforms, and their physiological impact could then 
be studied after overexpression in a transgenic animal model. 
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4.11 Popdc1 and -2 show different fibre type-specific expression levels 
 
As mentioned before, Popdc proteins are highly expressed in skeletal muscle as well. With our 
specific antibodies we were able to reveal subcellular localisation of Popdc1 and Popdc2 in muscle 
fibres. As expected, both proteins were predominantly expressed at the cell surface. Also t-tubular 
staining could be observed. However, neither Popdc1 nor Popdc2 were homogenously expressed 
across the whole muscle. In fact, a strict correlation between levels of highest expression and fibre 
type could be observed for Popdc1 as well as for Popdc2. 
However, whereas Popdc1 was predominantly detected in type IIb fibres, the highest Popdc2 levels 
could be observed in type IIa fibres (Figure 3.37, Figure 3.38, Figure 3.39). It would be interesting to 
determine and compare contractility of muscles and muscle fibres isolated from wildtype, Popdc1 and 
Popdc2 single and double null mutants. As the fibre composition is not the same in each muscle, 
different muscles may be differently affected by the loss of Popdc1 or Popdc2. For example, the 
soleus muscle contains nearly no type IIb fibres, whereas in the EDL muscle IIb is the prominent fibre 
type (Agbulut et al. 2003). Interestingly, preliminary studies on the contractility of EDL muscles 
showed significantly increased time to peak and half relaxation times in the EDL but not soleus muscle 
of Popdc1 null mutants compared to heterozygous controls (Thomas Brand, personal communication), 
however, no data yet exist for other Popdc deficient animals. 
 
Importantly, muscle fibre type and their oxidative potential are at least partially regulated via cAMP 
(reviewed in (Berdeaux and Stewart 2012)). This also includes metabolic properties such as the 
regulation of glycogen breakdown, which has been shown to be stimulated by adrenaline in type II but 
not in type I fibres (Jensen and Dahl 1995; Jensen et al. 2011). 
It would be interesting to see whether Popdc proteins and their ability to bind cAMP are involved in 
those processes. 
 
 
4.12 Muscle regeneration is different in wildtype and Popdc2-/- mice 
 
It was described by Andree and colleagues that Popdc1
-/-
 mice exhibit retarded muscle regeneration 
upon Ctx-induced injury (Andree et al. 2002). Muscle regeneration is a complex process involving an 
inflammatory process for the clearance of necrotic tissue, the activation and differentiation of stem 
cells, and the growth and maturation of newly formed fibres (reviewed in (Ciciliot and Schiaffino 
2010)).  
 
Given the fact that Popdc1 and Popdc2 did not only show overlapping subcellular distribution but also 
formed heteromeric complexes, it was investigated whether the lack of Popdc2 also affects muscle 
regeneration. Therefore, regeneration was assessed by measuring cross-sectional area (CSA) of 
newly regenerated fibres in a Ctx-induced injury mouse model. We found that 5d or 14d after 
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Ctx-injection the CSA was significantly increased in Popdc2
-/-
 mice compared to wildtype controls 
showing that regenerative capacity may actually be enhanced in Popdc2 null mutants (Figure 3.43). It 
appears that Popdc2 is a negative regulator of muscle regeneration. Popdc2 is expressed in activated 
myoblasts and also in small newly regenerated fibres. In myoblasts, Popdc2 is not present at the 
plasma membrane, but in vesicular cytoplasmic structures and in the nucleus. In regenerating muscles 
the protein can be found very early at the plasma membrane, however, the overall levels are 
considerably lower compared to mature fibres. These different subcellular localisations and expression 
levels may be indicative of diverging functions during different stages of regeneration. These 
differences could be dissected using a conditional Popdc2 null mutant model. With the help of a 
tamoxifen-inducible Cre/loxP system, Popdc2 could be inactivated before or at different time points 
during regeneration, and regeneration could be assessed in comparison to un-induced animals. 
Additionally, a Cre mouse line could be used expressing the Cre recombinase under the control of the 
Pax7 promoter (Lepper et al. 2009) to get specific Popdc2 inactivation in quiescent satellite cells and 
in activated myoblasts, or under the control of the Myogenin (Li et al. 2005) or MyoD promoter (Chen 
et al. 2005) for Popdc2 depletion in differentiated cells and fibres.  
It has been speculated that skeletal muscle phenotypes observed in Popdc1
-/-
 mice might be due to 
impaired vesicular trafficking and altered cell motility in myoblasts (Benesh et al. 2013), however, 
experimental data to support this hypothesis are not available. Interestingly, Dysferlin is expressed in 
activated myoblasts and plays a role in myoblast–myotube fusion (De Luna et al. 2004; Demonbreun 
et al. 2011). It may be possible that Popdc proteins are involved in the regulation of different stages of 
muscle regeneration through different protein-protein interactions. 
 
Unexpectedly, our results for Popdc2
-/-
 mice are in contrast to previously published data of 
regeneration in Popdc1 null mutants, which was retarded in comparison to heterozygous Popdc1
+/-
 
mice (Andree et al. 2002). It is presently unclear to what extent these differences are due to different 
physiological roles of Popdc1 and Popdc2 during muscle regeneration. Popdc1 localisation in newly 
formed myotubes was different to Popdc2, as it was only found to a minor extent to be at the plasma 
membrane, but predominantly in vesicular structures. This may be the basis of physiological 
differences between Popdc1 and Popdc2 during muscle regeneration. 
However, it has to be considered that Andrée and colleagues employed a different model than the one 
used in this work, as they injected 100µl of 10µM cardiotoxin into gastrocnemius and soleus muscles 
of female mice, whereas in this work, 25µl of 100µM Ctx were injected into the TA muscle of male 
mice. It has been shown that the number of satellite cells per fibre varies in different muscles (Shefer 
et al. 2006). Moreover, differences in number of satellite cells between male and female mice have 
been reported with higher numbers in male mice (Neal et al. 2012). Thus, the pool of satellite cells 
available may have an impact on the outcome of skeletal muscle regeneration in Popdc1
-/-
 and 
Popdc2
-/-
 mice. 
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4.13 Popdc1 and Popdc2 are also nuclear proteins 
 
Nuclear localisation was observed in undifferentiated myoblasts expressing Pax7 and differentiated 
cells expressing Myogenin, but not after fusion to form myotubes (chapter 3.13). 
In quiescent satellite cells, Popdc1 and Popdc2 were not or only at very low levels expressed, but 
levels were strongly up-regulated by activation. This is in agreement with previously published data of 
Popdc1-LacZ expression, which was also up-regulated in activated myoblasts (Andree et al. 2002). 
 
Importantly, nuclear localisation was not only seen in cultured myoblasts grown on collagen-coated 
surfaces. It was also observed in myoblasts of cultured fibres isolated from EDL muscles, albeit at 
lower levels (Figure 3.46A, Figure 3.48). It can therefore be concluded, that nuclear localisation does 
not represent a culture artefact. However, culture conditions apparently influence the ratio of nuclear 
versus cytoplasmic Popdc protein levels. Moreover, nuclear localisation was also observed by 
immunohistochemical staining performed on sections of regenerating muscle, providing additional 
evidence for a physiological role of nuclear localisation (Figure 3.49). Interestingly, nuclear localisation 
was also seen in established myoblasts, cardiac myocytes, and epithelial cell lines, suggesting that 
nuclear localisation is a feature in different cell types (Figure 3.53). These cell lines could be helpful to 
further study the functional impact of nuclear localisation of Popdc proteins.  
 
Popdc proteins are well-established transmembrane proteins (Andree et al. 2000; Andree et al. 2002; 
Knight et al. 2003). In this work, we found nuclear fragments of about ≥15kDa in size, which were 
co-fractionated together with histone H1 (Figure 3.50). Also other nuclear Popdc isoforms may exist. 
Nuclear fractionation coupled to protein mass spectrometry may help to identify all fragments and to 
determine what domains of Popdc proteins they contain.  
The mechanism of how Popdc proteins achieve nuclear localisation is currently only poorly 
understood. Experiments in this work indicate that alternative splicing is not necessary to produce 
nuclear fragments, since transfection of full-length cDNA into primary myoblasts also resulted in 
nuclear localisation (Figure 3.54). Thus, the nuclear portion may be generated by alternative 
translation initiation or by posttranslational cleavage of the protein.  
Interestingly, nuclear localisation of fragments of transmembrane proteins has been reported before. 
Gomez-Ospina et al. and others established that the C-terminus of the L-type voltage-gated calcium 
channel Cav1.2 also acts as a transcription factor, which is produced by post-translational proteolytic 
cleavage (Gomez-Ospina et al. 2006; Schroder et al. 2009). Interestingly, among the candidates of 
possible Popdc interacting proteins identified by CoIP coupled to mass spectrometry were also 
proteases, which should be tested whether they are able to cleave Popdc proteins and whether they 
may be involved in achieving nuclear localisation. 
In addition, to study how nuclear localisation is achieved it will be important to find out what the 
nuclear functions of Popdc proteins are. Interaction with nuclear proteins are likely, since a significant 
number of candidates identified by CoIP coupled to mass spectrometry are proteins with known 
nuclear functions. In addition, direct DNA binding may be possible as well. It is noteworthy that 
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bacterial CAP (catabolite activator protein) or CRP (cAMP receptor protein) proteins show high 
similarity to Popdc proteins. These proteins are transcription factors that are modulated by cAMP. 
They are controlling the expression of enzymes that are regulating carbohydrate metabolism 
(Schindler et al. 2012; Simrick et al. 2013). Thus, it is not unlikely that Popdc proteins are involved in 
the regulation of gene expression. Chromatin immunoprecipitation (ChIP) experiments may be helpful 
to identify genes being differently regulated when Popdc proteins are nuclear.  
Remarkably, nuclear localisation was only seen in proliferating myoblasts, but not in quiescent satellite 
cells or in myotubes. Thus, it is likely that Popdc proteins control genes, which are important for 
proliferation or for preventing differentiation. Moreover, myoblasts isolated from null mutant mice 
showed enhanced fusion even when cultured in growth medium containing FCS and growth factors 
(not shown). Thus, Popdc proteins, may keep myoblasts in a proliferative state, and nuclear 
localisation may be the way of accomplishing this regulation.  
In favour for this hypothesis is the abnormal development of craniofacial muscles in zebrafish popdc2 
morphants, showing severely reduced or even missing craniofacial muscles, which may be the result 
of premature fusion of precursor cells (Kirchmaier et al. 2012).  
During regeneration, by preventing fusion Popdc proteins may increase the pool of activated 
myoblasts, which are available for replacing degenerated fibres. In the Popdc2
-/-
 regeneration model 
used in this work, the satellite cell pool may have been large enough to repair the muscle efficiently. 
Moreover, an enhanced myoblast-myotube fusion may explain the increased CSA 14d after 
Ctx-injection.  
Preventing myoblasts to fuse may also increase the number of cells, which go back into the quiescent 
state and become new satellite cells. Therefore, Popdc proteins may be involved in maintaining the 
pool of muscle stem cells. Thus, lack of Popdc proteins may lead to a depletion of muscle satellite 
cells over time. It would therefore be interesting whether the efficiency of regeneration is declined or 
the time course altered in older Popdc null mutants compared to age-matched controls, or after 
several cycles of regeneration of the same muscle. 
 
 
4.14 Summary of novel interaction partners 
 
Several Popdc-interacting proteins have been identified so far (Table 4.1). Many functions of these 
interactions have been described in various epithelial cells (Osler et al. 2005; Smith et al. 2008; Hager 
et al. 2010; Wu et al. 2012; Benesh et al. 2013). Although expression of Popdc proteins in cardiac and 
skeletal muscle is much higher than in epithelia (Andree et al. 2000), protein networks in muscle cells, 
in which Popdc proteins are involved in, were largely unknown. In this work, it was possible to identify 
several novel interaction partners for Popdc proteins, which help to further elucidate Popdc function 
(Table 4.1 and Figure 4.1). 
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Table 4.1: List of proteins interacting with Popdc proteins 
 interacting protein first reported in 
Popdc1 
ZO-1 (Osler et al. 2005) 
GEFT (Smith et al. 2008) 
Vamp3 (Hager et al. 2010) 
Vamp2 (Hager et al. 2010) 
TREK-1 (Froese et al. 2012) 
aPKC (Wu et al. 2012) 
NDRG4 (Benesh et al. 2013) 
  
Ankyrin-B this thesis 
Ankyrin-G this thesis 
Caveolin-3 (Alcalay et al. 2013)/this thesis 
Dysferlin this thesis 
Dystrophin this thesis 
Popdc2 this thesis 
Popdc3 this thesis 
SCN5A this thesis/Niels Decher 
Popdc2 
TREK-1 (Froese et al. 2012) 
  
Ankyrin-B this thesis 
Ankyrin-G this thesis 
Popdc1 this thesis 
NCX-1 this thesis 
Popdc3 
TREK-1 (Froese et al. 2012) 
  
Popdc1 this thesis 
 
 
It is known that Popdc1 and Popdc2 are important for cardiac pacemaking. Depletion of either Popdc1 
or -2 results in a maladaptation of heart rates to stress, resulting in a bradycardia phenotype 
characterised by sinus pauses (Froese et al. 2012). Although further experiments will be required, the 
novel interaction partners are of high significance given their established roles for cardiac and skeletal 
muscle function. Particularly crucial may be the heteromerisation and the interaction with Ankyrins. 
Ankyrins are adaptors for many proteins and known organisers of macromolecular complexes. Popdc 
proteins emerge to be membrane-bound Ankyrin receptors, which may regulate precise localisation of 
these adaptor proteins. Thereby, they may be indirectly involved in a variety of cellular processes 
including the regulation of electrical activity, membrane integrity, and many others. This hypothesis is 
further supported by the identification of several other interacting proteins, which also have known 
functions in the cardiac pacemaker context, and which are partly dependent on Ankyrins. For 
example, NCX-1 is a known Ankyrin-B interacting protein and is essential for cardiac electrophysiology 
(Mohler et al. 2005).  
Strikingly, several of the Popdc interacting proteins identified here are physically or functionally 
connected, e.g. Caveolin-3 interacts with Dysferlin and Dystrophin, all three of these proteins have 
been shown to be involved in maintenance of membrane integrity, and mutations in either of these 
proteins are associated with muscular dystrophies. Interestingly, Popdc1 was found to interact with 
Caveolin-3, Dysferlin, and Dystrophin, and mutations in POPDC1 are associated with muscular 
dystrophy in human patients. This gives further evidence for the involvement of Popdc proteins in the 
regulation of membrane integrity.  
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In addition, Popdc proteins may function in mechanosensing and -transduction, since many of the 
interaction partners are playing roles in these processes, e.g. TREK-1 (Honore 2007) or Caveolin-3 
(Calaghan 2011). Moreover, Popdc proteins are associated with the cytoskeleton, e.g. via Ankyrins, 
and able to re-organise actin filaments via interaction with GEFT (Smith et al. 2008), which gives 
further support for a role of Popdc proteins in mechanical sensing or transduction. 
Moreover, a function of Popdc proteins in vesicular trafficking is apparent. Interaction with the SNARE 
protein Vamp3 was demonstrated previously (Hager et al. 2010) and could be confirmed in this work 
by CoIP coupled to mass spectrometry. Furthermore, TREK-1 membrane localisation was  
up-regulated in the presence of Popdc proteins in Xenopus oocytes (Froese et al. 2012). Moreover, 
also by interacting with NDRG4 vesicular transport processes are modulated (Benesh et al. 2013). 
 
Popdc proteins are involved in nuclear processes. Nuclear localisation could be identified for Popdc1 
and Popdc2 in activated myoblasts, in some cell lines, and, in the case of Popdc2, also in isolated 
adult ventricular cardiomyocytes (Subreena Simrick, personal communication). In addition, Popdc 
proteins seem to be also components of the nuclear envelope, as Popdc2 was identified recently to be 
a nuclear envelope transmembrane protein (Wilkie et al. 2011; Korfali et al. 2012). Moreover, 
overexpression of Popdc1 (Figure 3.58) and Popdc3 (Figure 3.35C) results in a rim-like staining 
around the nucleus. Intriguingly, subcellular localisation seems to be regulated through alternative 
splicing, as the Popdc3c isoform showed predominant localisation in the nuclear envelope (Figure 
3.35D).  
Taken together, Popdc proteins are platforms for many interacting proteins. They may be involved in 
the regulation of many cellular processes, e.g. as organisers of macromolecular complexes. Moreover, 
through their ability to bind cAMP, Popdc proteins may play key roles in ß-adrenergic responses. 
The presence of different splice isoforms and posttranslationally modified Popdc proteins allows 
members of this protein family to take roles in different cellular processes. Homo- and 
heteromerisation enables fine tuning of Popdc protein function in different contexts, making this 
protein family to highly versatile regulators and modulators of physiological processes. 
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Figure 4.1: Schematic model of Popdc interactions and functions 
Popdc proteins are present in different subcellular compartments, including the plasma membrane, 
vesicles, and the nucleus. They are interacting with each other to form homo- and heteromeric 
complexes. By interacting with a variety of other proteins they may function in the control of vesicular 
trafficking, as regulators of electrical activity, mechanosensing and -transduction, signalling events, 
membrane integrity, as well as transcription. 
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